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1 Introduction 
 
Chapter 1.1, 1.2, 1.3, 1.4 (partly) have been adapted from: 
Katharina Müller, Ernst Wagner, “RNAi-based Nano-Oncologicals – Delivery and Clinical 
Applications.” In Nano-Oncologicals: New Targeting and Delivery Approaches, Alonso, 
M. J.; Garcia-Fuentes, M., Eds. Controlled Release Society and Springer 2014, 245-268.
 
 
 
1.1 RNA interference (RNAi) 
 
Sequence-specific, post-transcriptional gene silencing in animals (miRNA) and plants 
(siRNA) proceeds in significantly different fashion. In animals, endogenous miRNAs 
regulate gene expression during embryonic development and cellular differentiation. 
miRNA genes derive from independent transcription units or from introns of protein-
coding genes [1]. They are mainly clustered in the human genome and miRNAs within a 
cluster are often related to each other [2]. miRNA genes are transcribed by RNA 
polymerase II (Pol II) into long primary transcripts (pri-miRNAs) in the nucleus [3] (Figure 
1A). Here, they are processed firstly by a RNase-III-type endonuclease termed Drosha, 
along with the double-stranded (ds) RNA-binding protein of DiGeorge syndrome critical 
region gene 8 (DGCR8) into so called miRNA precursor (pre-miRNA), a ~70 nucleotide 
(nt) stem-loop structure [4]. Afterwards pre-miRNA is transported into the cytoplasm by 
exportin 5, a dsRNA-binding protein. Once in the cytoplasm, pre-miRNA is recognized by 
another RNase III, called Dicer. Dicer and its ds-RNA-binding protein partners, HIV-1 
TAR RNA-binding protein (TRBP) and protein activator of protein kinase PKR (PACT), 
process pre-miRNA into ~22 nt mature miRNA [5]. This RNA duplex possessing a 
5´phosphate and ~2 nt 3`overhang, which is characteristic of a RNAase III product [6], is 
then loaded into the RNA-induced silencing complex (RISC). RISC contains one member 
of the Argonaute protein family (Ago 1 to Ago 4). Only one of the Argonaute proteins 
(Ago2) provides the RISC with endonuclease activity under special conditions (see 
below). The so called antisense or guide strand of miRNA which enters the RISC is the 
one whose 5´end is less firmly paired [7]. If the guide strand shows imperfect sequence 
homology, the passenger strand is unwinded and discarded by a bypass mechanism that 
necessitates helicase activity. If the guide strand has perfect sequence complementary 
to its passenger strand and Ago2 is part of the RISC, the passenger strand is cleaved. 
The extent of sequence complementary also influences the further procedure of RISC. In 
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the rare case of perfect or near perfect Watson-Crick base pairing between the miRNA 
and the 3`untranslated region (3`UTR) of its target mRNA, this leads to direct sequence 
specific cleavage of the mRNA, comparable to the siRNA pathway (Figure 1B). However, 
the more common mechanism of miRNA induced gene silencing occurs with miRNA 
binding with imperfect base pairing. The first 2-7 or 2-8 nucleotides from the 5´end of the 
miRNA, the seed sequence, must have perfect complementarity. Mismatches at the 
3´end of the miRNA are tolerated. In this case miRNA induces mRNA degradation and 
therefore translational repression [5]. Because of their gene silencing capability without 
perfect match, one miRNA can regulate up to hundreds of different mRNAs [1]. In 2005 
Lim et al. already observed this effect using microarray analysis [8]. Moreover, Dicer can 
process pre-miRNA into miRNAs altering their length in 1-2 nt. This length difference 
influences the miRNA seed sequences as well as guide strand loading into the RISC, 
thus increasing the target mRNAs for a single miRNA [9]. In contrast, different miRNAs 
can silence a common single mRNA [10]. Therefore, reestablishment or overexpression 
of a single miRNA or silencing of miRNAs using antagomirs in cancer could lead to off-
target effects that must be considered carefully.  
The siRNA mechanism is also based on endogenous double–stranded RNAs, which 
often derive from mRNAs, transposons, viruses or heterochromatic DNA [11]. These 
RNAs are processed by Dicer (Figure 1B) but, in contrast to miRNA, request a perfect 
match with the target mRNA along about 20 nucleotides and therefore, at least in theory, 
each siRNA has only one specific mRNA target. siRNA triggered gene silencing mainly 
serves as an innate immune defense protecting nematodes, insects and plants against 
invasive nucleic acids from pathogens [12]. The siRNA guide strand always has to have 
perfect complementary to its target mRNA and therefore leads to mRNA cleavage. The 
guide strand interacts with the catalytic, RNase H-like PIWI domain of Ago2 at the 5`end 
and with a PIWI-Argonaute-Zwille (PAZ) domain at the 3`end [3]. The targeting mRNA is 
cleaved between bases 10 and 11 relative to the 5`end of the siRNA guide strand [5]. In 
contrast to miRNA, targeted cleavage sites can be both translated and untranslated 
regions of the target mRNA.  
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Figure 1. Mechanism of RNAi in mammalian cells. A) miRNA pathway. Endogenous miRNA genes are 
transcribed by RNA polymerase II into primary miRNA (pri-miRNA). The endonuclease Drosha and ds-RNA 
binding protein DGCR8 then process pri-miRNA into precursor miRNA (pre-miRNA), which is exported into 
cytoplasm by Exportin 5. In the cytoplasm pre-miRNA is cut by the RNAse III, Dicer, together with TRBP (HIV-1 
TAR RNA-binding protein) and PACT (protein activator of protein kinase PKR) into a dsRNA consisting of ~22 nt 
and a 5´phosphate and ~2 nt 3`overhang. The miRNA guide strand is then loaded into the RISC (RNA-induced 
silencing complex) - Argonaute (Ago 1 or Ago 2) complex and recognizes its targeting mRNA. In mammalian 
cells, the guide strand has imperfect complementarity to the target mRNA, which leads to translational repression 
and therefore less protein. B) siRNA pathway. Analogous to pre-miRNA exogenous dsRNA is processed in the 
cytoplasm by Dicer, TRBP and PACT into siRNA. Alternatively exogenous siRNA can be directly delivered. 
siRNA/Ago2 RISCs require perfect complementary for target mRNA cleavage. Adapted from [13]. 
 
Mammalian cells do not express siRNAs or miRNAs with perfect match to mRNA targets. 
However, artificially delivered or transfected, perfectly matched exogenous dsRNA can 
be processed in the cytoplasm similar to pre-miRNA by Dicer into siRNA of 21-25 
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nucleotides in length [14]. The siRNA duplex is then incorporated into the RISC and the 
passenger strand is cleaved and expelled. Sequence –specific gene silencing by such 
artificial RISCs is found. Short siRNAs can directly intervene with the RNAi pathway 
without need for cleavage by Dicer, when introduced into the cytoplasm. Therefore 
synthetic 21 bp siRNA are widely used for research and therapeutic applications of RNAi 
[12, 15-17]. The gene knockdown caused by a siRNA is often temporary. Edinger et al. 
found a maximum downregulation at mRNA level after 24 h and at protein level after 48 h 
in in vitro studies [18]. In other studies a silencing of 3-4 weeks in nondividing liver cells 
was observed in vivo indicating that the transient gene knockdown is due to dilution 
effects of siRNA concentration in the cytosol through cell division [19]. Zimmermann et 
al. observed silencing of apolipoprotein B for 11 days, when they applied a liposomal 
siRNA formulation systemically into cynomolgus monkeys [20]. Considering these 
different findings, the dose regime for RNAi based nanodrugs should be calculated 
carefully, when transferred to clinical application [19].  
 
1.2 Nucleic acid therapy 
 
Several human clinical trials using RNAi or related RNA-modulating nano-oncological 
drugs for cancer therapy are currently carried out. Major investments in the development 
of these therapeutics have been made in the last years with the prospect of commercial 
drugs in the next 5-10 years [21, 22].  
 
1.2.1 siRNA therapeutics 
 
Davis and colleagues firstly reported systemic siRNA delivery in humans for cancer 
treatment via targeted nanoparticles. Their formulation consisted of a cyclodextrin-
containing polymer, adamantane conjugated to polyethylene glycol (PEG) for steric 
stabilization, adamantane-PEG (AD-PEG) with the targeting ligand transferrin binding to 
transferrin receptors, which are frequently upregulated in cancer cells, and siRNA 
targeting the M2 subunit of ribonucleotide reductase (RRM2), a crucial factor of tumor 
malignancy. These nanoparticles, named CALAA-01, were systemically administered to 
patients with solid cancers. The phase I study implied a phase Ia open-labelled, multi-
center, dose escalation study (3-30 mg m
-2
) and a phase Ib extension study (18-27 mg 
m
-2
) of patients suffering from solid tumors. Biopsies from tumor tissues were analyzed 
and a reduction of mRNA and protein levels of RRM2 was observed. The RNAi was 
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confirmed by 5´-RNA-ligand-mediated RACE PCR technique detecting a RRM2 mRNA 
fragment in tumor tissue of the patient receiving the highest dose [23-25].  
 
Atu027 is a lipid-based siRNA nanoparticle approach which has recently been tested in a 
phase I clinical trial. Atu027 contains siRNA targeting protein kinase N3 (PKN3). PKN3 
mediates malignant cell growth [26]. Atu027 has been shown to silence PKN3 when it 
was systemically delivered in mice, rats and nonhuman primates without stimulation of 
the innate immune system.  In pancreatic and prostate cancer mouse models Atu027 
decreased tumor growth and lymph node metastasis formation [27]. In a phase I clinical 
trial 34 patients suffering from advanced solid tumors were treated with Atu027. Atu027 
was well tolerated, 41 % of patients showed disease stabilization and some patients 
showed reduction of metastases demonstrating the potential of this siRNA delivery 
system [28]. Furthermore, Atu027 was examined in combination with gemcitabine in a 
phase Ib/IIa study to examine safety, pharmacokinetics and efficacy in advanced 
pancreatic carcinoma. The combinatorial treatment was safe and well tolerated and 
tendency towards twice-weekly dosing regimen could be observed [29]. 
ALN-VSP consists of a lipid nanoparticle with two siRNAs, one targeting vascular 
endothelial growth factor A (VEGF), the other one targeting kinesin spindle protein 
(KSP). RNAi specific effectiveness of ALN-VSP as well as antitumor activity has been 
proven in preclinical animal studies. In a phase I dose- escalation study 41 patients with 
advanced tumors and hepatic and extrahepatic metastases were intravenously treated 
with ALN-VSP with doses of 0.01-1.5 mg/kg every two weeks. ALN-VSP was generally 
well tolerated and occurring adverse events were comparable to other targeted 
chemotherapies. Furthermore, both siRNAs and cleavage products of VEGF mRNA 
could be detected in hepatic and extrahepatic tumor biopsies indicating that the 
antitumoral effects of ALN-VSP underlie an RNAi mechanism. Fifty percent of patients 
treated with doses greater than 0.7 mg/kg achieved stable disease including one patient 
with endometrial cancer and multiple liver metastases, who attained a major response 
meaning disappearance of all target and non-target lesions [25, 30].   
 
1.2.2 miRNA replacement therapy 
 
MRX34 was developed to deliver miR-34 mimic, a synthetic double stranded miRNA of 
20-25 nucleotides, which was the first microRNA assessed in a clinical phase I study. 
MRX34 is a delivery system based on a mixture of different lipids. miR-34 is frequently 
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downregulated in many human cancer types leading to metastasis, anti-apoptosis, 
chemoresistance and tumor proliferation [31]. Anti-tumor activity of miR-34 has been 
shown in non-small cell lung cancer in mice. miR-34 was systemically delivered using a 
neutral lipid emulsion, which led to a decrease of proliferation markers, increased 
apoptosis of tumors and therefore to reduced tumor burden [32]. The efficiency of 
MRX34 has been proven in preclinical studies. In a survival study MRX34 was 
intravenously delivered in mice with hepatocellular carcinoma. All treated animals stayed 
alive and appeared healthy in comparison to control groups. In a phase I trial MRX34 has 
shown partial responses in patients with renal cell carcinoma, acral melanoma and 
hepatocellular carcinoma. Furthermore, MRX34 revealed a manageable safety profile 
and led to long-term stable disease in some patients [33, 34]. Currently, participants are 
recruited for an open-label, multicenter, dose-escalation phase I study to examine safety, 
pharmacokinetics and pharmacodynamics of MRX34 in patients with primary liver 
cancer, advanced or metastatic cancer (see www.clinicaltrials.gov for details, 
ClinicalTrials.gov Identifier: NCT01829971). 
 
1.3 siRNA and miRNA design 
 
There are several barriers that restrict the direct use of miRNA or siRNA for therapeutic 
application. First of all, naked RNA is rapidly cleaved by ribonucleases (RNAses), which 
are commonly occurring in a wide variety of organisms. RNAse interacts with the RNA 
backbone catalyzing its hydrolysis [35]. Therefore, the poor RNAse resistance limits the 
application of non-modified RNA in vitro and in vivo. Moreover, synthetic miRNAs or 
siRNAs are eliminated from the blood-stream by excretion in urine or bile. Due to their 
small size RNA molecules are able to pass the capillaries of the kidney glomerulus easily 
[36]. The biological half-life of siRNA has been reported to be 2-6 minutes, whereas 
chemically stabilized siRNA circulated for 30-50 minutes [37].  
Another limiting factor concerning direct use of siRNA and miRNA is toxicity. Naked 
dsRNAs are able to cause off-target effects (OTEs). For example, one siRNA can 
regulate numerous unintended transcripts. This emerges when siRNA acts in a miRNA-
related manner with partial sequence complementary. It has been reported, that many 
off-targets silenced by siRNA showed 3´UTR perfect complementary to the seed region 
of the siRNA, but not throughout the entire guide strand [38, 39].  
In addition, siRNA can induce an innate immune response. This immunogenicity is 
divided into two groups: activation of toll-like receptors (TLR) or non-TLR-mediated 
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immune response [40] and derives from the stimulation of pattern recognition receptors 
(PRRs). PRRs recognize invariant molecular structures of pathogens [36, 41]. Relating to 
siRNA, two classes of PPRs are affected: TLRs and cytoplasmic receptors. TLR3, TLR7 
and TLR8 recognize synthetic siRNA [42]. TLR3 located in endosomes and cell surfaces 
is only activated by dsRNA, which is typically for viruses [43]. After siRNA detection 
TLR3 activates interferon-γ (INFγ) and interleukin-12 (IL-12) causing anti-angiogenic 
effects [40]. TLR7 and TLR8 are stimulated by either single-stranded RNA (ssRNA) or 
RNA duplexes. They are expressed in endosomes and lysosomes and in the 
endoplasmic reticulum of plasmacytoid dendritic cells, B cells and myeloid cells [36]. 
TLR7 and TLR8 cause nuclear translocation of nuclear factor ĸ-light-chain-enhancer of 
activated B cells (NF-ĸB) and downstream activation of interferon-α (INFα) and 
inflammatory cytokines [40, 44]. siRNAs can also provoke a non-TLR-mediated immune 
response by activating cytoplasmic receptors. dsRNA-binding protein kinase leads to 
inhibition of protein translation and interferon response after recognizing siRNA. In 
addition, retinoic acid-inducible gene 1, another cytoplasmic PRR, causes interferon 
response and upregulation of other inflammatory mediators [36]. Chemical modification 
and variations in siRNA design reduce the risk of OTEs and immune responses [42]. In 
correlation to siRNA, the risk of miRNAs causing toxicity is likely to be lower since 
physiologic gene expression networks have managed to adapt to regulatory effects of 
endogenous miRNAs [45]. Nevertheless, side effects of miRNA-based therapies have to 
be examined before usage in clinical application. Chemical changes in the backbone of 
siRNA and miRNA were introduced to improve stability and reduce immunogenicity of 
these molecules. A common strategy comprises the modification of the ribose 2´-OH 
group of siRNA (Figure 2), which is involved in the hydrolysis mechanism of many serum 
RNAses. The substitution of this functional group with 2´-O-methyl (2´OMe), 2´-deoxy 
(2´H), 2´-fluoro (2´F) or 2´-methoxyethyl (2´-MOE) ribonucleotides (Figure 2A) have 
proven to increase RNAse resistance without losing the ability to enter the RISC and to 
interact with Ago2 [46-48]. Furthermore, 2´-OMe uridine or guanosine modifications have 
been shown to prevent stimulation of the innate immune system by avoiding activation of 
TLRs [49]. Other established procedures are the incorporation of phosphorothioate 
backbone linkages at the 3´-end of the siRNA strand to improve the stability against 
endonucleases or the replacement of a nonbridging phosphodiester oxygen by an 
isoelectronic borane (BH3-) moiety to increase activity and RNAse resistance (Figure 2B) 
[50]. Locked nucleic acid (LNA) (Figure 2C) includes a methylene bridge linking the 2´-
oxygen to the 4´-carbon of the ribose ring. This modification ensures that the ribose ring 
is locked in the 3´-endo conformation and therefore increases nuclease resistance to 
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RNA oligonucleotides. Moreover, LNAs are processed by the siRNA machinery, because 
they maintain an A-form helix geometry typical for RNA-RNA duplexes, in a normal way 
and reduce unintended OTEs [51]. LNAs are widely used as antagomirs because of their 
thermodynamic stability and therefore efficient binding to miRNA seeds. Antagomirs are 
single-stranded oligonucleotides with perfect complementary to a miRNA. If hybridized 
with its corresponding miRNA, target mRNA recognition and therefore gene regulation is 
hampered [52]. 
 
 
Figure 2. Chemical modifications of RNA.    A) Stabilizing 2´-OH modifications. 2´OMe: X = OCH3; 2´deoxy: X 
= H; 2´fluoro: X = F; 2´methoxyethyl (2´-MOE): X = OCH2H4OCH3   B) Stabilizing backbone modifications. 
phosphorothioate linkage (PS): Y = S-; boranophosphate (BP): Y = BH3-   C) Locked nucleic acid (LNA); 
methylene bridge between 2´-oxygen and 4`-carbon of the ribose ring   D) endosomolytic INF7-siRNA; the pH-
triggered fusogenic peptide INF7 (sequence: GLFE AIEG FIEN GWEG MIDG WYGC) is covalently linked to the 
5´-end of the siRNA sense strand. Adapted from [13]. 
 
Strategies to increase the delivery of RNA molecules comprise their conjugation to small 
molecules or peptides. A prominent example is the attachment of lipophilic moieties to 
siRNA. Cholesterol was linked to the 3´-end of the siRNA sense strand resulting in 
silencing of its target apolipoprotein B (apoB) in vitro and in vivo in liver and jejunum [37]. 
This is accomplished by interactions of siRNA with lipoproteins in the circulation and 
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uptake into cells by low-density-lipoprotein-receptor (LDL-receptor). Long-chain fatty 
acids and bile acids conjugated to apoB-siRNA also mediate silencing of apoB in mice 
and hamsters [53]. Furthermore, improved delivery due to cholesterol conjugation has 
been reported for antisense oligonucleotides [54]. Krützfeldt et al. successfully silenced 
miR-122, frequently expressed in hepatocytes, by treating mice with a chemically 
modified cholesterol antagomir. In liver, levels of miR-122 and 3-hydroxy-3-
methylglutaryl-CoA-reductase (Hmgcr), a miR-122 target, were decreased after tail-vain 
injection of miR-122 antagomir. Furthermore, due to the fact that Hmgcr is involved in 
endogenous cholesterol biosynthesis, cholesterol levels in plasma were significantly 
reduced [55]. To improve the endosomal escape Dohmen et al. conjugated INF7 [56], an 
acidic peptide analogue of the amino terminus of the influenza virus hemagglutinin HA2 
subunit, to the 5´-end of the siRNA sense strand (Figure 2D). This INF7-siRNA showed  
pH-dependent lytic activity and therefore an increased gene silencing efficiency when 
delivered with sequence defined oligomers in vitro [57]. 
 
1.4 RNA delivery via sequence defined oligomers 
 
Naked siRNA or miRNA in the circulation have to find their site of action, such as a 
specific tissue or cancer cells. Since these molecules do not possess any targeting 
domain and because of their polyanionic nature do not passively enter cells across cell 
membranes, they have to be delivered by conjugation or formulations with targeting 
ligands and shielding domains [58]. Mammalian cells are surrounded by the complex 
extracellular matrix (ECM), a dense mesh of fibrous proteins and glycosaminoglycans, 
which has to be overcome by the RNA molecules, as well [59]. After siRNA and miRNA 
entered their target cell via endocytosis, they must escape from endosomes, avoiding 
entrapment and degradation in lysosomes [60]. These extracellular and intracellular 
barriers have to be addressed during the development of potent delivery systems [61, 
62]. Using classical polymers it is impossible to incorporate various functional domains in 
precise manner. As a solution, sequence defined oligomers have been designed, which 
combine multifunctionality with chemical precision. These potent nucleic acid delivery 
vehicles are obtained via solid phase-supported synthesis (SPS). This method has been 
adapted by Hartmann et al. for the synthesis of defined polyamides starting from a fixed 
resin and alternate assembly of diacids and diamines [63]. Schaffert et al. extended the 
strategy to the synthesis of larger cationic oligomers using Fmoc-protected artificial 
polyamino acids [64]. With this method our group has established a library of over 1000 
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oligomers with different shapes, arms, stability motifs, motifs to enhance the endosomal 
escape, with or without shielding or targeting ligands [65-70]. The positively charged 
oligomers are able to complex nucleic acids via electrostatic interactions forming so 
called polyplexes (see chapter 1.4.1). For stable polyplex formation using different 
nucleic acid cargos (such as siRNA versus pDNA), in general different polymer 
requirements have been observed [71, 72]. Also with sequence-defined oligomers, 
additional stabilization was required for siRNA (as opposed to pDNA) to form stable 
polyplexes. Oligomers modified with two fatty acids (oleic acid or linolic acid) at central 
(T-shape) or terminal (i-shape, U-shape) positions showed enhanced stability due to 
hydrophobic interactions (Figure 3). In addition, terminal cysteines (two-arms, three-
arms) which are able to form disulfide bridges after siRNA complexation stabilize 
polyplexes in a covalent manner. High stability is a very important feature for sufficient 
polyplex application. Incorporation of tyrosine trimers increased stability in vitro, in full 
serum (as evaluated by FCS) and in vivo (as evaluated by NIR fluorescence bioimaging 
in mice) [73-75]. 
 
 
Figure 3. Schematic illustration of oligomers.  49 (T-shape), 278 (U-shape), 229 (i-shape), 454 (T-shape with 
tyrosines), 386 (three-arm), 356 (two-arm with PEG and folate targeting). C, cysteine; K, lysine; Y3, tyrosine 
trimer; Stp, succinoyl tetraethylene pentamine; FolA, folic acid; OleA, oleic acid; LinA, linolic acid. Adapted from 
[13]. 
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Figure 4. siRNA and miRNA delivery using sequence defined oligomers. Polyplex formation through RNA 
complexation via electrostatic interactions with oligomers (1). Polyplexes that are equipped with targeting ligands 
(blue ellipse) bind to receptors on the target cell surface and are internalized via endocytosis (2). Polyplexes 
escape the endosome via proton sponge (3) and the cargo RNA is set free in the cytosol (4) where RNAi takes 
place.  
 
1.4.1 RNA complexation 
 
Negatively charged RNA can be complexed by positively charged oligomers via 
electrostatic interactions (Figure 4 (1)) [76]. Different artificial oligoamino acids were 
generated (Figure 5) based on the idea to lend an effective microdomain from the gold 
standard for gene delivery polyethylenimine (PEI) [77]: the protonatable diaminoethane 
motif (Figure 5, bottom left). The artificial building blocks differ in the type of acid (glutaric 
acid, phthalic acid, succinic acid) and in the number of protonable amine repeats: 
triethylene tetramine (tt), tetraethylene pentamine (tp), and pentaethylene hexamine (ph).  
 
  Introduction 
 
 
12 
 
 
Figure 5. Sequence-defined oligomers as RNA carriers. Artificial amino acids: glutaroyl tetraethylene 
pentamine (Gtp), succinoyl tetraethylene pentamine (Stp), glutaroyl triethylene tetramine (Gtt), succinoyl 
pentaethylene hexamine (Sph), and phthaloyl tetraethylene pentamine (Ptp). Endosomal protonation of the 
diaminethane motif is presented in the box (bottom left). Adapted from [13]. 
 
Artificial cationic building blocks such as Gtp, Stp, Ptp, or Sph could be easily merged 
with natural peptide sequences or lipidic domains, resulting in precise and pure carriers 
for nucleic acid delivery. The oligoamine components are only partly cationic at 
physiological pH, but sufficiently charged for binding nucleic acids via electrostatic 
interactions. Upon endosomal acidification, they gain additional cationic charges required 
for destabilizing lipid membranes and escape from endolysosomes to the cytoplasm [78] 
(see chapter 1.4.3) 
 
1.4.2 Targeting ligands and shielding domains 
 
Nanoparticles <1 µm in size are uptaken by cells via unspecific endocytosis [79, 80]. In 
vivo particles up to 400 nm can accumulate in solid tumors due to the enhanced 
permeability and retention (EPR) effect as they often have high vascular density and 
gaps in blood vessels [81, 82]. However, a more elegant way to direct particles specific 
to cells is the use of targeting ligands in vitro and in vivo [61, 83] (Figure 4 (2)). Cancer 
cells often overexpress receptors on their surface, which can be used for targeted 
delivery [23, 84-86].  
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The folate receptor (FR) is a prominent example. It is overexpressed in various cancer 
types including ovarian, breast, colon and kidney cancer [87-89]. FR is a membrane 
glycoprotein, which binds folic acid, an essential vitamin, with high affinity (Kd≈10
-9 
M). 
Two isoforms of FR have been found in humans: α and β [90, 91]. As most normal 
mammalian cells do not express FR, but maintain their folate level via a low affinity 
reduced folate carrier or proton-coupled folate transporter, FR is favourable to target [92, 
93]. Once folic acid containing polyplexes or other folic acid containing drugs have bound 
to FR, the membrane around this receptor complex invaginates by forming an 
endosome. With increasing acidification of the endosome receptor conformation changes 
and the conjugate is released [94, 95]. Folate mediated delivery has been widely used 
for different therapeutic anticancer agents [96], for example for protein toxins [97], 
liposomes [98], micelles [99] or polymer-based formulations [100-103]. To elaborate the 
folate targeting concept for siRNA delivery via sequence defined oligomers, Dohmen et 
al. developed folic acid modified oligomers containing Stp (Figure 3, 356). The 
polyplexes consisting of these oligomers and INF7-siRNA showed efficient and ligand 
specific gene silencing in vitro and an increased retention in KB tumor tissue due to 
targeting effects in vivo [57].  
 
Targeting the epidermal growth factor receptor (EGFR) is another strategy for the 
specific delivery of nanoparticles [104-106]. EGFR is a transmembrane receptor tyrosin 
kinase involved in cell proliferation, survival, adhesion, migration and differentiation [107]. 
EGFR is overexpressed in bladder, cervix, oesophagus, head and neck, ovary, breast, 
endometrium, colon, lung and brain [108, 109]. Specific drugs have been developed to 
target the EGFR in cancer therapy [110]. Erlotinib and gefitinib for example reversibly 
inhibit the tyrosine kinase domain of the EGFR. The monoclonal antibodies cetuximab 
and panitumumab inhibit ligand binding to the EGFR, enhance receptor internalization 
and promote cytotoxicity [111]. This shows that the EGFR is an interesting receptor for 
targeted delivery of polyplexes. Li et al. used phage display to identify a peptide ligand 
(GE11) that bound specifically and efficiently to the EGFR [112]. GE11 consists of the 
amino acid sequence YHWYGYTPQNVI and revealed less mitogenic activity than 
epidermal growth factor (EGF), the natural ligand of EGFR. Coupling GE11 to 
pDNA/LPEI polyplexes led to efficient gene delivery without receptor activation [113] and 
polyinosine/cytosine (polyIC)/PEI polyplexes had similar antitumor effects when linked to 
GE11 compared to EGF in vitro and in vivo [114]. Mickler et al. demonstrated a slower 
uptake mechanism via clathrin-mediated endocytosis for GE11-pDNA/PEI polyplexes 
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compared to EGF-pDNA/PEI polyplexes. The delayed uptake of GE11 polyplexes turned 
out to be as efficient as for EGF polyplexes with less receptor activation [104]. 
 
A drawback to specific targeted delivery of polyplexes is their positive charge. Usually a 
surplus of cationic oligomer at the surface is used, which can lead to aggregation and 
unspecific interaction with blood compounds and non-target cells [115]. Flexible water-
soluble polymers such as PEG are widely used for nanoparticle shielding to overcome 
this drawback. Furthermore, the incorporation of PEG protects polyplexes from 
recognition by the innate immune system, decreases cytotoxicity and increases solubility, 
stability and circulation time [116-118]. PEG can also serve as spacer between a 
targeting ligand and the cationic oligomers increasing the binding of ligand and receptor 
[57, 119]. Despite of the advantages offered by PEG, a high degree of PEGylation may 
reduce polyplex compaction and stability, cellular uptake and endosomal escape of 
nanoparticles [120-122].  
 
1.4.3 Endosomal escape 
 
After uptake into cells via unspecific or specific endocytosis polyplexes have to be 
released from the endosome to find their site of action in the cytosol (Figure 4 (3),(4)). 
Naturally endosomes become late endosomes and lysosomes or return to the membrane 
to recycle its contents for example receptors [123]. Over time an acidification of 
endosomes from 5.5 - 6.3 to less than 5.5 (late endosomes) and 4.6 for lysosomes takes 
place [124]. This acidification driven by V-ATPases is important for vesicular trafficking 
[125]. In case of cationic polymers containing diaminoethane motifs (see chapter 1.4.1) 
acidification leads to protonation of oligomer amines, enhanced endosomal Cl
- 
accumulation, osmotic swelling and rupture of the endosome, the so called “proton 
sponge effect” [126, 127]. To enhance the endosomal escape, sequence-defined 
oligomers were modified with lipid moieties or histidines. Lipids did not only improve the 
stability of polyplexes, but also the endosomal escape by lysing membranes in a 
favorable pH-specific manner due to their amphiphilic character and cationization at 
endosomal pH of 5 to 6 [65]. Oleic or linolic acid emerged as most potent fatty acids in 
gene silencing without significant cytotoxicity [75]. Furthermore, Lächelt et al. integrated 
histidines into targeted and shielded oligomers for pDNA delivery. These polyplexes 
demonstrated an enhanced total buffer capacity and therefore a more continuous 
cationization pH profile resulting in increased endosomal escape [78]. Alternatively, lytic 
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peptides can be introduced to enhance endosomal escape due to their ability to directly 
disrupt endosomal membranes [128]. The influenza peptide INF7 electrostatically bound 
to polyplexes [56] or influenza peptide-siRNA conjugates delivered with oligomers (as 
mentioned before) [57] have proven to enhance the endosomal escape successfully. 
Furthermore, a pH-responsive endosomolytic form of the peptide melittin has been 
shown to improve transfection efficiency when incorporated into polymers. The amines of 
melittin had to be modified with dimethylic anhydride (DMMAn) to reduce extracellular 
toxicity. In the acidic endosome these protecting groups are cleaved and the lytic activity 
of melittin is restored [116, 129]. 
 
1.5 Mesoporous silica nanoparticles 
 
Mesoporous silica with ordered pores in the size range between 2 µm and 10 µm was 
first reported in the early 1990 [130]  Several attempts were later made to reduce the 
particle size of these new materials down to only about a hundred nanometers; however, 
it took about another decade that individual porous silica particles were synthesized in 
this size-range. At some point these mesoporous silica nanoparticles became known as 
MSN. Their colloidal stability and their good biocompatibility opened the way for their use 
in biomedical applications [131]. MSNs consist of a non-crystalline, amorphous silicon 
dioxide body interwoven by numerous pores imparting them with large surface areas and 
huge void volumes. These empty channels (mesopores) can absorb and encapsulate 
large amounts of bioactive materials with similar dimensions. Typical MSNs are about 
100-200 nm in size, have surface areas around 1000 m
2
/g, pore sizes around 2-3 nm 
and pore volumes of about  1 cm
3
/g [132]. Due to progress and development in MSN 
synthesis their particle size, morphology, pore size, and pore structure can be freely 
designed, and the surface chemistry can be widely controlled [133]. In 2001 micrometer-
sized silica particles were first explored for drug delivery purposes by Vallet-Regi et al., 
who studied particles with different pore sizes for the loading and release of ibuprofen 
[134]. Since the development of their nanometer-sized counterparts, MSNs have been 
studied for the delivery of various therapeutic agents to cells in order to control different 
diseases like diabetes, inflammation and cancer [135-137]. In the area of cancer 
research MSNs are recently used for the delivery of siRNA. In this regard MSNs are 
often coated with PEI to bind siRNA via electrostatic interactions, enhance cellular 
uptake and facilitate endosomal escape [138]. Tamanoi and coworkers demonstrated 
sufficient siRNA delivery and knockdown of eGFP and the cancer targets Akt and K-ras 
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using PEI-modified MSNs [139]. Instead of binding siRNA on the surface of MSNs Li et 
al. loaded siRNA in the pores of magnetic mesoporous silica nanoparticles and capped 
them with PEI. These particles showed effective eGFP silencing as well. Additionally 
they knocked down the endogenous B-cell lymphoma 2 (Bcl-2) gene [140]. Another 
approach for siRNA delivery with MSNs is the encapsulation of these particles into 
liposomes. Brinker and coworkers encapsulated MSNs loaded with siRNA into a lipid 
bilayer consisting of DOPC, DOPE and cholesterol. This particle formulation led to higher 
siRNA encapsulation capacity and was more stable when incubated under physiological 
conditions. In addition to PEG for shielding, a peptide targeting ligand (SP94) and an 
endosomolytic peptide (H5WYG) were added to the lipid bilayer. Loaded with different 
siRNA these MSNs were able to silence 90% of cyclin A2, B1, D1, and E and killed 
>90% of HCC within 48 h of hepatocellular carcinomas [141]. Furthermore, MSNs can be 
used for dual delivery of anticancer therapeutics as they offer two surfaces (exterior and 
interior) that can be functionalized individually. He et al. loaded doxorubicin into the 2.9 
nm small pore MSNs and attached siRNA targeting Bcl-2 via polyamidoamine (PAMAM) 
dendrimers to the outside of the MSNs. They demonstrated efficient Bcl-2 silencing 
leading to a significant suppression of nonpump resistance and an enhanced anticancer 
action of doxorubicin in multidrug resistant A2780/AD human ovarian cancer cells [142]. 
A similar approach was achieved by Meng et al. by loading doxorubicin into phosphate-
coated small pores of MSN and attaching siRNA targeting the P-glycoprotein drug 
exporter to PEI onto the outer surface both via electrostatic interactions. With this 
formulation a synergistic inhibition of tumor growth and a significant Pgp knockdown was 
shown in multidrug resistant MCF-7 cells tumor-bearing mice [143]. Additionally, MSNs 
displayed high biocompatibility, elimination through the renal route and accumulation in 
tumor xenografts [137].  
In summary, mesoporous silica nanoparticles offer several attractive features for siRNA 
delivery such as their dual-functional surfaces, high loading capacity, large surface 
areas, biocompatibility, biodegradability and stable framework. 
 
1.6 Aim of the thesis 
 
The use of RNAi in cancer treatment is an excellent opportunity for new highly 
sophisticated therapies. But, even though the discovery of RNAi dates back nearly 20 
years already, only a few siRNA or miRNA delivery systems are in clinical studies. 
Several barriers have to be overcome in the biological environment for sufficient delivery. 
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The formulations have to withstand the forces in the blood stream thus an adequate 
stability is required. Furthermore, they have to be in a suitable size range, so that they 
are not eliminated immediately by the urinary tract, and possess shielding domains to 
avoid unspecific interactions with blood components or cell membranes, and targeting 
ligands for receptor specific delivery. Once the delivery systems have reached their 
target tissue, they have to be uptaken into cells, normally via endocytosis, subsequently 
they have to escape from the endosome again and finally they should set their cargo free 
in the cytosol. To meet all these requirements, sequence-defined oligomers offer an 
outstanding platform as they can be designed precisely, flexibly and with multiple 
functionalities. Thus, the focus of the thesis was the development of efficient tumor-
targeted siRNA and miRNA delivery systems using sequence-defined oligomers with 
suitable sizes, stability, targeting ligands and biocompatibility.  
The first aim of the thesis was the evaluation of a new stability motif, the CRC motif, for 
its suitability in polyplex stabilization and influence on transfection efficiency. Therefore, 
non-targeted and shielded and targeted oligomers with and without CRC motif should be 
examined and compared. Here, the highly efficient targeting ligand folic acid (FolA) had 
to be used. 
The second aim was the evaluation and screening of a small oligomer library, which 
combined different oligomer topologies, stability motifs and endosomal escape domains. 
All oligomers contained the shielding reagent polyethylene glycol (PEG) and the 
targeting ligand FolA for efficient and receptor specific gene silencing. This study aimed 
at the investigation of structure-activity relationships and at the determination of the 
optimal candidate for folate receptor (FR) - targeted siRNA delivery. 
The third aim of the thesis was the examination of oligomers with shielding and FR-
targeting obtained via native chemical ligation (NCL). The feasibility of this method to 
identify candidates for successful targeted delivery from our existing library without 
completely new synthesis should be shown. 
The fourth aim was the application of post-PEGylation to optimize polyplexes towards 
highly efficient and targeted siRNA and miRNA delivery vehicles. Defined T-shaped lipo-
oligomers containing several stability motifs had to be used as core polyplexes and 
modified with different targeting ligands via maleimide reaction. Resulted particles should 
be of suitable size and stability for FR-targeted siRNA delivery in vitro and in vivo. 
Therefore different PEGylation ratios were to be examined biophysically and biologically 
and a modification of the FolA ligand was to be established. Moreover, this concept had 
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to be transferred to other targeting ligands for the delivery of therapeutic nucleic acids. 
For this purpose, post-PEGylated EGFR targeted lipo-oligocation polyplexes had to be 
developed for antitumoral treatment with miR-200c and EG5 siRNA. 
The fifth aim of the thesis was the evaluation of a siRNA delivery system based on 
mesoporous silica nanoparticles (MSNs). MSNs with different compositions, surfaces 
and pore sizes should be examined for their siRNA loading capacity, transfection 
efficiency and biocompatibility.  
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2 Materials and Methods 
 
2.1 Materials 
2.1.1 Chemicals and reagents 
 
Chemicals and reagents Source 
Agarose NEEO ultra-quality Carl Roth (Karlsruhe, Germany) 
Alexa fluor 488-labelled secondary antibody Invitrogen (Carlsbad, USA) 
Allophycocyanin (APC)-conjugated anti folic acid 
receptor 1 IgG1 antibody 
R&D Systems (Minneapolis, USA) 
ATP Roche (Penzberg, Germany) 
Boric acid Sigma-Aldrich (Munich, Germany) 
Bromophenol blue Sigma-Aldrich (Munich, Germany) 
Cell culture consumables NUNC (Langenselbold, Germany) 
CellTiter-Glo® Promega, (Wisconsin, USA) 
Coenzyme A Sigma-Aldrich (Munich, Germany) 
Collagen Biochrom (Berlin, Germany) 
DAPI (4′,6-diamidino-2-phenylindole) Sigma-Aldrich (Munich, Germany) 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich (Munich, Germany) 
D-luciferin sodium Promega (Mannheim, Germany) 
DOTAP(1,2-dioleoyl-3-trimethylammonium-propane 
(chloride salt, 18:1 TAP) 
Avanti Polar Lipids (Alabaster, USA) 
Doxorubicin Sigma-Aldrich (Munich, Germany) 
DTNB Sigma-Aldrich (Munich, Germany) 
DTT Sigma-Aldrich (Munich, Germany) 
Dulbecco`s modified Eagle`s medium (DMEM) Sigma-Aldrich (Munich, Germany) 
DMEM/Ham`s F12 medium Sigma-Aldrich (Munich, Germany) 
Dimethylsulfoxid (DMSO) Bernd Kraft (Duisburg, Germany) 
EDTA disodium salt dihydrate Sigma-Aldrich (Munich, Germany) 
EGFR antibody Dako (Glostrup, Denmark) 
Ethidium bromide (EtBr) Sigma-Aldrich (Munich, Germany) 
Fetal bovine serum (FBS) Life Technologies (Carlsbad, USA) 
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GelRed™ Biotum (Hayward, USA) 
L-Glutathion Sigma-Aldrich (Munich, Germany) 
Glycylglycine Sigma-Aldrich (Munich, Germany) 
Heparin-sodium-25000 (source: pig) Ratiopharm (Ulm, Germany) 
HEPES (N-(2-hydroxyethyl)piperazine-N´-(2-
ethanesulfonic acid) 
Biomol GmbH (Hamburg, Germany) 
INF7 peptide  Biosyntan (Berlin, Germany) 
Lipofectamine® 2000 Thermo Fisher (Waltham, USA) 
Lysis buffer Promega (Mannheim, Germany) 
Magnesium chloride hexahydrate AppliChem (Darmstadt, Germany) 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) 
Sigma-Aldrich (Munich, Germany) 
Paraformaldehyde Sigma-Aldrich (Munich, Germany) 
Penicilline Biochrom (Berlin, Germany) 
Propidium iodide Sigma-Aldrich (Munich, Germany) 
Puromycin Sigma-Aldrich (Munich, Germany) 
Restriction enzymes (BamHI, NotI, SpeI) New England Biolabs (Ipswich, USA) 
RPMI-1640 (folate free) Life Technologies (Carlsbad, USA) 
Sodium citrate Sigma-Aldrich (Munich, Germany) 
Streptomycin Biochrom (Berlin, Germany) 
Triton X-100 Sigma-Aldrich (Munich, Germany) 
Trizma® base Sigma-Aldrich (Munich, Germany) 
Trypsin/EDTA Biochrom (Berlin, Germany) 
 
2.1.2 RNA duplexes 
 
All RNA duplexes were purchased from Axolabs GmbH (Kulmbach, Germany):  
 
eGFP siRNA  
- sense: 5´-AuAucAuGGccGAcAAGcAdTsdT-3´,  
- antisense: 5´-UGCUUGUCGGCcAUGAuAUdTsdT-3´;  
 
control siRNA (ctrl siRNA)/ control RNA (ctrl RNA)  
- sense: 5´-AuGuAuuGGccuGuAuuAGdTsdT-3′  
- antisense: 5´-CuAAuAcAGGCcAAuAcAUdTsdT-3′ 
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AHA1 siRNA  
- sense: 5´-GGAuGAAGuGGAGAuuAGudTsdT-3′ 
- antisense: 5´-ACuAAUCUCcACUUcAUCCdTsdT-3′ 
- Cy5 and Cy7 labelled AHA1-siRNA was labelled at the sense strand:  
(Cy5/Cy7) (NHC6)-GGAuGAAGuGGAGAuuAGudTsdT 
 
EG5 siRNA  
- sense: 5´-ucGAGAAucuAAAcuAAcudTsdT-3´ 
- antisense: 5´-AGUuAGUUuAGAUUCUCGAdTsdT-3´ 
 
miRNA-200c  
- sense: 5´-UCCAUCAUUACCCGGCAGUAUUA-3` 
- antisense: 5`- UAAUACUGCCGGGUAAUGAUGGA-3’ 
 
Peptide modified INF7-siRNAs were synthesized as published in [57]. INF7 in free 
mercapto form was obtained from Biosyntan (Berlin, Germany): 
 
INF7-eGFP siRNA 
- sense: INF7-ss-C6−5´-AuAucAuGGccGAcAAGcAdTsdT-3´ 
- antisense: 5´-UGCUUGUCGGCcAUGAuAUdTsdT-3´ 
 
control INF7-ctrl siRNA  
- sense: INF7-ss-C6−5´-AuGuAuuGGccuGuAuuAGdTsdT-3´ 
- antisense: 5´-CuAAuAcAGGCcAAuAcAUdTsdT-3´  
 
small letters: 2´-methoxy; s: phosphorothioate 
 
2.1.3 Sequence defined oligomers and MSNs 
 
Sequence defined oligomers were synthesized by: 
- chapter 3.1: Philipp Klein as described in [144]. 
- chapter 3.2: Dr. Dongsheng He as described in [67]. 
- chapter 3.3: Dr. Can Yang Zhang as described in [145]. 
- chapter 3.4: Resynthesis of 454 [73] and 595 [144] by Philipp Klein. 
post-PEGylation reagents by Philipp Klein as described in [146] and 
[147]. 
Chapter 3.5: Mesoporous silica nanoparticles (MSNs) were synthesized by Dr. Karin 
                     Möller as described in [148]. 
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2.2 Methods 
 
2.2.1 Polyplex formation 
 
For polyplex formation 500 ng siRNA or miRNA were used for non-targeted CRC 
polyplexes (chapter 3.1) and for polyplexes before post-PEGylation (chapter 3.4). For 
targeted polyplexes (chapter 3.1, 3.2, 3.3) and unmodified polyplexes before NCL 
(chapter 3.3) 200 ng siRNA were used. The calculated amount of oligomer at indicated 
N/P ratios were diluted in separate tubes (10 µL each) in HBG (pH 7.4, 20 mM HEPES, 5 
% glucose). The polymer solution was added to the RNA solution, mixed by pipetting and 
incubated for 45 min at RT. In case of post-PEGylation, the PEGylation reagent 
calculated at indicated molar equivalents of the amount of oligomer was added in 5 µL 
HBG and incubated for 15 min at RT. 
 
2.2.2 Mesoporous silica nanoparticles (MSN) with oligomer capping 
 
Oligomer 454 was attached to MSN samples after loading with siRNA. The oligomer was 
added directly to the loading solution after the complete siRNA uptake had been 
confirmed by Nanodrop 2000c spectrometer (Thermo Scientific) analysis and after 
redispersion of the sample. Usually, 50 μg of oligomer 454 were added to 100 μg MSN 
and shaken for 1 h at 37 °C. This was followed by a 7 minute centrifugation at 14000 
rpm. The supernatant was taken off (and measured as a reference in the cell transfection 
experiments) and was replaced with PBS buffer at pH = 7.4. Cell transfections were 
performed shortly thereafter. Experiments were carried out by Dr. Karin Möller 
(Department of Chemistry, LMU Munich). 
 
2.2.3 MSNs with DOTAP capping 
 
DOTAP layer was attached to MP-MSN samples after loading with siRNA. Here, the 
supernatant loading solution was removed, and to 100 μg of MSN sample 25 μL of a 30 
wt% DOTAP solution (2.5 mg/mL in 60:40 H2O:EtOH) was added by micropipette. The 
solution was carefully redispersed with the pipette tip, followed by short sonification for 2 
seconds. Afterwards, 225 μL cold water (4°C) was subsequently added and again mixed 
with the pipette for 30 seconds. A 2-fold washing in 100 μl sterile PBS at pH = 7.4 
(centrifugation for 3.5 minutes at 14000 rpm) was performed to remove excess lipid. The 
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final sample was kept in PBS buffer for cell transfection. Experiments were carried out by 
Dr. Karin Möller (Department of Chemistry, LMU Munich). 
 
2.2.4 Particle size and zeta potential 
 
Particles were measured in a folded capillary cell (DTS 1070) using a Zetasizer Nano ZS 
with backscatter detection (Malvern Instruments, Worcestershire, UK). For the 
measurement of CRC-oligomers (chapter 3.1) and NCL-oligomers (chapter 3.3) 10µg of 
nucleic acid and the calculated amount of oligomer at the indicated N/P ratio were 
incubated in a total volume of 50 μL HEPES buffer  (20 mM,  pH 7.4). After polyplex 
formation the solution was diluted 1:20 with HEPES buffer.  For the measurement of 
post-PEGylated polyplexes (chapter 3.4) particles were prepared as described above 
with a threefold approach in order to have enough material for measurements. For size 
measurements, the equilibration time was 0 min, the temperature was 25 °C and an 
automatic attenuator was used. The refractive index of the solvent was 1.330 and the 
viscosity was 0.8872 mPa·s. Each sample was measured three times. In case of post-
PEGylated polyplexes the sample was diluted 1:16 with HEPES buffer for zeta potential 
measurements. Zeta potentials were calculated by the Smoluchowski equation. Ten to 
fifteen subruns lasting 10 s each at 25 °C (n = 3) were measured. 
 
2.2.5 Agarose gel shift assays 
 
A 2.5% agarose gel was prepared by dissolving agarose in TBE buffer (Trizma® base 
10.8 g, boric acid 5.5 g, disodium EDTA 0.75 g, and 1 L of water) and boiling it up to 
100 °C. GelRed® was added and the agarose gel was casted in the electrophoresis unit. 
Polyplexes were prepared as described above. MSN samples containing 500 ng siRNA 
were used. For the gel shift with reducing agents 5 μL of a L-glutathione (GSH) solution 
was added to 20 μL of the polyplex solution to indicated concentrations. The GSH stock 
solution had a concentration of 50 M and was adjusted to pH 7.4. HEPES buffer (20mM, 
pH 7.4) was used as negative control (0 M GSH). For serum gel shifts CRC polyplexes 
were formed with 2.5 µg control siRNA and oligomers were diluted in separate tubes to a 
total volume of 12.5 µL HEPES. For serum gel shifts with post-PEGylated polyplexes 
particles were formed as described above with a final siRNA concentration of 250 µg/mL 
and final siRNA concentration of 200 µg/mL after PEGylation. Afterwards FBS was 
added to the samples to a final concentration of 90% FBS. The samples were incubated 
either at room temperature or 37 °C for the indicated time points. In all cases, 20 µL of 
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polyplex solution were placed into the sample pockets after 4 μL of loading buffer (6 mL 
of glycerine, 1.2 mL of 0.5 M EDTA, 2.8 mL of H2O, 0.02 g of bromophenol blue) was 
added. Electrophoresis was run at 120 V for 40 min, if not stated otherwise. 
 
2.2.6 Ellman´s assay 
 
The polyplex solution (containing 500 ng siRNA, N/P 10) without or with post-PEGylation 
was diluted to 30 µL with HBG, and 170 µL working solution (2.44 mL Ellman´s buffer 
and 60 µL DTNB solution (c= 4 mg/mL)) were added. After 15 min incubation at 37 °C 
absorption at 412 nm was measured using a GENESYS
TM
 UV-VIS spectrophotometer 
(Thermo Fisher, Waltham, USA). The percentage of free mercapto groups is based on 
the theoretical amount (100%) of cysteines (i.e. 2 or 4 molar equivalents in oligomers 
454 or 595, respectively) applied in the polyplex formation. 
 
2.2.7 Ethidium bromide compaction assay 
 
A Cary Eclipse spectrophotometer (Varian, Germany) was used for the quantification of 
ethidium bromide (EtBr) fluorescence at the excitation wavelength λex = 510 nm and 
emission wavelength λem = 590 nm. FolA-targeted polyplexes (chapter 3.2) were formed 
with 5 µg siRNA in 200 µL HBG. LPEI (synthesized by Wolfgang Rödl, Pharmaceutical 
Biotechnology, LMU Munich, as described in [149]) polyplexes at N/P 6 were chosen as 
positive control. After polyplex formation 800 µL EtBr solution (c=0.4 µg/mL) was added. 
Post-PEGylated polyplexes (chapter 3.4) were prepared as described above containing 
500 ng siRNA at N/P 10. A threefold approach was prepared in order to have enough 
material for measurements. The polyplex solution was filled up to 1 mL with EtBr solution 
(c = 0.5 µg/mL) before measurements. A HBG and EtBr solution in the defined volumes 
was used as blank. Free siRNA (corresponding amount in HBG and EtBr solution) was 
assigned to 100 %. The fluorescence intensity of EtBr measured after 3 min of incubation 
was determined in relation to the 100 % value. Triplicates were measured. 
 
2.2.8 Transmission electron microscopy (TEM) 
 
TEM measurements of MSNs were performed on a Jeol JEM-2011 microscope operating 
at 200 kV with a CCD detection unit. Samples were dispersed in ethanol and one drop of 
the resulting solution was then dried on a carbon-coated copper grid. TEM was carried 
out by Steffen Schmidt (Department of Chemistry, LMU). 
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2.2.9 siRNA loading and desorption of MSN 
 
siRNA concentrations were determined by UV measurements performed with the 
Nanodrop 2000c spectrometer (Thermo Fisher, Waltham, USA), with the nucleic acid 
module (sample volume 1.5 μL). siRNA adsorption was performed with aliquots of MSN 
samples. Usually amounts of 100 μg that were exposed to 100 μL siRNA solutions 
(either in water or MES buffer solution at pH = 5) of predetermined concentration. 
Samples were vortexed and shaken at 37 °C for defined adsorption times between 15 
minutes to several hours. Subsequently, samples were centrifuged (14000 rpm, 7 min) 
and the supernatant was measured again with the Nanodrop to determine the adsorbed 
amount by difference calculations. To study the desorption process, the supernatant from 
the loading process was taken off by micropipette and was replaced with 100 μL PBS 
buffer desorption solution at pH = 7.4. The cumulative desorption was measured in the 
supernatant solution after centrifugation at preset time intervals. Samples were vortexed 
and again shaken after each measurement without change of the buffer solution. 
Experiments were carried out by Dr. Karin Möller (Department of Chemistry, LMU 
Munich). 
 
2.2.10 Cell culture 
 
Nuro2A/eGFPLuc cells (mouse neuroblastoma), T24, T24/eGFPLuc-200cT (human 
bladder cancer) cells and MDA-MB 231 (human breast cancer) cells were cultivated in 
Dulbecco`s modified Eagle`s medium (DMEM). In case of T24/eGFPLuc-200cT cells 
media was supplemented with 0.4 µg/mL puromycin. KB/eGFPLuc (human cervix 
carcinoma) cells were grown in folate-free RPMI-1640 and Huh7 or Huh7/eGFPLuc 
(human hepatocellular carcinoma) in a 1:1 mixture of DMEM and Ham`s F12 medium. All 
cell lines were cultivated at 37 °C in humidified atmosphere containing 5 % CO2. All 
media were supplemented with 10 % fetal bovine serum (FBS), 100 U/mL penicillin and 
100 μg/mL streptomycin. 
 
2.2.11 Generation of T24/eGFPLuc-200cT cells 
 
The sequence coding for the eGFP-luciferase fusion protein was PCR-amplified from 
peGFPluc (Clontech, Saint-Germain-en-Laye, France) using the oligonucleotides 
eGFPluc_fw (AGTCGGATCCACCATGGTGAGCAAGGGCGAGG) and eGFPluc_rv 
(GACTACTAGTGCGCAGCTTTCATTACACGGCGATCTTTCCG) (Sigma-Aldrich, 
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Munich, Germany). BamHI and SpeI were included as restriction sites. The fragment was 
inserted into the open reading frame of miR-200c Reporter Vector (LR-0073, Biocat, 
Heidelberg, Deutschland) with the miR-200c binding site 
TCCATCATTACCCGGCAGTATTA via the restriction sites. The completed new plasmid 
(eGFPLuc-200cT) was transformed into E.Coli DH5α and purified using Endo Free 
Plasmid Maxi Kit (Qiagen, Hilden, Germany). Correctness of the sequence was 
confirmed by sequencing (GATC Biotech, Konstanz, Germany). Foresaid experiments 
were carried out by Philipp Heissig (PhD student, Pharmaceutical Biotechnology, LMU 
Munich). Afterwards, eGFPLuc-200cT was linearized with NotI and purified using High 
Pure PCR Product Purification Kit (Roche, Penzberg, Germany). Linearized eGFPLuc-
200cT was transfected into T24 WT cells using Lipofectamine® 2000 according to the 
manusfacturer´s protocol and seeded in low density into plates with Dulbecco`s modified 
Eagle`s medium (DMEM) containing 0.4 µg/mL puromycin. Clones that successfully grew 
under puromycin selection were picket and analyzed for their luciferase expression using 
a Centro LB 960 plate reader luminometer (Berthold Technologies, Bad Wildbad, 
Germany). Clones that successfully integrated the eGFPLuc-200cT plasmid were sorted 
by Dr. Joachim Ellwart (Helmholtz Zentrum München) with flow cytometry.  
T24/eGFPLuc-200cT cells were authentificated by DSMZ (Braunschweig, Germany). 
 
2.2.12 Gene silencing 
 
 Gene silencing of polyplexes 2.2.12.1
 
Gene silencing experiments were performed with the indicated cell line and with the 
indicated RNAs. Silencing experiments were performed in triplicates in 96-well plates. 
One day prior to transfection 5000 Neuro2A/eGFPLuc, 4000 KB/eGFPLuc (on collagen 
coated plates), 3500 T24/eGFPLuc-200cT or 5000 Huh7/eGFPLuc cells/well were 
seeded. Used RNAs were either siRNA against eGFP for silencing the eGFPLuc fusion 
protein (optional with INF7 modification), miRNA-200c mimic or control RNA with 
scrambled sequences (optional with INF7 modification). Before transfection the medium 
was replaced by 80 µL fresh medium for CRC/FolA-PEG containing polyplexes (chapter 
3.1/3.2), NCL polyplexes (chapter 3.3) or core polyplexes without PEGylation (chapter 
3.4) or 75 µL for post-PEGylated polyplexes (chapter 3.4). Polyplexes were prepared as 
described above, 20 µL (CRC, FolA-PEG, NCL polyplexes, core polyplexes without 
PEGylation) or 25 µL (post-PEGylated polyplexes) polyplex solution were added to each 
well and incubated at 37 °C. Medium was replaced at the indicated time. At 48 h after 
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initial transfection, cells were treated with 100 μL cell lysis buffer. Luciferase activity in 35 
µL cell lysate was measured using a Centro LB 960 plate reader luminometer (Berthold 
Technologies, Bad Wildbad, Germany) and a luciferin-LAR (1M glycylglycine, 100mM 
MgCl2, 500mM EDTA, DTT, ATP, coenzyme A) buffer solution. The relative light units 
(RLU) were presented as percentage of the luciferase gene expression obtained with 
buffer treated control cells. 
 
 Gene silencing of MSNs 2.2.12.2
 
Gene silencing experiments were performed in KB/eGFPLuc cells. siRNA against eGFP 
for silencing the eGFPLuc fusion protein or its negative control sequence ctrl siRNA were 
used. Silencing experiments were performed in triplicates in 96-well plates. 24 h prior to 
transfection plates were coated with collagen and 4000 cells/well were seeded. Before 
transfection, the medium was replaced with 80 μL fresh growth medium. 20 μl of MSN 
suspension (containing usually 10 μg MSN, but also as low as 0.06 μg MSN in PBS 
buffer at pH = 7.4) were added to each well and incubated at 37°C. The medium was 
replaced after the indicated incubation time. 48 h after initial transfection, cells were 
treated with 100 μL cell lysis buffer per well and luciferase activity was measured as 
described above. 
 
2.2.13 Flow cytometry 
 
 Cellular internalization of CRC containing oligomers, FolA-PEG  2.2.13.1
oligomers and NCL-oligomers 
 
KB/eGFPLuc cells were seeded into 24-well plates coated with collagen at a density of 
5*10
4
 cells/well. After 24 h, culture medium was replaced with 400 μL fresh growth 
medium. Polyplexes (N/P 20) in 100 μL HBG, containing 1.35 μg siRNA (20% of the 
nucleic acid was Cy5-labelled) were added to each well and incubated at 37 °C for the 
indicated time. All experiments were performed in triplicates. Subsequently, cells were 
washed with 500 μL PBS containing 500 I.U./mL of heparin (source pig) for 15 min to 
remove any polyplexes sticking to the cell surface. After an additional PBS washing step, 
cells were detached with trypsin/EDTA and taken up in growth medium, centrifuged and 
taken up in PBS with 10% FBS. Cellular internalization was assayed by excitation of Cy5 
at 635 nm and detection of emission at 665 nm. Cells were gated by forward/sideward 
scatter and pulse width for exclusion of doublets. DAPI (4′,6-diamidino-2-phenylindole) 
was used to discriminate between viable and dead cells. Data were recorded by Cyan™ 
  Materials and Methods 
 
 
28 
 
ADP flow Cytometer (Dako, Hamburg, Germany) using Summit™ acquisition software 
(Summit, Jamesville, NY, USA) and analyzed by FlowJo® 7.6.5 flow cytometric analysis 
software. 
 
 Cellular internalization of post-PEGylated polyplexes 2.2.13.2
 
KB/eGFPLuc (collagen coated plates), T24/eGFPLuc-200cT, MDA-MB 231, 
Huh7/eGFPLuc cells were seeded 24 h before transfection in 24-well plates with a 
density of 5x10
4
 cells/ well in 1000 µL growth media. After 24 h, media was replaced by 
400 µL fresh media for polyplexes without PEGylation or 375 µL for post-PEGylated 
polyplexes. For receptor blocking experiments, the cells were incubated with the same 
volume of folic acid saturated media 30 min before transfection at 37 °C. Polyplex 
solution containing 2.5 µg siRNA (10% Cy5 labelled) in 100 µL (non-PEGylated 
polyplexes) or 125 µL (PEGylated polyplexes) was added and incubated for 45 min at 37 
°C. After incubation, cells were washed twice with 500 µL PBS and incubated with 500 
I.U./mL of heparin in PBS for 15 min on ice, to remove non-internalized polyplexes from 
the cell surfaces. After an additional PBS washing step, cells were detached with 
trypsin/EDTA and taken up in growth medium, centrifuged and taken up in PBS with 10 
% FBS. Cellular internalization was assayed by flow cytometry at a Cy5 excitation 
wavelength of 635 nm and detection of emission at 665 nm. Cells were gated by 
forward/sideward scatter and pulse width for exclusion of doublets. DAPI (4′, 6-
diamidino-2-phenylindole) was used to discriminate between viable and dead cells. Data 
were recorded by Cyan™ ADP flow Cytometer (Dako, Hamburg, Germany) using 
Summit™ acquisition software (Summit, Jamesville, NY, USA) and analyzed by FlowJo® 
7.6.5 flow cytometric analysis software. All experiments were performed in triplicates. 
 
 Receptor level studies 2.2.13.3
 
To examine the expression of different receptors 1 x 10
6
 cells of the indicated cell line 
were collected in 150 μL FACS buffer (10% FCS in PBS). For the detection of the folate 
receptor 10 µL allophycocyanin (APC)-conjugated anti folic acid receptor 1 IgG1 antibody 
was added and incubated on ice for 1 h. For the detection of the EGFR antibody (IgG1 
mouse anti-human) was added (1 µL) and incubated on ice for 1 h. In case of EGFR 
detection cells were resuspended in 100 μL flow cytometry buffer, an Alexa Fluor 488-
labelled secondary antibody (IgG goat anti-mouse) was added and incubated again for 1 
h on ice. After the incubation on ice cells were washed twice with FACS buffer, 
resuspended in 500 μL FACS buffer and analyzed using a Cyan® ADP flow cytometer 
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(Dako, Hamburg, Germany) in both cases. Doublets were discriminated by gating 
forward/sideward scatter and forward scatter/pulse width, while counterstaining with 
DAPI allowed distinguishing between dead and living cells. The amount of folic acid 
receptor positive cells was analyzed through excitation of the dye at 635 nm and 
detection of emission at 665/20 nm. The amount of EGFR positive cells was analyzed at 
alexa 488 excitation wavelength of 517 nm and detection of emission at 492 nm. Data 
were recorded by Cyan™ ADP flow Cytometer (Dako, Hamburg, Germany) using 
Summit™ acquisition software (Summit, Jamesville, NY, USA) and analyzed by FlowJo® 
7.6.5 flow cytometric analysis software.  
 
 FolA-PEG-CF cell binding studies 2.2.13.4
 
KB/eGFPLuc cells were seeded 24 h before transfection in 24-well plates coated with 
collagen with a density of 5x10
4
 cells/ well in 1 mL of growth medium. After 24 h, medium 
was replaced by 500 µL fresh growth medium. L1210 cells (2x10
5
) were collected in 
500µL growth media. An aqueous solution containing 0.2 nmol carboxyfluorescein (CF) 
tagged FolA (FolA-PEG24-K-CF) or PEG (H6-PEG12-CF) (synthesized by Dr. Ulrich 
Lächelt, Pharmaceutical Biotechnology, LMU Munich) as a negative control was added 
and incubated for 45 min on ice. After incubation, cells were washed with 500 µL PBS. 
KB cells were detached with trypsin/EDTA and taken up in growth medium, centrifuged 
and taken up in PBS with 10 % FBS. L1210 cells were centrifuged and taken up in PBS 
with 10 % FBS. Cellular internalization was assayed by flow cytometry at a FITC 
excitation wavelength of 494 nm and detection of emission at 518 nm. Cells were gated 
by forward/sideward scatter and pulse width for exclusion of doublets. DAPI was used to 
discriminate between viable and dead cells. Data were recorded by Cyan™ ADP flow 
Cytometer (Dako, Hamburg, Germany) using Summit™ acquisition software (Summit, 
Jamesville, NY, USA) and analyzed by FlowJo® 7.6.5 flow cytometric analysis software. 
All experiments were performed in triplicates. 
 
2.2.14 Laser scanning microscopy 
 Cellular internalization of CRC-containing oligomers 2.2.14.1
 
KB cells or Neuro2A cells were seeded into an 8-well Labtek chamber slide coated with 
collagen at a density of 3 × 10
4
 cells/well in 300 μL of growth medium 24 h prior to 
treatment. Polyplexes were formed as described using a mixture of 80% unlabelled and 
20% Cy5 labelled nucleic acid (in total 1.2 µg siRNA for PEGylated polyplexes and 1.5 
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µg siRNA for non-PEGylated polyplexes) and oligomer at N/P 20 in 60 μL of HBG. 
Medium was replaced with 240 μL of fresh growth medium, and the polyplex solution 
was added. For PEGylated polyplexes the chamber slide was incubated at 37°C for 
45min. Afterwards medium was changed and cells were incubated again for 4h. Then 
cells were washed twice with 500 µL PBS and fixed with 4% paraformaldehyde (PFA) 
solution for 30 min at room temperature.  For non-PEGylated polyplexes cells were 
incubated for 24 h and washed and fixed as described before. Cell nuclei were stained 
with DAPI and actine was stained with rhodium phalloidin (Life technologies). A Leica 
TCS SP8 confocal microscope was used for image acquisition. 
 
 Cellular internalization of post-PEGylated polyplexes 2.2.14.2
 
KB/eGFPLuc cells were seeded 24 h before transfection in an 8-well Labtek chamber 
slide coated with collagen with a density of 2x10
4
 cells/ well in 300 µL media 24 h before 
treatment. After 24 h, medium was replaced by 280 µL for polyplexes without PEGylation 
or 275 µL for post-PEGylated polyplexes. Afterwards, polyplexes containing 500 ng 
siRNA were formed as described above, added to the cells and incubated for 45 min at 
37 °C. Twenty percent of siRNA were used in Cy5-labelled form, and the post-
PEGylation reagent was spiked with 0.2 molar equivalents of a maleimide-PEG28-
Alexa488 (synthesized by Philipp Klein, PhD student, Pharmaceutical Biotechnology, 
LMU Munich). Afterwards cells were washed twice with 500 µL PBS and fixed with a 4% 
PFA solution for 30 min at RT. After two washing steps, cells were incubated with DAPI 
in PBS (1:500). A Leica TCS SP8 confocal microscope was used for image acquisition. 
 
2.2.15 Cell viability 
 MTT assay of polyplexes 2.2.15.1
 
MTT assay was performed in triplicates in 96-well plates. One day prior to transfection, 
T24/eGFPLuc-200cT cells with a density of 3500 cells/well and Huh7/eGFPLuc cells with 
a density of 5000 cells/well were seeded. Before transfection the medium was replaced 
by 80 µL fresh medium for polyplexes without PEGylation or 75 µL for PEGylated 
polyplexes. Polyplexes (20 µL) containing 500 ng eGFP siRNA, miR-200c mimic or ctrl 
RNA, or 25 µL of PEGylated polyplexes were added to each well (final RNA 
concentration/well: 370 nM) and incubated at 37°C. Medium was replaced after 45 min 
incubation time. At 48 h after initial transfection, 10 µL of MTT solution (5 mg/mL) were 
added to each well. After 2 h incubation time at 37 °C, the supernatant was removed and 
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cells were lysed by freezing at -80 °C. 100 µL of DMSO were added and plates were 
incubated at 37 °C for 30 min under shaking. Adsorption at 590 nm against a reference 
wavelength of 630 nm was measured using SpectraFluorTM Plus microplate reader 
(Tecan, Groeding, Austria). Cell viability was calculated as percentage of absorption 
compared to wells treated with HBG buffer.   
 
 Cell viability after EG5 siRNA transfection 2.2.15.2
 
Huh7/eGFPLuc cells were seeded one day prior to transfection with a density of 5000 
cells/well. Before transfection the medium was replaced by 75 µL, 25 µL of PEGylated 
polyplexes containing 500 ng siRNA were added to each well (final siRNA 
concentration/well: 370 nM) and incubated at 37°C. Medium was replaced after 4 h 
incubation time. At 72 h after initial transfection cell viability was measured using 
CellTiter-Glo®. 
 
 Cell viability of MSNs 2.2.15.3
 
One day prior to transfection plates were coated with collagen and 4000 KB/eGFP Luc 
cells/well were seeded. Before transfection, medium was replaced with 80 μL fresh 
growth medium. 20 μl of MSN solution (with either eGFP-siRNA or control siRNA) were 
added to each well and incubated at 37 °C. Medium was replaced after the indicated 
incubation time. After 48 h CellTiter-Glo® assay was performed according to the 
manufacturer’s protocol. All experiments were performed in triplicates. 
 
2.2.16 RT-qPCR 
 
Cells were seeded 24 h before transfection in 6-well plates with a density 1.5x10
5
 cells/ 
well (T24) and 2x10
5
 cells/ well (MDA-MB 231, Huh7) in 2000 µL growth media. After 24 
h, media was replaced by 750 µL fresh media, polyplex solution containing 5 µg EG5 
siRNA, miR-200c mimic or ctrl RNA (in 250 µL) was added to each well (final RNA 
concentration/well: 370 nM) and incubated at 37 °C. Medium was replaced after 45 min 
incubation time. In case of L1210 suspension cells 1.5x10
5 
cells/well were seeded in 975 
µL growth media and transfected with 25 µL of post-PEGylated polyplexes containing 5 
µg siRNA after 2 h. At 24 h after initial transfection adherent and suspension cells were 
lysed and RNA was purified using miRCURY™ RNA Isolation Kit (Exiqon, Vedbæk, 
Dänemark). RNA was transcribed with the Transcriptor First Strand cDNA Synthesis Kit® 
(Roche, Penzberg, Germany) according to the manufacturer´s protocol. Quantitative 
  Materials and Methods 
 
 
32 
 
real-time PCR was performed using UPL Probes Master and Probes (Roche, Penzberg, 
Germany) on a LightCycler 480TM system with GAPDH as a housekeeper. Following 
primers were used: EG5 (probe #100): forward: TTCCCCTGCATCTTTCAATC, reverse: 
TTCAGGCTTATTCATTATGTTCTTTG (Sigma Aldrich, Munich, Germany); ZEB1 (probe 
#52): forward: GCCAACAGACCAGACAGTGTT, reverse: TCTTGCCCTTCCTTTCCTG; 
GAPDH (probe #45): forward: TCCACTGGCGTCTTCACC, reverse: 
GGCAGAGATGATGACCCTTT (Sigma Aldrich, Munich, Germany). Results were 
analyzed using the ΔCT method. 
 
2.2.17 Proliferation assay 
 
Cells were seeded 24 h before transfection in 6-well plates with a density of 1.5x10
5
 
cells/well for T24 cells and 2x10
5
 cells/well for MDA-MB 231 cells in 2000 µL growth 
media. After 24 h, media was replaced by 750 µL fresh media, polyplex solution 
containing 5 µg miR-200c mimic or ctrl RNA (in 250 µL) was added to each well (final 
siRNA concentration/well: 370 nM) and incubated at 37 °C. Medium was replaced after 4 
h incubation time. At 24 h after transfection cells were detached with trypsin/EDTA, taken 
up in growth medium, centrifuged and 2000 MDA-MB 231 cells and 750 T24 cells were 
seeded in 96-well plates. Proliferation was measured at the indicated time points using 
CellTiter-Glo®. 
 
2.2.18 Doxorubicin resistance assay 
 
One day prior to transfection 3500 cells/well (T24) or 5000 cells/well (MDA-MB 231) were 
seeded. Before transfection the medium was replaced by 75 µL and 25 µL of post-
PEGylated polyplexes containing 500 ng miR-200c mimic or ctrl RNA (prepared as 
described above) were added to each well and incubated at 37 °C (final RNA 
concentration/well : 370 nM). Medium was replaced after 4 h incubation time. At 24 h 
after transfection cells were treated with 10 µM (T24) or 15 µM (MDA-MB 231) 
doxorubicin and incubated for 72 h. After this incubation time a MTT assay was 
performed. 
 
2.2.19 Cell cycle analysis 
 
Cells were seeded 24 h before transfection in 24-well plates with a density of 1.75x10
4
 
cells/well (T24) or 2.5x10
4  
cells/well (Huh7) in 1000 µL growth media. After 24 h, media 
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was replaced by 375 µL and polyplex solution containing 2.5 µg EG5-siRNA, miR-200c 
mimic or ctrl RNA in 125 µL was added and incubated at 37°C (final siRNA 
concentration/well: 370 nM). Medium was replaced after 45 min (Huh7) or 4 h (T24) 
incubation time and cells were incubated for the indicated time.  Afterwards, cells were 
detached with trypsin/EDTA, taken up in growth medium, centrifuged and incubated on 
ice for 3 h in propidium iodide staining solution (0.1 % sodium citrate, 0.1 % Triton X-100 
and 50 µg/mL propidium iodide). Thereafter, cells were washed, taken up in PBS and cell 
cycle was analyzed by flow cytometry at an excitation wavelength of 488 nm and 
detection of emission with a 613/20 bandpass filter. Cells were gated by 
forward/sideward scatter and pulse width for exclusion of doublets. Data were recorded 
by Cyan™ ADP flow cytometer (Dako, Hamburg, Germany) using Summit™ acquisition 
software (Summit, Jamesville, NY, USA) and analyzed by FlowJo® 7.6.5 flow cytometric 
analysis software.  
 
2.2.20 Scratch assay 
 
MDA-MB 231 cells were seeded 24 h before transfection in 6-well plates with a density of 
2x10
5
 cells/ well in 2000 µL growth media. After 24 h, media was replaced by 750 µL 
fresh media, polyplex solution containing 5 µg miR-200c mimic or ctrl siRNA (in 250 µL) 
was added to each well (final RNA concentration/well: 370 nM) and incubated at 37 °C. 
Medium was replaced after 4h incubation time. After 24 h, cell layer was broken through 
a scratch using a 200 µL pipette tip. Cells were washed with PBS and microscope 
(Axiovert 200, Zeiss, Oberkochen, Germany) pictures were taken at different time points. 
Image J was used for statistical analysis. 
 
2.2.21 Mitotic aster formation 
 
Huh7/eGFPLuc cells were seeded 24 h before transfection in an 8-well Labtek chamber 
slide with a density of 2x10
4
 cells/ well in 300 µL media. After 24 h, media was replaced 
by 225 µL, 75 µL of PEGylated polyplexes containing 1.5 µg siRNA were added to each 
well (final siRNA concentration/well: 370 nM) and incubated for 45 min at 37 °C. 
Afterwards, media was replaced and cells were incubated for 48 h. Thereafter, cells were 
washed twice with 500 µL PBS and fixed with a 4% paraformaldehyde solution for 30 min 
at RT. After two washing steps, cells were incubated with DAPI in PBS (1:500) for 15 min 
at RT. An Axiovert 200 fluorescence microscope (Zeiss, Oberkochen, Germany) was 
used for image acquisition. 
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2.2.22 In vivo experiments 
 
All in vivo experiments were performed in female NMRI nu/nu mice (Janvier, Le Genest-
St-Isle) housed in isolated ventilated cages with a 12 h day/night interval and food and 
water ad libitum. For biodistribution in tumor bearing mice 1 × 10
6
 L1210 cells were 
injected subcutaneously into the left flank of animals. Animals were treated after tumors 
reached an appropriate volume of 500−700 mm3. Animal experiments were performed by 
Eva Kessel (vet MD student, Pharmaceutical Biotechnology, LMU Munich) according to 
guidelines of the German law of protection of animal life and were approved by the local 
animal experiments ethical committee. 
 
2.2.23 Biodistribution of polyplexes 
 
Polyplexes containing 50 μg of AHA1-siRNA, 50% Cy7-labelled and 50% nonlabelled, 
were mixed in a total volume of 200 μL for non-PEGylated polyplexes and 250 μL for 
PEGylated polyplexes. Mice were anesthetized with 3% isoflurane in oxygen, and 
polyplexes were injected into the tail vein. Distribution of polyplexes was measured after 
0 min, 15 min, 30 min, 1 h, 4 h, and 8 h using a CCD camera and analyzed via Living 
Image software. Experiments were performed in triplicates. 
 
2.2.24 RT-qPCR of AHA1-siRNA in organs 
 
RNA was extracted from organs using peqGOLD TriFastTM (PEQLAB Biotechnology 
GmBH, Germany) according to the manufacturer’s protocol. RNA (1 μg) was transcribed 
with qScript microRNA cDNA synthesis kit (Quanta BioScience, USA) into cDNA. RT-
qPCR was performed using PerfecTa SYBR Green SuperMix (Quanta BioScience, USA) 
on a LightCycler 480 system (Roche, Germany) with miR-191 as a housekeeper. 
Following primers were used: miR-191 forward, GCGCAACGGAATCCCAAAAG, and 
AHA1 forward, GAGACTAATCTCCACTTC (Sigma-Aldrich, Munich, Germany). Results 
were analyzed using the ΔCT method. 
 
2.2.25 Statistical analysis 
 
Unless otherwise stated, results are presented as arithmetic mean ± standard deviation 
(SD) and the number of replicates. Statistical significance was determined in two-tailed t-
tests or 2-way ANOVA. Significance levels were used as indicated. 
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3 Results 
 
3.1 Integration of twin disulfides into sequence-defined oligomers 
for stabilization of siRNA polyplexes  
 
This chapter has been partly adapted from: 
Philipp M. Klein, Katharina Müller, Christina Gutmann, Petra Kos, Ana Krhac Levacic, 
Daniel Edinger, Miriam Höhn, Jean-Christophe Leroux, Marc A. Gauthier, Ernst Wagner, 
“Twin disulfides as opportunity for improving stability and transfection efficiency of 
oligoaminoethane polyplexes”,  Journal of Controlled Release, 2015, 205:109-19. 
 
Efficient siRNA delivery with cationic oligomers is strongly dependent on polyplex 
stability. Therefore several stabilizing domains, such as hydrophobic and aromatic motifs 
and cysteines forming disulfide bridges have been integrated into oligomers [65, 73, 
150]. Wu et al. found a new bioreducible motif with orthogonal disulfide pairing forming 
stable dimers and multicyclic structures when integrated into peptides [151]. This so 
called twin disulfide motif consists of two cysteines with another amino acid in-between: 
CXC. Arginine as central amino acid (CRC) has been proven advantageous for stable 
peptide dimerization. As will be described in detail in the PhD thesis of Philipp Klein 
(Pharmaceutical Biotechnology, LMU Munich), the CRC motif was integrated into 
sequence defined oligomers to enhance the stability and transfection efficiency of siRNA 
polyplexes compared to carriers with a single cysteine residue [144]. Structure-activity 
relations of oligomers with and without PEG chains or targeting ligands were examined.  
 
3.1.1 Previous design and biophysical characterization of CRC containing 
oligomers 
 
The oligomer 386 (3arm) served as lead structure for the design of CRC containing 
oligomers (Figure 6). It consists of three arms, each containing three Stps for siRNA 
binding and endosomal buffering. 386 has proven high siRNA binding and gene silencing 
in previous studies [65, 150]. The CRC motif was incorporated into each arm replacing 
the cysteine residue of 386 in ascending numbers. Additionally, the influence on targeted 
delivery of CRC was examined using 2-arm oligomers, each arm with four Stps and a 
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terminal cysteine or CRC motif. FolA was used as targeting ligand and PEG24 as 
shielding reagent. FolA targeted polyplexes have been shown efficient siRNA delivery 
before in combination with the influenza hemagglutinin H2A derived peptide INF7 [56]  
coupled to siRNA for endosomal release [57]. To examine receptor specificity of targeted 
polyplexes FolA was additionally replaced by succinic acid (SucA), which has the same 
negative charge, but does not bind to the folate receptor. The library of CRC containing 
oligomers (synthesized by Philipp Klein, PhD student, Pharmaceutical Biotechnology, 
LMU Munich) is presented in Figure 6. 
 
 
Figure 6. Topology of sequence-defined 3-arm and PEGylated 2-arm oligomers. Schematic overview of the 
structures with different modifications (C: cysteine, CRC: cysteine-arginine-cysteine, FolA: folic acid, SucA: 
succinic acid Stp: succinoyl-tetraethylene-pentamine, K: lysine). Each structure has a short name and an internal 
database identification number. The formation of disulfide bonds, respectively twin disulfide bonds, occurs during 
the incubation with nucleic acid (bottom of figure). Adapted from [144]. 
 
Next, Philipp Klein examined particle sizes and zeta potentials of polyplexes via dynamic 
light scattering (DLS) and via the application of an electric field using a Zetasizer Nano 
ZS (Figure 7). 
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Figure 7. Particle size (Z-average) and zeta potential of siRNA polyplexes of A) three arm oligomers and B) 
PEGylated oligomers formed in HEPES buffer. Polyplexes were diluted 1:20 with HEPES before measurement. 
Variations refer to the median of three measurements of the sample. The study was performed by Philipp Klein 
(PhD student, Pharmaceutical Biotechnology, LMU Munich). Adapted from [65] and [144].  
 
3arm formed large particles almost in the micrometer range at N/P (ratio between 
protonatable amines of oligomers and phosphates of siRNA) 12 and 20 [65]. With the 
introduction of CRC the size successively decreased from about 800 nm for 3arm to less 
than 200 nm for 3CRC-3arm (Figure 7A) displaying a better siRNA compaction of 
oligomers containing the CRC motif. Additionally, the polydispersity index (PDI) 
decreased with increasing number of twin disulfides, which indicated uniform shaped 
particles. In contrast, the zeta potential increased from about 18 mV (3arm) to about 30 
mV (3CRC-3arm). For PEGylated oligomers suitable sizes were obtained for all 
formulations (Figure 7B). Oligomers containing the CRC motif (CRC-PEG-Cont, CRC-
PEG-FolA) displayed larger sizes compared to oligomers with only one terminal cysteine 
(PEG-Cont, PEG-FolA). Additionally, the influence of folic acid as hydrophobic ligand 
was very noticeably as FolA-particles were significantly larger (105 nm without CRC and 
171 nm with CRC) compared to untargeted controls (65 nm without CRC and 95 nm with 
CRC). The zeta potential was around 0 mV for all PEGylated particles showing a perfect 
shielding. 
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The siRNA binding ability of oligomers was examined in gel shift assays (Figure 8). In 
this assay free siRNA migrates in the gel due to its negative charge, whereas in 
polyplexes siRNA is retained in the pockets of the gel.  
 
 
Figure 8. Stability and siRNA binding of polyplexes of A) three-arm oligomers at indicated N/P ratios, B) 
PEGylated oligomers at indicated N/P ratios, C) PEGylated oligomers at N/P 20 incubated in serum at 37°C for 
indicated time points and D) PEGylated oligomers at N/P 20 after GSH incubation in different concentrations. Left 
lanes: free siRNA. Gel shifts were performed by Philipp Klein (PhD student, Pharmaceutical Biotechnology, LMU). 
Adapted from [144].  
 
The siRNA binding of 3arm in comparison to 1CRC-3arm, 2CRC-3arm and 3CRC-3arm 
was studied at N/P ratios from 3 to 20 (Figure 8A). All oligomers released siRNA at N/P 
3. With higher N/P ratios sufficient binding of siRNA could be observed in all cases. For 
PEGylated structures a clear effect of the CRC motif on siRNA binding could be 
demonstrated (Figure 8B). CRC containing oligomers revealed a higher siRNA binding at 
all N/P ratios in comparison to oligomers with only one terminal cysteine. The stability of 
PEG containing CRC oligomers was further investigated in the presence of serum at 
37°C (Figure 8C). These conditions should resemble in vivo conditions. Polyplexes were 
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incubated for 0 min, 10 min, 30 min and 90 min. After 90 min negatively charged heparin 
destroying the polyplexes via electrostatic disturbance was additionally added. Again, an 
enhanced stability could be observed with CRC containing oligomers at 0 min incubation 
time. With longer serum incubation siRNA was released in all cases regardless of the 
modification. Nevertheless, all oligomers bound the majority of siRNA after 90 min, which 
can be seen in comparison to released siRNA after heparin addition (90 min plus/minus 
heparin treatment). To obtain information about the behaviour of PEGylated polyplexes 
towards physiological reducing agents a gel shift in the presence of glutathione (GSH) 
was performed (Figure 8D). In nature, the GHS concentrations are 0.02 mM outside cells 
and 1-11 mM inside cells. Polyplexes should be stable outside cells and should 
disintegrate inside the cell to release their cargo. Therefore GSH concentrations from 0 
to 10 mM were tested. For oligomers having only one terminal cysteine the siRNA 
binding was weak at all GSH concentrations with a tendency towards less binding with 
increasing GSH. The incorporation of the CRC motif increased the stability of polyplexes 
significantly with no difference between GSH concentrations.  
 
3.1.2 Cellular internalization of CRC containing oligomers 
 
Within the current thesis, the intracellular distribution of polyplexes was examined by 
confocal laser scanning microscopy in mouse neuroblastoma Neuro2A/eGFPLuc cells or 
human cervix carcinoma KB/eGFPLuc cells (Figure 9). KB cells overexpress the folate 
receptor (FR) and are therefore used for the investigation of FolA targeted delivery. 
siRNA was spiked with Cy-5 labelled siRNA (red) and polyplexes were incubated on cells 
for 24 h (3-arm oligomers, Figure 9A) and 45 min (PEGylated oligomers, Figure 9B) at 
37°C. The short time incubation of 45 min should avoid unspecific uptake of particles.  
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Figure 9. Intracellular distribution of A) 3-arm siRNA polyplexes in Neuro2A/eGFPLuc cells and B) PEGylated 
siRNA polyplexes in KB/eGFPLuc acquired by confocal laser scanning microscopy. Polyplexes were formed at 
N/P 20. Nuclei were stained with Hoechst 33342 (blue), actin was stained with rhodamine phalloidin (green) and 
siRNA was spiked with 20% Cy5 labelled siRNA (red). The images show the overlay of the different channels. 
Blue arrows point at polyplexes inside cells. In vitro preparation was carried out by Katharina Müller; microscopy 
pictures were taken by Miriam Höhn (Pharmaceutical Biotechnology, LMU). Adapted from [144].  
 
An equal distribution of particles could be observed for all 3-arm oligomers (Figure 9A). 
3arm without twin disulfides revealed large aggregated polyplexes in cellular vehicles in 
comparison to 3CRC-3arm, which formed very small particles, consistent with DLS 
measurements. PEGylated polyplexes without targeting ligand were almost not visible in 
cells indicating a minor uptake. On the other hand, FolA containing polyplexes could be 
observed inside cells for both, PEG-FolA and CRC-PEG-FolA showing a clear targeting 
effect. For CRC-PEG-FolA a denser distribution in cells was found. The receptor specific 
uptake of PEGylated polyplexes was further investigated via flow cytometry (Figure 10). 
Once again, a superior uptake of PEGylated oligomers could be demonstrated with FolA 
containing oligomers in comparison to oligomers without targeting ligand with and without 
CRC motif.  
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Figure 10. Cellular internalization of Cy5-labelled siRNA (N/P 20) polyplexes after 45 min incubation time on cells 
determined by flow cytometry. The intensity of the Cy5 signal indicates the amount of polyplexes being 
internalized by KB/eGFPLuc cells. A) PEG-Cont (gMFI = 8.07) in solid gray, PEG-FolA (gMFI= 15.9) in solid black 
and HBG buffer only treated cells in dotted gray. B) CRC-PEG-Cont (gMFI= 18.3) in solid gray, CRC-PEG-FolA 
(gMFI = 31.4) in solid black and HBG buffer (gMFI= 4.54) only treated cells in dotted gray. gMFI indicates the 
geometric mean fluorescence intensity. Adapted from [144].  
 
 
3.1.3 Gene silencing of CRC containing oligomers 
 
Gene silencing experiments were performed in N2A/eGFPLuc cells or KB/eGFPLuc 
cells, both stably expressing an eGFP-luciferase fusion protein (Figure 11). Polyplexes 
were transfected with siRNA against eGFP (eGFP siRNA) or control siRNA (ctrl siRNA) 
with no silencing capacity (Figure 11 A,B). Additionally, INF7 was attached to eGFP 
siRNA or ctrl siRNA in order to enhance the endosomal escape (see chapter 1.3 and 
1.4.3) of PEGylated oligomers (Figure 11 C). Polyplexes were incubated on cells at 37 
°C for 48 h (Figure 11A) or, in case of targeted PEGylated oligomers, for 45 min to avoid 
unspecific uptake (Figure 11B,C). 
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Figure 11. Gene silencing of A) 3-arm structures and B, C) PEGylated structures. Polyplexes containing eGFP-
targeted siRNA (eGFP siRNA) or control siRNA (ctrl siRNA) were tested in (A) Neuro2A/eGFPLuc or (B) 
KB/eGFPLuc cells. C) Polyplexes containing eGFP-targeted INF7-siRNA (INF7-eGFP siRNA) or control INF7-
siRNA (INF7-ctrl siRNA) were tested in KB/eGFPLuc cells. Polyplexes at the indicated N/P ratios were incubated 
on cells for 45 min (B,C) or 48 h (A). Top: polyplexes with single cysteine oligomers. Bottom: polyplexes with twin 
disulfide-forming oligomers. PEI-Suc-10% serves as positive control. Data are presented as mean value (±SD) 
out of triplicates; notes on top of transfection bars without arrow indicate if there is statistical significance between 
single cysteine structure and its corresponding CRC analogous for same N/P (n. s.= p > 0.05; *p < 0.05; **p < 
0.01; ***p < 0.001, Student's t-test, two-tailed). Adapted from [144]. 
 
The oligomer 3arm showed very good gene knockdown at N/P ratios from 3 to 20. 
Interestingly, the insertion of the CRC motif abolished gene silencing in all cases (Figure 
11A). PEGylated oligomers revealed no gene silencing efficiency, when transfected 
without INF7-eGFP siRNA (Figure 11B). When INF7 was coupled to siRNA, gene 
silencing could be observed (Figure 11C). CRC-PEG-FolA showed gene silencing 
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efficiency up to 70 % at N/P 20 whereas only 20 % knockdown could be achieved with 
PEG-FolA. Here, the insertion of the twin-disulfide motif was beneficial in comparison to 
single terminal cysteines. For control structures without FolA (PEG-Cont and CRC-PEG-
Cont) only moderate gene knockdown could be observed confirming the FolA ligand-
dependent uptake.  
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3.2 Folate-PEG-oligomer conjugates for targeted siRNA delivery 
 
This chapter has been partly adapted from: 
Dongsheng He, Katharina Müller, Ana Krhac Levacic, Petra Kos, Ulrich Lächelt and 
Ernst Wagner, “Combinatorial Optimization of Sequence-Defined 
Oligo(ethanamino)amides for Folate Receptor-Targeted pDNA and siRNA Delivery”, 
Bioconjugate Chemistry, 2016, 27 (3), 647–659.  
 
FolA, which led to potent and receptor specific siRNA delivery when coupled to CRC-
oligomers, was furthermore attached to different oligomer topologies to figure out 
structure-activity relationships of targeted sequence-defined oligomers. Targeting the FR 
is a widely used strategy as it is overexpressed in many cancer types and binds folic acid 
with high affinity (see chapter 1.4.2). By using SPS various oligomer combinations can 
be synthesized fast, precise and pure. With this method 42 sequence-defined oligomers 
containing FolA or control amino acids without targeting effect were synthesized by Dr. 
Dongsheng He (PhD thesis 2016, Pharmaceutical Biotechnology, LMU Munich) and 
analyzed for their targeted pDNA or siRNA delivery efficiency. The current thesis 
focussed on the biological evaluation of siRNA polyplexes. 
 
3.2.1 Previous design and biophysical characterization of FolA-PEG- oligomer 
conjugates 
 
Based on the previously published and highly efficient oligomer 356 [57] different 
topologies and building block combinations were established. 356 formed only 
monomolecular particles, as the high PEG content prevented intermolecular nucleic acid 
compaction. Thus, the two-arm structure was only partially retained in this study. For 
some oligomers it was extended to four arms to enhance the amount of positive charges. 
The arms were branched through lysines and contained the cationic siRNA binding 
regions Stp (five nitrogens) or Sph (six nitrogens). As 356 transfected only with INF7 
modified siRNA, alternating histidines were added to some oligomers for endosomal 
buffering [78]. To enhance the stability of polyplexes tyrosine trimers for hydrophobic 
interactions [73] and terminal cysteines for disulfide bridge formation [57, 150] were 
additionally integrated.  
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Figure 12. Overview of oligomer topologies and compositions. L: FolA (folic acid) ligand or corresponding 
negative control (A, alanine; E, glutamate); PAA, poly(amino acid) (Stp, succinoyl-tetraethylene-pentamine; Sph, 
succinoyl-pentaethylene-hexamine); PEG, polyethylene glycol; K, lysine; H, histidine; Y, tyrosine; C, cysteine.  
K-(and K-[ refer to branchings by α- and ε-amino modification of lysines. Adapted from [67]. 
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Twenty-four PEG units served as shielding domains [118] and FolA as targeting ligand. 
In order to examine the targeting effect of these oligomers, FolA was replaced by 
alanine, glutamate or acetate. These combinations resulted in 42 oligomer structures 
(synthesized by Dr. Dongsheng He, PhD thesis 2016, Pharmaceutical Biotechnology, 
LMU Munich), which are presented in Figure 12. 
The siRNA binding ability of selected oligomers was examined in gel shift assays (Figure 
13). As already observed for 356 [57] only weak siRNA retention could be found for two-
arm oligomers, which slightly improved with high N/P ratios. In comparison, the siRNA 
binding was enhanced with four-arm structures, e.g. #6 vs. #30 or #18 vs. #40. 
Unexpectedly, the insertion of tyrosine trimers did not enhance the stability, but weaken it 
(#2 vs. #14 or #22 vs. #36). In contrary, more siRNA could be found in the pockets when 
histidines were included (#10 vs. #18 or #36 vs. #40).  
 
Figure 13. Gel retardation assays of siRNA polyplexes formed in HBG at the indicated N/P ratios. Left lanes: free 
siRNA. Gel shifts were performed by Dr. Dongsheng He (PhD thesis 2016, Pharmaceutical Biotechnology, LMU 
Munich). Adapted from [67].  
 
The siRNA compaction was further examined in an ethidium bromide exclusion assay 
(Figure 14). In this assay the compaction can be monitored by the fluorescence intensity 
of intercalating ethidium bromide. In most cases, a higher siRNA compaction could be 
found for four arm oligomers in comparison to two arm oligomers. The best siRNA 
compaction ability could be observed for the basic two-arm (#1-4) and four-arm (#21-28) 
oligomers without additional tyrosines and histidines. Again, oligomers containing 
tyrosine trimers revealed the worst siRNA compaction ability. 
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Figure 14.  siRNA compaction of oligomers determined by ethidium bromide exclusion assay at N/P 12 with LPEI 
N/P 6 as control. Measurements were performed by Dr. Dongsheng He (PhD thesis 2016, Pharmaceutical 
Biotechnology, LMU Munich). Adapted from [67].  
 
3.2.2 Gene silencing and cellular internalization of FolA-PEG-oligomer 
conjugates 
 
In the current thesis, gene silencing of the oligomer library was tested in KB/eGFPLuc 
cells because of their high FR expression (Figure 15, 2-arm oligomers, and Figure 16, 4-
arm oligomers). Polyplexes were transfected with eGFP siRNA in comparison to ctrl 
siRNA. Additionally, siRNA modified with INF7 peptide was used to enhance the 
endosomal escape. Here again, a short incubation time of 45 min at 37 °C was chosen to 
examine the targeting effect. Consistent with previous studies [57] 356 showed high 
gene silencing with INF7-eGFP siRNA and only moderate gene silencing with eGFP 
siRNA. In comparison, the same structure without FolA (188) did not transfect 
KB/eGFPLuc cells demonstrating a targeting effect. When Stp was replaced by three 
Sph (#1-2) (Figure 15) only moderate gene silencing could be observed with INF7-eGFP 
siRNA. On the other hand, oligomers containing four Sph (#3-4) showed superior gene 
silencing, but without receptor specificity. The insertion of histidines into two-arm 
oligomers (#5-8) did not lead to higher transfection efficiency compared to 356.  
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Figure 15. Gene silencing in folate receptor-expressing KB/eGFPLuc cells of 2-arm oligomers. Polyplexes formed 
with eGFP targeted siRNA (eGFP siRNA), control siRNA (ctrl siRNA), and corresponding INF7 peptide modified 
siRNA (INF7-eGFP siRNA and INF7-ctrl siRNA) at N/P 6, 12 and 20 or 24 were tested for eGFPLuc gene 
silencing. Cells were incubated with polyplexes for 45 min at 37°C. Luciferase activities at 48 h after transfection 
are presented as a percentage of relative light units (RLU) obtained with buffer treated control cells. Data are 
shown as mean ± SD (n = 3). Adapted from [67].  
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Figure 16. Gene silencing in folate receptor-expressing KB/eGFPLuc cells of 4-arm oligomers. Polyplexes formed 
with eGFP targeted siRNA (eGFP siRNA), control siRNA (ctrl siRNA), and corresponding INF7 peptide modified 
siRNA (INF7-eGFP siRNA and INF7-ctrl siRNA) at N/P 6, 12 and 20 or 24 were tested for eGFPLuc gene 
silencing. Cells were incubated with polyplexes for 45 min at 37 °C Luciferase activities at 48 h after transfection 
are presented as a percentage of relative light units (RLU) obtained with buffer treated control cells. Data are 
shown as mean ± SD (n = 3). Adapted from [67]. 
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Two-arm oligomers with tyrosine trimers (#9-16) displayed receptor specific, but still 
lower gene silencing. Very high knockdown efficiency (up to 93 %) could be obtained 
with the integration of both, histidines and tyrosine trimers (#17-20). These oligomers 
even transfected without INF7 modified siRNA, but not in a receptor specific manner. 
Basic four-arm oligomers (#21-28) showed effective gene silencing with INF7-eGFP 
siRNA, regardless of the cationic backbone, but again without targeting effect (Figure 
16). With the insertion of histidines (#29-34) the transfection efficiency was slightly 
reduced. Remarkably, oligomer #30 transfected receptor specifically as its negative 
control #29 showed worse gene silencing. Four-arm oligomers modified with tyrosine 
trimers completely lost their gene silencing ability (#35-38). Again, 4-arm oligomers 
modified with histidines and tyrosine trimers revealed very high, but unspecific, 
knockdown even without INF7-eGFP siRNA and at low N/P ratios (#39-42). These 
oligomers also reduced the luciferase activity with ctrl siRNA indicating an unspecific 
cytotoxicity. All other oligomers revealed sufficient biocompatibility as they did not show 
that high unspecific luciferase reduction. Figure 17 shows the cellular internalization in 
KB/eGFPLuc cells of oligomers determined by flow cytometry. Here, only oligomers that 
revealed receptor specific gene silencing and the highly efficient 2-arm-H-Y3 formulation 
were chosen. FolA containing oligomers #14, #18 and #30 were examined in comparison 
to their negative controls #13, #17 and #29. All FolA-oligomers showed a slightly higher 
cellular uptake than their corresponding oligomers without FolA with the clearest result 
for #30. The high cellular internalization of #17 and #18 confirmed the high transfection 
efficiency. 
 
Figure 17. Cellular internalization of Cy5-labelled siRNA (N/P 12) polyplexes after 45 min incubation time on 
KB/eGFPLuc cells determined by flow cytometry. The intensity of the Cy5 signal indicates the amount of 
polyplexes being internalized by KB/eGFPLuc cells. Light gray curve: HBG buffer treated cells; dark gray curve: 
ligand free control oligomers treated cells; and black curve, folate containing oligomers treated cells. All 
experiments were performed in triplicates. One representative histogram is shown. Adapted from [67].  
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3.3 Native chemical ligation for the equipment of siRNA polyplexes 
with shielding and folic acid targeting 
 
This chapter has been partly adapted from: 
Can Yang Zhang, Petra Kos, Katharina Müller ,Waldemar Schrimpf, Christina Troiber, 
Ulrich Lächelt, Claudia Scholz , Don C. Lamb and Ernst Wagner, “Native chemical 
ligation for conversion of sequence-defined oligomers into targeted pDNA and siRNA 
carriers”, Journal of  Controlled Release, 2014, 180:42-50. 
 
In this chapter, native chemical ligation (NCL) [152-154] was applied to facilitate the 
screening process of sequence defined oligomers for their ability to deliver siRNA 
receptor specifically. Here, in contrary to the previous chapters PEG and FolA were not 
attached to oligomers in the SPS process, but to already synthesized ones. With the 
NCL method, which was adapted for SPS by Blanco-Canosa et al. [155], oligomers 
without targeting ligand containing N-terminal cysteines could be selected from our 
existing library and easily equipped with PEG and FolA under mild conditions in almost 
quantitative yields. In the NCL reaction (performed by Dr. Can Yang Zhang (visiting PhD 
student at LMU Munich in 2013)) an amide bond is formed by transthioesterification 
followed by intramolecular nucleophilic rearrangement between the thioester and 
cysteine (Figure 18). For the successful reaction an oligomer with an N-terminal cysteine 
and a ligation partner with a C-terminal, aromatic N-acylurea moiety (such as N-acyl-
benzimidazolinone, Nbz) are necessary.  
 
 
Figure 18. Native chemical ligation (NCL) of Nbz-PEG24-L oligomer and an oligomer with N-terminal cysteines 
resulting in a new PEGylated oligomer. L: FolA or alanine; ligation buffer: 6 M guanidinium hydrochloride, 200 mM 
disodium hydrogen phosphate, 20 mM tris(2-carboxyethyl)phosphine hydrochloride (TCEP*HCl) and 200 mM 4-
mercapto-phenylacetic acid. Adapted from [145]. 
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3.3.1 Design of shielded and FolA-targeted oligomers obtained via NCL 
 
Six non-targeted oligomers of different topologies were selected for the modification via 
NCL (Figure 19). Two 2-arm structures (468, 465), three 3-arm structures (386, 512, 589) 
and one 4-arm structure (606) were chosen as they have proven efficient pDNA and/or 
siRNA delivery in previous studies [65, 73, 78]. Oligomers contained the siRNA binding 
domains Stp (468, 465, 386, 589) or Sph (512, 606), stabilizing tyrosine trimers (468, 
465, 589) and histidines (606) enhancing the endosomal escape. The most important 
prerequisites for the NCL reaction were N-terminal cysteines, which all oligomers offered. 
 
 
Figure 19. Oligomers of different topologies used for NCL reaction. Adapted from [145]. 
 
The NCL ligation substrates 500 and 501 were synthesized by Dr. Can Yang Zhang 
(visiting PhD student at LMU Munich in 2013) and Dr. Christina Gutmann (former 
Troiber, PhD thesis 2013, LMU Munich) via SPS (Table 1). Both oligomers contain 24 
PEG units for shielding and N-acyl-benzimidazolinone (Nbz) for the reaction with the 
oligomer cysteines. The targeting ligand FolA was integrated into 500; 501 served as 
control with alanine instead of FolA. For NCL a molar ratio of 1:1 (ligation substrate: 
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oligomer), in order to couple only one oligomer arm, was used resulting in twelve PEG-
shielded oligomers (659–670) with or without FolA-targeting (Table 1).  
 
Table 1. Activated NCL substrates and oligomers synthesized via NCL. All oligomers were synthesized by Dr. 
Can Yang Zhang (visiting PhD student at LMU Munich in 2013) and Dr. Christina Gutmann (former Troiber, PhD 
thesis 2013, LMU Munich). FolA: folic acid, targeting ligand; A: alanine, corresponding negative control. Adapted 
from [145].  
 topology No. sequence 
NCL 
substrates 
 
500 Nbz-G-PEG24-FolA 
501 Nbz-G-PEG24-A   
oligomers 
synthesized 
via NCL 
2-arm 
659 C-Y3-Stp2-K(K)-Stp2-Y3-C-G-PEG24-A  
660 C-Y3-Stp2-K(K)-Stp2-Y3-C-G-PEG24-FolA  
661 C-Stp2-K(K-(Y3)2)-Stp2-C-G-PEG24-A 
662 C-Stp2-K(K-(Y3)2)-Stp2-C-G-PEG24-FolA 
3-arm 
663 C-Sph3-K(Sph3-C)-Sph3-C-G-PEG24-A  
664 C-Sph3-K(Sph3-C)-Sph3-C-G-PEG24-FolA  
665 C-Stp3-K(Stp3-C)-Stp3-C-G-PEG24-A  
666 C-Stp3-K(Stp3-C)-Stp3-C-G-PEG24-FolA  
667 C-Y3-Stp3-K(Stp3-Y3-C)-Stp3-Y3-C-G-PEG24-A  
668 C-Y3-Stp3-K(Stp3-Y3-C)-Stp3-Y3-C-G-PEG24-FolA  
4-arm 
669 
A-K-(H-K-(H-Sph-H-Sph-H-Sph-H-C)2)-H-K-(H-Sph-H-Sph-H-
Sph-H-C)-H-Sph-H-Sph-H-Sph-H-C-G-PEG24-A  
670 
A-K-(H-K-(H-Sph-H-Sph-H-Sph-H-C)2)-H-K-(H-Sph-H-Sph-H-
Sph-H-C)-H-Sph-H-Sph-H-Sph-H-C-G-PEG24-FolA  
 
 
3.3.2 Biophysical characterization of shielded and FolA-targeted oligomers 
obtained via NCL 
 
Gel shift assays (Figure 20) revealed less siRNA binding ability of PEGylated oligomers 
compared to unmodified oligomers in all cases. The 2-arm topologies demonstrated 
almost no siRNA retention (659-662). 3-arm structures, especially with tyrosine trimers 
(667, 668), led to better siRNA binding at high N/P ratios. Significant, but moderate, 
siRNA retention was observed for the 4-arm structures (669-670). 
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Figure 20. siRNA binding of 2-arm (A), 3-arm (B) and 4-arm structures (C) at indicated N/P ratios. FolA-PEG: folic 
acid receptor targeted oligomer (FolA, folic acid); A-PEG: corresponding negative control for the evaluation of 
targeting effects (A, alanine); unmodified: oligomer before NCL reaction. Assays were performed by Dr. Can Yang 
Zhang (visiting PhD student at LMU Munich in 2013). Adapted from [145]. 
 
Polyplex sizes of unmodified and PEGylated oligomers were determined via DLS 
measurements (Table 2). Almost all oligomers formed big aggregates (>1800 nm) with 
siRNA. Only the 3-arm structures 589, 667 and 668 with tyrosine trimer modification 
revealed smaller particles (<600 nm). The zeta potential of polyplexes (Table 2) was 
significantly lowered through the modification with PEG. Unmodified oligomers revealed 
zeta potentials of +21 mV to +33 mV, which could be reduced to +1 mV to +10 mV for 
FolA-PEG polyplexes and to +7 mV to +17 mV for A-PEG polyplexes. Alanine controls 
demonstrated slightly higher zeta potentials than corresponding FolA-PEG oligomers 
presumably due to the terminal protonatable amine of alanine. 
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Table 2. Z-average [nm] and zeta potentials [mV] of siRNA polyplexes (N/P 16) formed in HEPES buffer 
determined with DLS. Variations refer to the median of three measurements of the same sample. Measurements 
were carried out by Dr. Can Yang Zhang (visiting PhD student in 2013). Adapted from [145]. 
topology No. modification Z-average [nm] Zeta potential [mV] 
2-arm 
468 unmodified 5423 ± 357 22.7 ± 0.7 
661  A-PEG 2978 ± 123 7.1 ± 0.3 
662  FolA-PEG 4215 ± 225 4.4 ± 0.1 
465  unmodified 4294 ± 205 23.1 ± 0.5 
659  A-PEG 1952 ± 173 9.2 ± 0.4 
660  FolA-PEG 3836 ± 214 1.3 ± 0.2 
3-arm 
512  unmodified 2000 ± 119 28.6 ± 0.8 
663  A-PEG 2108 ± 217 16.9 ± 0.5 
664  FolA-PEG 2530 ± 175 6.4 ± 0.15 
386  unmodified 2256 ± 126 23.3 ± 0.6 
665  A-PEG           2202 ± 12 15.3 ± 0.4 
666  FolA-PEG           2838 ± 39 4.3 ± 0.4 
589  unmodified           368 ± 27 21.3 ± 0.7 
667  A-PEG           276 ± 15 7.3 ± 0.8 
668  FolA-PEG           563 ± 44 2.5 ± 0.5 
4-arm 
606  unmodified           740 ± 31 33.5 ± 0.4 
669  A-PEG           833 ± 38 12.3 ± 0.6 
670  FolA-PEG 1725 ± 217 10.3 ± 0.5 
 
 
3.3.3 Gene silencing and cellular internalization of shielded and FolA-targeted 
oligomers obtained via NCL 
 
In the current thesis, the transfection efficiency was examined on FR-rich KB/eGFPLuc 
cells with 45 min incubation time at 37 °C in order to determine a targeting effect (Figure 
21). Polyplexes were tested with siRNA against eGFP, optionally with INF7 modification 
for enhanced endosomal escape and in comparison to ctrl siRNA. PEGylated polyplexes 
without targeting ligand (A-PEG), with FolA (FolA-PEG) and unmodified polyplexes were 
examined. No gene silencing was obtained with 2-arm polyplexes with central tyrosines 
(661, 662) in line with the insufficient siRNA binding ability as seen in gel shifts (Figure 
21A). PEGylated 2-arm polyplexes with peripheral tyrosine modification showed 
moderate transfection efficiency with INF7 for the untargeted structure (659) and no gene 
silencing with FolA ligand (660), whereas the unmodified corresponding structure (465) 
did transfect KB/eGFPLuc cells with and without INF7 (Figure 21B). FolA-PEGylated 3-
arm with Stp (666) showed high gene knockdown with INF7 modified siRNA and 
moderate gene knockdown without INF7 at high N/P ratios (Figure 21C). Corresponding 
A-PEG (665) and unmodified oligomer (386) demonstrated moderate gene silencing with 
INF7-siRNA, as well, but not as high as with FolA ligand. When Sph was inserted into 3-
arm oligomers high gene silencing with INF7-siRNA could be found for all modifications 
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without targeting effect (Figure 21D). In contrary, a clear targeting effect was 
demonstrated with 3-arm oligomers containing tyrosine trimers, when transfected with 
INF7-siRNA (667, 668) (Figure 21E). The negative control 667 did not transfect at all, 
whereas FolA targeted 668 showed gene silencing up to 70 %. Histidine modified 4-arm 
structures (Figure 21F) demonstrated minor transfection efficiency with FolA-PEG (670), 
that was nevertheless better than with the A-PEG control (669).  
 
 
 
 
Figure 21. Gene silencing (n=3, mean ± SD) of 2-arm oligomers with central (A) or peripheral (B) oligotyrosines; 
3-arms without (C (Stp), D (Sph)) or with oligotyrosines (E); and 4-arm oligomer with histidines (F) at indicated 
N/P ratios. Polyplexes were transfected on KB/eGFPLuc cells with 45 min incubation time. Each row compares A-
PEG, FolA-PEG or unmodified oligomers. For siRNA, different shadings from left to right indicate eGFP siRNA, 
ctrl siRNA, INF7-eGFP siRNA and INF7-ctrl RNA. Adapted from [145]. 
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The cellular internalization of oligomers showing targeting effects in transfections was 
further examined by flow cytometry (Figure 22). Here, 3-arm, 3-arm/Y3 or 4-arm/His 
polyplexes were incubated on KB/eGFPLuc cells for 45 min and 4 h. In all cases, FolA-
PEG (blue) polyplexes displayed higher cellular uptake in comparison to A-PEG (red) 
polyplexes confirming the enhanced FR mediated uptake. Unmodified polyplexes (green) 
displayed significant cellular internalization, as well, probably due to their positive charge 
and large sizes enhancing interactions with cell membranes. 
 
 
Figure 22. Cellular internalization of Cy5-labelled siRNA (N/P 12) polyplexes after 45 min and 4 h determined by 
flow cytometry. Dead cells (DAPI positive, less than 2%) were excluded from analysis. The intensity of the Cy5 
signal indicates the amount of polyplexes being internalized by KB/eGFPLuc. Unmodified oligomers are 
presented in green, FolA-PEG oligomers in blue, alanine-PEG controls in red and HBG buffer only treated cells in 
grey. All experiments were performed in triplicates. One representative histogram is shown. Adapted from [145]. 
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3.4 Post-PEGylation of siRNA lipo-oligoamino amide polyplexes for 
receptor specific siRNA and miRNA delivery 
 
3.4.1 Post-PEGylation principle 
 
Post-PEGylation has been applied to convert untargeted and non-shielded pDNA/PEI 
polyplexes into carriers having these functional domains [156-158]. In contrary to NCL, 
already formed polyplexes, not oligomers, were modified in order to avoid problems with 
siRNA packaging into the polyplex core. In this thesis, the established post-PEGylation 
concept was transferred to sequence-defined oligomers for siRNA delivery. For polyplex 
formation two precise T-shaped cationic lipo-oligomers, 454 (chapter 3.4.2 and 3.4.3) 
and 595 (chapter 3.4.2), were selected (Figure 23A). These structures were generated 
by SPS and contain four units Stp, two lysines for branching and linkage with the two 
central oleic acids, two hydrophobic tyrosine trimers, and two terminal cysteines (454) or 
CRC units (595). The incorporation of tyrosine trimers and the CRC motif has been 
shown to be beneficial for the stability of siRNA polyplexes in previous chapters. Oleic 
acids improved the stability of polyplexes via hydrophobic interactions and enhanced 
endosomal escape due to endosomolytic activity in previous studies [78, 150].  Terminal 
cysteines or twin disulfides are beneficial for siRNA polyplex stability due to their strong 
disulfide bridge formation [144, 151]. The two chosen oligomers combine foresaid 
moieties and were used as efficient and stable carriers for non-targeted siRNA delivery 
before [73, 144]. For polyplex formation an N/P ratio of 10 was used. After 45 min of 
polyplex formation, the particles were incubated for another 15 min with the post-
PEGylation reagents consisting of maleimide linked with PEG28 and a ligand (Figure 
23B). Maleimide reacts with free cysteine thiols of polyplexes that are not engaged in 
internal disulfide bridge formation.  
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Figure 23. Schematic overview (A) of oligomers 454 and 595. (B) Polyplex formation and post-PEGylation of 
polyplexes. L: targeting ligand. 454 and 595 were synthesized by Philipp Klein (PhD student, Pharmaceutical 
Biotechnology, LMU Munich). Adapted from [146]. 
  
3.4.2 Post-PEGylation using tetra-glutamylated folic acid as ligand for 
receptor-targeted delivery 
 
This chapter has been adapted from: 
Katharina Müller, Eva Kessel, Philipp M. Klein, Miriam Höhn and Ernst Wagner, “Post-
PEGylation of siRNA lipo-oligoamino amide polyplexes using tetra-glutamylated folic acid 
as ligand for receptor-targeted delivery”, Molecular Pharmaceutics, 2016, 13(7):2332-45. 
 
 
 
For the post-PEGylation of T-shaped lipo-oligomer siRNA polyplexes FolA was used as 
targeting ligand as it has shown its potency before. In addition to standard hydrophobic 
FolA, an alternative tetra-γ-glutamyl folic acid ligand (gE4-FolA) with four additional 
negative charges was applied (Figure 24). This biomimetic modification resembles the 
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natural cellular polyglutamylation of FolA [159, 160]. Studies with methotrexate-
containing polymers have confirmed the beneficial effect of such an oligoglutamylation in 
FR-targeted delivery [68, 161]. Twenty-eight PEG units were used as shielding domains.  
 
 
Figure 24. Amino acid sequence of the post-PEGylation reagents Mal-PEG28-FolA (FolA), Mal-PEG28-gE4-FolA 
(gE4-FolA) and ligand free Mal-PEG28-OH (Mal-PEG). Post-PEGylation reagents were synthesized by Philipp 
Klein (PhD student, Pharmaceutical Biotechnology, LMU Munich). Adapted from [146]. 
 
 Biophysical characterization of post-PEGylated polyplexes 3.4.2.1
 
The equivalents of added post-PEGylation reagents were defined as relative molar ratios 
to the oligomer molecules 454 or 595 applied in the polyplex formation. As each oligomer 
contains two (454) or four (595) cysteines, in theory maximum 2 or 4 eq of PEG-reagent 
for 454 or 595, respectively, might be coupled to bind all cysteines. However, the number 
of mercapto groups available after siRNA polyplex formation is reduced because of the 
intended, stabilizing oxidative disulfide cross-linkage of oligomers. The coupling reaction 
between oligomer cysteines and ligand-free maleimide-PEG (Figure 24) was verified by 
an Ellman’s assay (Figure 25).  
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Figure 25. Percentage of residual cysteine mercapto (SH) groups as determined with Ellman´s assay (n=3, mean 
±SD) for A) 454 and B) 595 polyplexes (formed by incubation for 45 min at RT with 500 ng siRNA at N/P 10) after 
modification with increasing molar equivalents of Mal-PEG for further 15 min at RT. The percentage of free 
mercapto groups is based on the theoretical amount (100%) of cysteines (i.e. 2 or 4 molar equivalents in 
oligomers 454 or 595, respectively) applied in the polyplex formation. Adapted from [146].  
 
The percentage of residual free cysteine mercapto groups after polyplex formation, but 
before PEGylation (Figure 25, “0 eq Mal-PEG”) was 36 % (0.72 mol eq of mercapto 
groups) in the case of 454 and 37 % (1.48 mol eq of mercapto groups) in the case of 
595, demonstrating that the majority of mercapto groups had already reacted during the 
45 min polyplex formation. After reaction with PEGylation reagent for further 15 min a 
PEG equivalents-dependent decrease of free cysteines could be observed, 
demonstrating successful post-PEGylation of polyplexes. A difference in 454 and 595 
polyplex reactivity toward PEG within this short 15 min time period was observed. For 
454 polyplexes, one molar equivalents (1 eq) of Mal-PEG resulted in a consumption of 
mercapto groups to residual 17 % (0.34 molar eq of mercapto groups) and did not further 
reduce unless an excess of more than 5 eq of PEG was applied. Most likely, mercapto 
groups hidden within the polyplex but not engaged in disulfide bridges are sterically 
hindered and not available for PEGylation. Zeta potential measurements (see below) 
indicate further PEGylation beyond 1 eq, most probably by maleimide reaction with the 
oligomer amines [162]. In contrast 595 polyplexes reacted more avidly, reducing the 
mercapto equivalents from 1.48 (non-PEGylated) to 17 %/0.68 molar mercapto 
equivalents (by 1 eq of Mal-PEG) and to 0.7 %/0.03 molar mercapto equivalents by 3 eq 
of Mal-PEG. Particle sizes and zeta potentials of post-PEGylated polyplexes modified 
with Mal-PEG-FolA reagents were examined via dynamic light scattering (DLS) and via 
the application of an electric field using a Zetasizer Nano ZS (Figure 26). At low molar 
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equivalents the size of FolA ligand-PEG modified 454 and 595 particles ranged around 
100−150 nm in all cases (Figure 26C,D). With increasing amount of PEGylation reagent, 
the particles started to agglomerate. These findings are consistent with earlier reports 
describing the tendency of polymer-conjugated hydrophobic FolA to agglomerate [163]. 
PEGylation with ligand-free Mal-PEG did not display such an agglomeration 
phenomenon over a broad range of PEG equivalents, unless a very high excess of >5 eq 
was applied (Figure 26E,F). In case of the tetra-glutamylated folic acid ligand (gE4-FolA) 
and 454, the agglomeration started at 0.1 eq (Figure 26A), and in the case of 595, gE4-
FolA at 0.5 eq (Figure 26B). The same situation was found with maleimide-PEG28-folic 
acid (FolA), where particles agglomerated at 0.5 eq with 454 (Figure 26C) and at 1 eq 
with 595 (Figure 26D). Beyond one equivalent of gE4-FolA, the size of particles 
decreased again to an appropriate size of around 150 nm for both oligomers (Figure 
26A,B). This result demonstrated an improved repulsion of polyplexes modified with the 
tetraglutamylated PEGylation reagent due to the highly negative surface charge. 
Particles with suitable sizes also showed a PDI ≤ 0.2. In the case of standard FolA 
ligand, the agglomeration (sizes between 2000 nm and 8000 nm) was observed also at 
higher degrees of PEGylation equivalents, resulting into heterogeneous particles (Figure 
26C,D). The heterogeneity of FolA-particles could be seen in number size distributions 
as well (Figure 27). 
 
 
Figure 26 (first part). Z-average [nm], PDI determined in DLS and zeta potential [mV] (n=3, mean ± SD) of 454 
polyplexes (A, C, E) and 595 polyplexes (B, D, F) post-PEGylated with increasing molar equivalents of gE4-FolA 
(A, B), FolA (C, D) or Mal-PEG (E, F). Adapted from [146].  
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Figure 26 (continued) Z-average [nm], PDI determined in DLS and zeta potential [mV] (n=3, mean ± SD) of 454 
polyplexes (A, C, E) and 595 polyplexes (B, D, F) post-PEGylated with increasing molar equivalents of gE4-FolA 
(A, B), FolA (C, D) or Mal-PEG (E, F). Z-average (harmonic intensity averaged particle diameter) is given by 
cumulants analysis. Core polyplexes were formed at N/P 10 with a siRNA concentration of 25 µg/mL and a final 
siRNA concentration of 20 µg/mL after PEGylation. Adapted from [146].  
 
The effect of post-PEGylation on the surface charge of polyplexes is shown by zeta 
potential measurements in Figure 26. With no or low equivalents of PEGylation reagents 
(≤0.05 eq for 454; ≤0.1 eq for 595) the zeta potential was around +20 to +30 mV. In the 
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case of gE4-FolA the zeta potential was neutral at 0.1 eq for 454 (+1.43 mV) and 0.5 eq 
for 595 (−3.07 mV). At these equivalents polyplexes formed agglomerates (Figure 
26A,B). With higher molar equivalents of gE4-FolA the zeta potential decreased to 
around −20 mV for both oligomers.  
 
 
 
Figure 27. Number size distribution determined with DLS of 454 polyplexes (A) and 595 polyplexes (B) post-
PEGylated with increasing molar equivalents FolA. Three measurements are presented in different colours. Core 
polyplexes were formed at N/P 10 with a siRNA concentration of 25 µg/mL and a final siRNA concentration of 20 
µg/mL after PEGylation. Number averages were calculated from intensity distribution using Mie theory [164]. 
Adapted from [146].  
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Zeta potentials for particles post-PEGylated with FolA (Figure 26C,D) did not decrease 
as fast as with gE4-FolA and could not fall below −12 mV, as FolA only contains one 
negative charge, while gE4-FolA has five negative charges due to the tetra-
glutamylation. Considering these findings particles with suitable sizes and zeta potentials 
were obtained with molar equivalents of gE4-FolA of ≥2 eq. The number size distribution 
of polyplexes post-PEGylated with FolA is shown in Figure 27. A heterogeneous particle 
formation can be assumed as the measurements demonstrated different sizes for one 
formulation. Figure 28 shows the siRNA compaction within the PEGylated polyplexes 
determined with an EtBr assay. Polyplexes formed with oligomers without PEGylation 
showed 80% reduction of EtBr fluorescence, demonstrating good compaction of siRNA. 
For FolA-PEGylation, the siRNA compaction did not change (Figure 28C,D). PEGylation 
with gE4-FolA led to a higher EtBr fluorescence (only 60% reduction), indicating a 
reduction of siRNA compaction. 
 
 
Figure 28. siRNA compaction of post-PEGylated polyplexes determined with ethidium bromide. Lower intensity of 
EtBr fluorescence indicates better compaction of the nucleic acid within the polyplex. 100 % presents siRNA 
without oligomers (n=3, mean ± SD). 454 polyplexes (A, C) and 595 polyplexes (B, D) post-PEGylated with 
increasing molar equivalents of gE4-FolA (A, B) or FolA (C, D). Core polyplexes were formed at N/P 10 with a 
siRNA concentration of 25 µg/mL and a final siRNA concentration of 20 µg/mL after PEGylation. Adapted from 
[146].  
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  Gene silencing of post-PEGylated polyplexes 3.4.2.2
 
The transfection efficiency was determined in human cervix carcinoma KB/eGFPLuc 
cells overexpressing the folic acid receptor (Figure 29). Cells were incubated with 
formulations for a short period of only 45 min at 37 °C to avoid unspecific uptake of 
particles. Polyplexes were transfected with eGFP siRNA targeting the eGFP-luciferase 
and control siRNA (ctrl siRNA) with no gene silencing capacity. At low ratios of molar 
equivalents (0.01−0.05 eq) of both gE4-FolA and FolA PEG reagents, a moderate gene 
silencing comparable with non-PEGylated polyplexes (0 eq) was observed. PEGylated 
454 polyplexes with gE4-FolA ligand (Figure 29A) showed potent gene silencing of about 
90% for ≥1 eq PEG reagent. The knockdown remained high until 7 eq of applied PEG 
reagent. The transfections with control siRNA indicated some nonspecific effects for 1 eq 
(40%), which however resolved with a higher PEGylation. The transfection efficiency of 
PEGylated 595 polyplexes with gE4-FolA was highest for 1 eq (Figure 29B), but 
decreased with increasing equivalents of >1. At 4 eq gene silencing was not observed 
anymore. The reasons remained unclear; possibly free ligand-PEG reagent or ligand-
PEG reacted with free polymer could block the FR, making it inaccessible for targeted 
polyplexes; alternatively endosomal escape of polyplexes might have been hampered by 
abundant PEGylation. Toxic effects were not observed for 595 at any ratio of gE4-FolA. 
Encouragingly, extended incubation of cells for 1 and 2 days (instead of 45 min only) with 
595 PEGylated with 1.5 eq of gE4-FolA demonstrated a still retained receptor specificity 
of silencing (Figure 30A,B) and lack of cytotoxicity (Figure 30C,D). Polyplexes post-
PEGylated with standard FolA ligand (Figure 29C,D) led to efficient gene silencing with 
higher molar equivalents (≥1 eq) both for 454 and 595. In the case of 595 a 
heterogeneous gene silencing for 1 to 3 eq (50%, 83%, 50%) and a robust knockdown 
for 4−6 eq (about 86%) was observed. This heterogeneity in transfection efficiency might 
be explained with the tendency of these FolA-PEGylated particles to agglomerate (Figure 
26) leading to heterogeneous structures (Figure 27). 
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Figure 29. Gene silencing (n = 3, mean ± SD) of 454 polyplexes (A,C) and 595 polyplexes (B,D) post-PEGylated 
with increasing molar equivalents of gE4-FolA (A,B) or FolA (C,D). Polyplexes were incubated on KB-eGFP/Luc 
cells with 500 ng of siRNA targeting eGFP (eGFP siRNA) and 500 ng of control siRNA (ctrl siRNA) for 45 min. 
Oligomer 356, applied with 200 ng of Inf7 peptide-conjugated (eGFP or ctrl) siRNAs, served as positive control 
[57]. Core polyplexes were formed at N/P 10 with a siRNA concentration of 25 µg/mL and a final siRNA 
concentration of 20 µg/mL after PEGylation. Adapted from [146].  
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Figure 30. Gene silencing (A, B) and cell viability (C, D) of KB/eGFPLuc cells at extended incubation times with 
595 polyplexes PEGylated with 1.5 eq of gE4-FolA, 1.5 eq Mal-PEG or without PEGylation (n=3, mean ± SD). 
Polyplexes were incubated on cells for 24 h (A, C) or 48 h (B, D). Polyplexes were tested in KB-eGFP/Luc cells 
with siRNA targeting eGFP (eGFP siRNA) and ctrl siRNA. Core polyplexes were formed at N/P 10 with a siRNA 
concentration of 25 µg/mL and a final siRNA concentration of 20 µg/mL after PEGylation. Oligomer 356 is a 
folate-PEG containing oligomer serving as positive control. For endosomal escape, 356 polyplexes depend on 
INF7 peptide-conjugated (GFP or ctrl) siRNAs. Adapted from [146]. 
 
To evaluate the receptor specificity of transfections, folate receptors were blocked by 
incubating cells with folic acid-saturated medium at 30 min before transfection (Figure 
31). Gene silencing of gE4-FolA-PEGylated 454 and 595 polyplexes was completely lost 
at PEGylation >1 eq (Figure 31A,B). This, together with the data presented in Figure 29 
verifies a folic acid receptor-dependent gene silencing process, similar as for the 356 
positive control polyplexes. Figure 31 also revealed for both polymers a receptor-
independent transfection of 454 and 595 polyplexes when PEGylated with only 1 eq of 
gE4-FolA or when PEGylated with FolA at any equivalent (Figure 31C,D). The known 
agglomeration of these polyplexes (Figure 26) obviously reduces the folate receptor 
specificity. 
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Figure 31. Gene silencing (n = 3, mean ± SD) of 454 polyplexes (A,C) and 595 polyplexes (B,D) post-PEGylated 
with increasing molar equivalents of gE4-FolA (A,B) or FolA (C,D). Polyplexes were incubated on KB-eGFP/Luc 
cells with 500 ng of siRNA targeting eGFP (GFP siRNA) and 500 ng of control siRNA for 45 min. Cells were 
incubated 30 min before transfection with saturated folic acid media to block the folate receptor. Oligomer 356, 
applied with 200 ng of INF7 peptide-conjugated (GFP or control) siRNAs, serves as positive control [57]. Adapted 
from [146]. 
 
 Cellular internalization of post-PEGylated polyplexes 3.4.2.3
 
The cellular internalization of post-PEGylated particles into KB cells was investigated by 
flow cytometry (Figure 32). The uptake experiments were performed without or with 
blockade of the folic acid receptor, to examine receptor specificity. Cellular uptake of 
non-PEGylated polyplexes was high for both oligomers. For 100−200 nm small 454 or 
595 polyplexes, which were PEGylated with >1 eq of gE4-FolA, the uptake could be 
completely blocked with free folic acid (Figure 32A,B). For agglomerated particles formed 
with 1 eq of gE4-FolA or with PEG-FolA at any PEGylation ratio, cellular uptake was 
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extremely high, saturating the Cy5 fluorescence channel. Folic acid competition could 
only partly block internalization of these polyplexes (Figure 32C,D). This finding is 
consistent with the presence of particle agglomerates (Figure 27), resulting partly in 
receptor-independent uptake and gene silencing (Figure 31). 
 
 
 
Figure 32 (first part). Cellular internalization of Cy5-labelled siRNA determined by flow cytometry of 454 
polyplexes (A, C) and 595 polyplexes (B, D) post-PEGylated with increasing molar equivalents of gE4-FolA (A, B) 
or FolA (C, D). Internalization of polyplexes was examined in KB-eGFP/Luc cells after 45 min incubation at 37 °C. 
The intensity of the Cy5 signal resembles the amount of internalized polyplexes. “Count” represents cumulative 
counts of cells with indicated Cy5 fluorescence after gating by forward/sideward scatter and pulse width. Dead 
cells (DAPI positive, less than 2 %) were excluded from analysis. Post-PEGylated polyplexes are presented in 
black, blockade of post-PEGylated polyplexes (0.5 h incubation of cells with a saturated folic acid solution at 37 
°C) in orange and HBG buffer in grey. Core polyplexes were formed at N/P 10 with a siRNA concentration of 25 
µg/mL and a final siRNA concentration of 20 µg/mL after PEGylation. Experiments were performed in triplicates. 
One representative blot is shown. Adapted from [146]. 
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Figure 32 (continued). Cellular internalization of Cy5-labelled siRNA determined by flow cytometry of 454 
polyplexes (A, C) and 595 polyplexes (B, D) post-PEGylated with increasing molar equivalents of gE4-FolA (A, B) 
or FolA (C, D). Post-PEGylated polyplexes are presented in black, blockade of post-PEGylated polyplexes (0.5 h 
incubation of cells with a saturated folic acid solution at 37 °C) in orange and HBG buffer in grey. Core polyplexes 
were formed at N/P 10 with a siRNA concentration of 25 µg/mL and a final siRNA concentration of 20 µg/mL after 
PEGylation. Experiments were performed in triplicates. One representative blot is shown. Adapted from [146]. 
 
Confocal laser scanning microscopy provided information on the intracellular distribution 
of PEGylated polyplexes (Figure 33). Fluorescently labelled siRNA (red) and Mal-PEG 
(green) were used for spiking the siRNA and the PEGylation reagent, respectively. 
Without PEGylation (0 eq) considerable unspecific uptake was observed for both 454 
and 595 lipo-oligomers. For 454 polyplexes with 1 eq of gE4-FolA, big yellow punctuated 
structures were detectable (Figure 33A), based on polyplex agglomeration. The yellow 
colour, resulting from the overlay of siRNA and PEGylation agent, confirmed a 
successful PEGylation. With higher molar equivalents of gE4-FolA (avoiding aggregate 
formation) instead of the big punctuate structures a more even cell binding with smaller 
yellow structures (Figure 33A, 3 to 7 eq and Figure 33B, 4 eq) and uptake into cells 
(Figure 33A, 3 and 7 eq and Figure 33B, 3 and 4 eq) was observed, consistent with 
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transfections and flow cytometry data. The red dots in the cytoplasm indicate free siRNA 
after separation from the polyplex or polyplex without PEGylation reagent. For 595 
polyplexes (Figure 33B,D) with 1 eq of gE4-FolA, the yellow structures were not as big 
as for 454. For 4 eq, free ligand (green) was located at the cell membrane, and for 
equivalents ≥5 eq, only a few particles were observed in cells (Figure 33B), both findings 
explain the insufficient transfection efficiency of 595 polyplexes at higher PEGylation 
degrees. For particles post-PEGylated with FolA a similar result was found for 454 and 
595 for all ratios (Figure 33C,D). Small particles, but no agglomerates, that were 
sufficiently post-PEGylated (yellow) could be found again supporting the hypothesis of a 
heterogeneous size distribution. As agglomerates are washed away in the process, only 
small particles could be found in cells. 
 
 
Figure 33 (first part). Intracelluar distribution of 454 polyplexes (A, C) and 595 polyplexes (B, D) post-PEGylated 
with increasing molar equivalents of gE4-FolA (A, B) or FolA (C, D) acquired by confocal laser scanning 
microscopy. Polyplexes were tested in KB/eGFPLuc cells with 500 ng control siRNA. Nuclei were stained with 
DAPI (blue), actin cytoskeleton was stained with rhodamine phalloidin (orange), siRNA was spiked with 10 % Cy5 
labelled siRNA (red) and the incorporated PEGylation agent was spiked with a defined amount (0.2 eq) Alexa 
488-PEG-Mal (green). Yellow presents the overlay of siRNA and PEG. Core polyplexes were formed at N/P 10 
with a siRNA concentration of 25 µg/mL and a final siRNA concentration of 20 µg/mL after PEGylation. The 
images show the overlay of the different channels. In vitro preparation was carried out by Katharina Müller; 
microscopy pictures were taken by Miriam Höhn (Pharmaceutical Biotechnology, LMU Munich). Adapted from 
[146]. 
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Figure 33 (second part). Intracelluar distribution of 454 polyplexes (A, C) and 595 polyplexes (B, D) post-
PEGylated with increasing molar equivalents of gE4-FolA (A, B) or FolA (C, D) acquired by confocal laser 
scanning microscopy. Nuclei were stained with DAPI (blue), actin cytoskeleton was stained with rhodamine 
phalloidin (orange), siRNA was spiked with 10 % Cy5 labelled siRNA (red) and the incorporated PEGylation agent 
was spiked with a defined amount (0.2 eq) Alexa 488-PEG-Mal (green). Yellow presents the overlay of siRNA and 
PEG. In vitro preparation was carried out by Katharina Müller; microscopy pictures were taken by Miriam Höhn 
(Pharmaceutical Biotechnology, LMU Munich). Adapted from [146]. 
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Figure 33 (continued). Intracelluar distribution of 454 polyplexes (A, C) and 595 polyplexes (B, D) post-
PEGylated with increasing molar equivalents of gE4-FolA (A, B) or FolA (C, D) acquired by confocal laser 
scanning microscopy. Nuclei were stained with DAPI (blue), actin cytoskeleton was stained with rhodamine 
phalloidin (orange), siRNA was spiked with 10 % Cy5 labelled siRNA (red) and the incorporated PEGylation agent 
was spiked with a defined amount (0.2 eq) Alexa 488-PEG-Mal (green). Yellow presents the overlay of siRNA and 
PEG. In vitro preparation was carried out by Katharina Müller; microscopy pictures were taken by Miriam Höhn 
(Pharmaceutical Biotechnology, LMU Munich). Adapted from [146]. 
 
 In vivo biodistribution of post-PEGylated polyplexes 3.4.2.4
 
Biodistribution of PEGylated 454 and 595 polyplexes was examined in NMRI nu/nu mice 
after intravenous tail vein administration. Cy7 labelled siRNA against human AHA1 
(without gene target in mice) was detected via near-infrared (NIR) fluorescence imaging. 
First experiments were carried out with rather high degree of 3 eq of gE4-FolA-
PEGylation for both oligomers, as these formulations showed convincing sizes, zeta 
potentials, and targeting effects in vitro. In vivo experiments were not performed with 
standard PEG-FolA, as post-PEGylated polyplexes with this reagent formed 
agglomerates. It quickly became apparent that the selected gE4-FolA PEGylated 454 
and 595 siRNA polyplexes were highly labile in vivo, showing a high bladder signal of 
siRNA already after 15 min, similar as for free siRNA, and no detectable signal after 4 h 
(Figure 34). Therefore, in further studies a lower degree of PEGylation (2 and 1.5 eq) 
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was tested for both oligomers. DLS measurements showed suitable sizes between 130 
and 300 nm for all polyplexes prepared at the 10-fold higher concentration that has to be 
used for in vivo studies (Figure 35). PEGylation with 1.5 eq led to a longer persistence of 
siRNA in livers of mice for both oligomers, which still could be detected after 8 h when 
livers were examined ex vivo (Figure 34). A lower PEGylation degree could not be tested 
in vivo because of the tendency of this polyplexes to agglomerate. 
 
 
Figure 34 (first part). Time-dependent biodistribution of siRNA polyplexes after intravenous administration (n=3) 
in mice and ex vivo analysis of organs. A) 454 without PEGylation, 1.5 eq, 2 eq and 3eq gE4-FolA and B) 595 
without PEGylation, 3 eq, 2 eq and 1.5 eq gE4-FolA. Core polyplexes were formed at N/P 10 with a siRNA 
concentration of 250 µg/mL and a final siRNA concentration of 200 µg/mL after PEGylation. Ventral and dorsal 
position of one representative mouse of each group is shown. Animal experiments were carried out by Eva Kessel 
(vetMD student, Pharmaceutical Biotechnology, LMU Munich). Adapted from [146]. 
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Figure 34 (continued). Time-dependent biodistribution of siRNA polyplexes after intravenous administration 
(n=3) in mice and ex vivo analysis of organs. A) 454 without PEGylation, 1.5 eq, 2 eq and 3eq gE4-FolA and B) 
595 without PEGylation, 3 eq, 2 eq and 1.5 eq gE4-FolA. Animal experiments were carried out by Eva Kessel 
(vetMD student, Pharmaceutical Biotechnology, LMU Munich). Adapted from [146]. 
 
 
Figure 35. Z-average [nm], PDI, zeta potential [mV] of siRNA polyplexes determined by DLS (n=3 ± SD), 
generated at in vivo concentration (250 µg siRNA/mL) by PEGylation of 454 and 595 polyplexes with 1.5 eq, 2 eq 
or 3 eq of gE4-FolA. Adapted from [146]. 
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Further biodistribution experiments were performed in mice bearing L1210 tumors. 
L1210 cells overexpress the FR as well and are able to bind FolA even to a higher 
degree compared to KB cells (Figure 36).  
 
Figure 36. Cellular association of an allophycocyanin labelled folate antibody against the folate receptor (A,B) 
(black) and of carboxyfluorescein tagged FolA (C,D) (black) determined by flow cytometry of L1210 cells (A,C) 
and KB/eGFPLuc cells (B,D). As negative controls an allophycocyanin labelled IgG1 isotype control antibody 
(A,B) and carboxyfluorescein tagged PEG (C,D) were used (dark grey). Control cells (buffer treated cells) are 
presented in light grey. “Count” represents cumulative counts of cells with indicated Cy5 fluorescence after 
appropriate gating by forward/sideward scatter and pulse width. Dead cells (DAPI positive, less than 2 %) were 
excluded from analysis. Experiments were performed in triplicates. One representative blot is shown. Adapted 
from [146]. 
 
For further in vivo studies 595 polyplexes PEGylated with 1.5 eq of gE4-FolA were 
selected, as they showed favourable stability and targeted gene silencing in comparison 
to 454 (Figure 37A). Additionally,  in vitro experiments with L1210 cells using 595 
polyplexes PEGylated with 1.5 eq of gE4-FolA demonstrated specific silencing of 
endogenous EG5 gene (as chosen reporter) by RT-qPCR (Figure 37B) and specific 
uptake compared to 595 PEGylated with Mal-PEG or 595 without PEGylation (Figure 
37C). 
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Figure 37. A) Gene silencing (n=3, mean ± SD) of 454 and 595 polyplexes PEGylated with 1.5 eq of gE4-FolA. 
Cells were incubated 30 min before standard transfection with a saturated folic acid solution to block the folate 
receptor, if specified. Polyplexes were tested in KB/eGFPLuc cells with siRNA targeting eGFP (eGFP siRNA) and 
control siRNA (ctrl siRNA). B) Relative EG5 expression in L1210 cells determined with RT-qPCR (n=3, mean ± 
SD). Cells were transfected with 595 PEGylated with 1.5 eq gE4-FolA or 1.5 eq Mal-PEG using siRNA against 
EG5 (EG5 siRNA) or control siRNA. C) Cellular internalization of Cy5-labelled siRNA into L1210 cells determined 
by flow cytometry of 595 PEGylated with 1.5 eq gE4-FolA, 1.5 eq Mal-PEG and without PEGylation (n=3) after 45 
min incubation at 37 °C. Post-PEGylated polyplexes are presented in black, blockade of post-PEGylated 
polyplexes (0.5 h incubation of cells with a saturated folic acid solution at 37 °C) in dotted black and HBG buffer in 
grey. Core polyplexes were formed at N/P 10 with a siRNA concentration of 25 µg/mL (A,C) or 250 µg/mL (B) and 
a final siRNA concentration of 20 µg/mL (A,C) or 200 µg/mL (B) after PEGylation. Adapted from [146]. 
 
Figure 38 shows the biodistribution of 595 PEGylated with 1.5 eq gE4FolA and the 
control groups 595 polyplexes without PEGylation or with PEGylation but without 
targeting ligand (Mal-PEG), and free siRNA in mice bearing L1210 tumors. Figure 38A 
clearly shows the rapid clearance of free siRNA by the kidney. After 4 h no signal could 
be detected anymore, meaning a total removal of siRNA. In contrary, all 595 groups 
revealed persistence of NIR-labelled siRNA up to 8 h in mice, when animals had to be 
sacrificed to analyze their organs. PEGylated 595 polyplexes with gE4-FolA largely 
accumulated in the liver after initial distribution. Similar results were obtained for 
PEGylated polyplexes without ligand and non-PEGylated polyplexes.  
  Results 
 
 
79 
 
 
Figure 38. Biodistribution of siRNA polyplexes after intravenous administration into NMRI nu/nu mice bearing 
subcutaneous L1210 tumors (n = 3 mice). Mice were treated with 50 μg of free siRNA, 595 polyplexes PEGylated 
with 1.5 eq of gE4-FolA, 595 polyplexes PEGylated with 1.5 eq of Mal-PEG, and 595 polyplexes without 
PEGylation. Core polyplexes were formed at N/P 10 with a siRNA concentration of 250 μg/mL and a final siRNA 
concentration of 200 μg/mL after PEGylation. A) Time-dependent distribution. Dorsal position of one 
representative mouse of each group is shown. The orange arrow represents a lung signal, the blue one a liver 
signal, and the green one a bladder signal. B) Lateral position of one representative mouse at indicated time 
points. The rose arrow points to tumors with measurable fluorescence signal. C) Ex vivo images of lung, kidney, 
spleen, liver and tumor at 8 h after administration. a) lung b) kidney c) liver d) spleen e) tumor. Animal 
experiments were carried out by Eva Kessel (vetMD student, Pharmaceutical Biotechnology, LMU Munich 
Biotechnology, LMU). Adapted from [146]. 
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A short-term L1210 tumor-associated signal was detected for all 595 groups, however 
disappearing after 30 min for gE4-FolA, after initial application for PEG polyplexes, and 
after 1 h for non-PEGylated polyplexes (Figure 38B). Interestingly, PEGylation of 595 
polyplexes led to a reduced lung signal as seen in mice during treatement and in ex vivo 
lungs (Figure 38A,C). To verify this observation, a more quantitative RT-qPCR analysis, 
detecting intact AHA1-siRNA present in the tissue at the end of the experiment (8 h), was 
performed (Figure 39). The highest relative siRNA amount in lung was detected for 595 
polyplexes without PEGylation, followed by PEGylated particles, the lowest abundance in 
lung was found for the gE4-FolA particles (Figure 39A). No siRNA was found in lungs 
from animals treated with free siRNA and in untreated animals (control). Additionally, 
qPCR analysis of AHA1-siRNA was performed in the subcutaneous FR-positive L1210 
tumors and livers (Figure 39B,C). As expected from imaging results only a low siRNA 
amount was found in the tumor as compared to the lungs and livers. Nevertheless, when 
normalized to lung accumulation, the siRNA quantity in tumors of gE4-FolA particles was 
higher as for ligand-free PEGylated 595 polyplexes and in the same range as for the 
more stable non-PEGylated particles (Figure 39D). 
 
 
Figure 39. Relative amounts of AHA1-siRNA in A) lung, B) tumor, C) liver (n = 3 ± SD, one-way ANOVA, ***p < 
0.05) determined at 8 h after delivery with polyplexes of 595 PEGylated with 1.5 eq gE4-FolA, 595 PEGylated 
with 1.5 eq Mal-PEG, and 595 without PEGylation. (C) Normalized tumor to lung distribution ratio of AHA1-siRNA. 
Core polyplexes were formed at N/P 10 with a siRNA concentration of 250 µg/mL and a final siRNA concentration 
of 200 µg/mL after PEGylation. Adapted from [146]. 
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3.4.3 Post-PEGylation using the peptide ligand GE11 for EGF receptor 
targeted siRNA and miRNA delivery 
 
 
This chapter has been adapted from: 
Katharina Müller, Philipp M. Klein, Philipp Heissig, Andreas Roidl and Ernst Wagner, 
“EGF receptor targeted lipo-oligocation polyplexes for antitumoral siRNA and miRNA 
delivery”, Nanotechnology, 2016, 27(46):464001. 
 
The presented post-PEGylation principle can be easily transferred to other ligands. 
Accordingly, the peptide ligand GE11 (see chapter 1.4.2) was used for epidermal growth 
factor receptor (EGFR) targeted delivery with the core polyplex 454. Here, not only eGFP 
siRNA was delivered, but also two therapeutic RNAs: miRNA-200c and siRNA targeting 
EG5. The tumor suppressor miR-200c [165-174] regulates epithelial to mesenchymal 
transition by targeting ZEB1 and ZEB2. ZEB1 and ZEB2 downregulate the epithelial 
marker E-cadherin inducing invasion and migration of cancer cells [166, 167, 175, 176]. 
Besides miRNA-200c suppresses anoikis resistance by targeting TrkB [168] and 
stemness by targeting Bmi1 [169] [170]. Kopp et al. showed that miRNA-200c 
additionally targets the proto-oncogene Kras [171]. Kras is a GTPase regulating cell 
differentiation, proliferation and survival. Mutations mainly in the codon 12, 13 and 61 
convert the proto-oncogene into an activated oncogene [177]. By transfecting miRNA-
200c targeting KRAS or pre-miRNA 200c Kopp et al. could enhance chemosensitivity 
towards doxorubicin and reduce cell proliferation and migration in breast cancer cells. As 
miRNA-200c is frequently downregulated in many human cancers including breast 
cancer, ovarian cancer, prostate cancer, endometrial cancer and bladder cancer [178-
182] and because of its negative effects on tumor progression it can be seen as 
important tumor suppressor miRNA and interesting therapeutic RNA. Another antitumoral 
RNA is siRNA against EG5 [183, 184]. EG5 (Eglin-5, also known as Kinesin-5, KSP, or 
KIF11) is a member of the kinesin superfamily and necessary for the formation of the 
spindle apparatus during mitosis. Several small molecule inhibitors for EG5 have been 
found and used for cancer therapy [185-187] as blockade of EG5 leads to prolonged 
mitotic arrest, formation of mono-astral spindles and apoptosis of tumor cells [188]. 
Therefore EG5 is a favourable target gene for siRNA knockdown. Delivery of EG5 siRNA 
into cancer cells resulted in cytotoxicity, antitumoral effects and reduced tumor growth in 
mice [68, 102, 189, 190]. 
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Post-PEGylated particles were formed as described in chapter 3.4.1 (Figure 23B). Mal-
GE11 was used as post-PEGylation reagent. GE11 consists of the amino acid sequence 
YHWYGYTPQNVI and was synthesized and coupled to maleimide-PEG28 using SPS 
(Figure 40).  
 
Figure 40. Amino acid sequence of the post-PEGylation reagent Mal-GE11. Mal-GE11 was synthesized by 
Philipp Klein (PhD student, Pharmaceutical Biotechnology, LMU Munich). Adapted from [147]. 
 
 Biophysical characterization of EGFR targeted post-PEGylated 3.4.3.1
polyplexes 
 
Nanoparticle formation and successful PEGylation was confirmed using dynamic light 
scattering (DLS) and zeta potential measurements. Increasing molar equivalents from 
0.2 eq to 1 eq of Mal-GE11 (Figure 40) or Mal-PEG (Figure 24) calculated on the molar 
amount of 454 were tested (Figure 41A,B). The Z-average values demonstrated suitable 
siRNA polyplex sizes from 120 nm to 150 nm with uniform particle populations. Only in 
case of polyplexes with 1 eq Mal-GE11, probably due to agglomeration as seen in 
chapter 3.4.2, larger particles (~ 400 nm) were detectable. The zeta potential of 454 
without PEGylation (0 eq) was +40 mV. After reaction with the PEG reagents it 
decreased to +15 mV with Mal-GE11, and to +8 mV with Mal-PEG, respectively, showing 
the charge shielding effect of PEGylation. 
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Figure 41. A) Nanoparticle sizes (Z-average, in nm) and B) zeta potentials [mV] of 454 polyplexes PEGylated 
with increasing molar equivalents of Mal-GE11 and Mal-PEG (n=3, mean ± SD). C) Gel retardation of 454 
polyplexes PEGylated with increasing molar equivalents of Mal-GE11 and Mal-PEG. Core polyplexes were 
formed at N/P 10 with a siRNA concentration of 25 µg/mL, resulting in a final siRNA concentration of 20 µg/mL 
after PEGylation. Adapted from [147]. 
 
The siRNA binding ability of PEGylated polyplexes was evaluated in a gel retardation 
assay (Figure 41C). siRNA / 454 lipo-polyplexes without PEGylation (0 eq) showed high 
siRNA binding, as evidenced by the entire siRNA retained in the gel loading pocket. 
Consistent with gE4-FolA PEGylated polyplexes (Figure 28), PEGylation slightly reduced 
siRNA polyplex stability. In case of Mal-GE11 the amount of released siRNA correlated 
with the PEGylation degree, in case of Mal-PEG polyplexes the content of free siRNA 
remained constant. Nevertheless, most of the siRNA remained polyplex-bound and 
stayed in the loading pockets. To test the stability of PEGylated formulations in full 
serum, siRNA nanoparticles were incubated in 90 % FBS for 2 h and 24 h at 37 °C 
(Figure 42). Only a minor siRNA fraction was released for 454 polyplexes without or with 
Mal-GE11 modification even after 24 h. In contrary, Mal-PEG polyplexes modified at 0.8 - 
1 molar equivalents released siRNA significantly. These results indicate a higher stability 
of 454 / Mal-GE11 polyplexes.  
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Figure 42. Gel retardation assay of 454 polyplexes PEGylated with increasing molar equivalents of Mal-GE11 
and Mal-PEG after A) 2 h and B) 24 h incubation in 90 % FBS. Core polyplexes were formed at N/P 10 with a 
siRNA concentration of 250 µg/mL, resulting in a final siRNA concentration of 200 µg/mL after PEGylation. 
Adapted from [147]. 
 
 Cellular internalization and gene silencing of EGFR targeted post-3.4.3.2
PEGylated polyplexes 
 
For the in vitro examination of the EGFR targeted polyplexes three cancer cell lines were 
selected: T24 bladder cancer cells, MDA-MB 231 breast cancer cells and Huh7 
hepatocellular carcinoma cells. Chosen cell lines expressed the EGFR to a high degree 
as shown via flow cytometry in Figure 43. 
 
 
Figure 43. EGFR expression of (A) T24/eGFPLuc-200cT cells, (B) MDA-MB 231 cells and (C) Huh7/eGFPLuc 
cells. Control cells (buffer treated cells) are presented in grey, EGFR positive cells are presented in black. “Count” 
represents cumulative counts of cells fluorescence after gating by forward/sideward scatter and pulse width. Dead 
cells (DAPI positive, less than 2 %) were excluded from analysis. Adapted from [147]. 
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Figure 44 shows the cellular internalization of the post-PEGylated 454 polyplexes. Cy5-
siRNA polyplexes shielded with 0.2 eq up to 1 eq Mal-GE11 (blue line) were compared 
with polyplexes without ligand (Mal-PEG, green line) or with polyplexes without 
PEGylation (black line). At the low PEGylation degree of 0.2 eq, no ligand or shielding 
effects could be observed. With ≥0.4 eq PEGylation, Mal-GE11 polyplexes showed a 
clear increase in uptake and significant ligand effect on all three cell lines. The uptake 
further increased with 0.8 eq Mal-GE11 equivalents. Polyplexes with 1 eq Mal-GE11 
displayed extremely high internalization, saturating the Cy5 fluorescence flow cytometry 
channel; such a high fluorescence, however, is typical for association of aggregated 
polyplexes (compare Figure 41) which are not considered as useful for further 
development.  
 
 
Figure 44. Cellular internalization of Cy5-labelled siRNA determined by flow cytometry of 454 polyplexes which 
were PEGylated with increasing molar equivalents of Mal-GE11 or Mal-PEG. Internalization of polyplexes after 45 
min incubation at 37 °C was examined in T24/eGFPLuc-200cT, Huh7/eGFPLuc and MDA-MB 231 cells. The 
intensity of the Cy5 signal after removal of externally bound polyplexes by a heparin wash resembles the amount 
of internalized polyplexes. “Count” represents cumulative counts of cells with indicated Cy5 fluorescence after 
gating by forward/sideward scatter and pulse width. Dead cells (DAPI positive, less than 2 %) were excluded from 
analysis. Mal-GE11 modified polyplexes are presented in blue, Mal-PEG modified polyplexes are presented in 
green and non-PEGylated polyplexes are presented in black. Buffer treated cells are presented in grey. Core 
polyplexes were formed at N/P 10 with a siRNA concentration of 25 µg/mL, resulting in a final siRNA 
concentration of 20 µg/mL after PEGylation. Experiments were performed in triplicates. One representative blot is 
shown. Adapted from [147]. 
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The gene silencing efficiency of PEGylated 454 polyplexes was examined in 
T24/eGFPLuc-200cT and Huh7/eGFPLuc cells (Figure 45). Both cell lines stably express 
the eGFP-luciferase fusion protein. T24/eGFPLuc-200cT cells additionally offer a binding 
site for miR-200c in the eGFP-luciferase mRNA, which therefore can be blocked by 
delivered miR-200c. The stable T24/eGFPLuc-200cT cells were specially prepared as 
test cell line to monitor miR200c delivery in a simple fashion via luciferase read-out. Cells 
were transfected with polyplexes of siRNA against eGFP (eGFP siRNA), a synthetic 
miR-200c mimic (with a 23 bp siRNA-like structure), or control siRNA without any target 
gene (ctrl siRNA).  
 
Figure 45. Gene silencing (n=3, mean ± SD) of A) T24/eGFPLuc-200cT cells transfected with eGFP siRNA and 
ctrl siRNA, B) Huh7/eGFPLuc cells transfected with eGFP siRNA and ctrl siRNA and C) T24/eGFPLuc-200cT 
cells transfected with miR-200c mimic or ctrl siRNA. Core polyplexes were formed with 454 at N/P 10 with a RNA 
concentration of 25 µg/mL, resulting after PEGylation with increasing molar equivalents of Mal-GE11 or Mal-PEG 
in a final RNA concentration of 20 µg/mL. Polyplexes were incubated on cells for only 45 min to highlight receptor-
specific transfection, gene silencing effects were analyzed at 48 h after transfection. For statistical analysis two-
tailed t-test was performed (n=3, mean ± SD, ns (not significant) p> 0.05, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p 
< 0.0001). Indicated statistical significance on top of transfection bars without connecting line shows statistical 
significance between eGFP siRNA/ miR-200c mimic and ctrl siRNA at specified PEGylation equivalents. Indicated 
statistical significance with connecting line shows statistical significance between 0.8 eq GE11 and 0.8 eq PEG of 
eGFP siRNA/miR-200c mimic. Adapted from [147]. 
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Neither non-PEGylated nor Mal-PEG modified 454 polyplexes showed sufficient gene 
silencing (Figure 45A-C). In contrast, eGFP siRNA Mal-GE11 polyplexes mediated up to 
70 % gene silencing in T24/eGFPLuc-200cT cells (Figure 45A) and up to 55 % in 
Huh7/eGFPLuc (Figure 45B) cells. Also with miR-200c mimic polyplexes, only for the 
Mal-GE11 modified nanoparticles a knockdown up to 60 % could be observed (Figure 45 
C).  Best silencing efficiency was observed for 0.8 to 1 molar equivalents of Mal-GE11. 
Polyplexes formed with ctrl siRNA did not show significant unspecific knockdown of gene 
expression, excluding significant toxic effects. This finding could be confirmed by MTT 
assays (Figure 46), where cell viability was not affected by the transfections. In sum, as 
polyplexes without targeting ligand or without silencing RNAs did not lead to gene 
knockdown, the experiments confirm the receptor specificity and potency of the GE11-
PEG lipo-polyplexes.  
 
 
Figure 46. Cell viabilities (n=3, mean ± SD) of A) T24/eGFPLuc-200cT cells transfected with eGFP siRNA and ctrl 
siRNA, B) Huh7/eGFPLuc cells transfected with eGFP siRNA and ctrl siRNA, and C) T24/eGFPLuc-200cT cells 
transfected with miR-200c mimic or ctrl siRNA. PEGylated 454 polyplexes with increasing molar equivalents of 
Mal-GE11 and Mal-PEG were tested. Polyplexes were incubated on cells for 45 min. Core polyplexes were 
formed at N/P 10 with a RNA concentration of 25 µg/mL, resulting in a final RNA concentration of 20 µg/mL after 
PEGylation. Adapted from [147]. 
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Gene silencing was additionally examined on the mRNA level for the therapeutic miR-
200c mimic and therapeutic EG5 siRNA (Figure 47). As the polyplexes modified with 0.8 
eq of Mal-GE11 had revealed most suitable particle sizes, zeta potential and gene 
silencing efficiency they were used for all further experiments.  
 
 
Figure 47. RT-qPCR of ZEB1 expression (A,B) and EG5 expression (C) in A) T24, B) MDA-MB 231 and C) Huh7 
cells. Cells were transfected with 0.8 eq Mal-GE11/454 polyplexes containing miR-200c mimic (A,B) or EG5 
siRNA (C). Core polyplexes were formed at N/P 10 with a siRNA concentration of 25 µg/mL resulting in a final 
siRNA concentration of 20 µg/mL after PEGylation and were incubated on cells for 45 min. Gene expression 
levels at 24 hours after transfection were analyzed. For statistical analysis a two-tailed t-test was performed (n=3, 
mean ± SD, ** p < 0.01, **** p < 0.0001). Adapted from [147]. 
 
In case of silencing with miR-200c, ZEB1 mRNA expression was analyzed, since it is 
degraded as a direct miR-200c target and involved in mesenchymal to epithelial 
transition associated with tumor cell migration and invasion. T24 bladder carcinoma and 
MDA-MB 231 breast cancer cells were used, because these aggressive, advanced 
mesenchymal cancer types do not express miR-200c [171, 182]. By the delivery of miR-
200c, the malignant phenotype of these cell lines should be partly reverted. After 
transfection with Mal-GE11 454 miR-200c polyplexes, ZEB1 mRNA was significantly 
downregulated in both cell lines (Figure 47A,B) in comparison with analogous control 
siRNA polyplexes. Interestingly, particles transfected with ctrl siRNA however also 
reduced ZEB1 levels in comparison to only buffer-treated cells. Probably GE11 polyplex 
binding to EGFR (GE11 lipo-poly-fection) followed by intracellular uptake may to some 
extent affect relative cellular gene expression [191, 192]. As a third additional example of 
gene silencing, knockdown of the EG5 gene by siRNA was examined on Huh7 cells 
(Figure 47C). Again a high, significant silencing of EG5 mRNA could be demonstrated by 
the GE11 polyplexes.  
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 Antitumoral effects of miR-200c delivery by GE11 polyplexes 3.4.3.3
 
Next, miRNA-200c Mal-GE11 454 polyplexes were used to inhibit tumor cell growth, 
chemoresistance and migration. To examine the effect on proliferation, T24 and MDA-
MB 231 cells were transfected using miR-200c in comparison to ctrl siRNA with and 
without GE11 ligand, and tumor cell growth was monitored for six days (Figure 48A). On 
both cell lines a significant reduced proliferation could be observed when transfected with 
miR-200c polyplexes with GE11 but not without GE11 ligand, indicating the receptor-
dependent uptake and biological function of these particles, consistent with preceding 
transfections and flow cytometry. As advanced mesenchymal tumor cells often display 
significant resistance against chemotherapeutics [170], the effect of miR-200c mimic on 
doxorubicin treatment was studied. MDA-MB 231 and T24 cells were treated for 72 h 
with 15 µM or 10 µM doxorubicin, respectively, after transfection with Mal-GE11 
polyplexes (Figure 48B).  
 
 
Figure 48. Antitumoral effects of miR-200c mimic transfected with EGFR-targeted polyplexes. A) Proliferation of 
T24 and MDA-MB 231 cells, B) Sensitivity towards doxorubicin of MDA-MB 231 and T24 cells at 72 hours after 
treatment with 15 µM or 10 µM doxorubicin, respectively and C) cell cycle analysis of T24 cells at 72 hours after 
treatment via flow cytometry. Cells were transfected with miR-200c mimic in comparison to ctrl RNA using 454 
polyplexes PEGylated with 0.8 eq Mal-GE11 or Mal-PEG. Core polyplexes were formed at N/P 10 with a siRNA 
concentration of 25 µg/mL resulting in a final siRNA concentration of 20 µg/mL after PEGylation and incubated 
with cells for 4 h. For statistical analysis, 2-way ANOVA (A, C) and two-tailed t-test (B) was performed (n=3, mean 
± SD, * p < 0.05, ** p < 0.01, **** p < 0.0001). Adapted from [147]. 
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Cell viability was reduced for both cell lines only with miR-200c mimics and not with 
control siRNA, demonstrating a higher sensitivity towards doxorubicin. In addition, a miR-
200c mediated effect of GE11 polyplexes was demonstrated by cell cycle analysis 
(Figure 48C). The number of cells in the G1 phase was significantly reduced, and in the 
S phase significantly enhanced; this was observed only in the miR-200c GE11 group.  
To study the effect of miR-200c polyplexes on tumor cell migration, a scratch assay was 
performed (Figure 49). MDA-MB 231 cells were transfected using nanoparticles post-
PEGylated with 0.8 eq Mal-GE11 or Mal-PEG, either containing miR-200c mimics or ctrl 
RNA.  After 24 h a scratch was created, and closure of the scratch, which is an indicator 
for cell migration, was measured after 24 h and 48 h. For cells treated with miR-200c and 
Mal-GE11 the scratch size was still 60 % of the initial scratch after 48 h. The effect of 
GE11 polyplexes became obvious when compared to the almost closed scratch of miR-
200c Mal-PEG polyplexes, which after 48 h was only 16 % of the initial scratch size. A 
slight RNAi-independent effect of GE11 ctrl siRNA nanoparticles could be observed, with 
a remaining scratch size of 24 % closure (as compared with the 16% of non-targeted 
miR-200c particle control). This is consistent with a slight anti-tumoral effect of GE11 
ligand nanoparticles as also observed in Figure 47.   
 
Figure 49. Inhibition of tumor cell migration. MDA-MB 231 cells were treated with 454 polyplexes PEGylated 
with 0.8 eq Mal-GE11 or Mal-PEG for 4 h. Cell layer was broken through a scratch after 24 h and its closure was 
monitored. A) Images of scratches taken at different time points.  B) Scratch closure represented as percentage 
of initial scratch. For statistical analysis 2-way ANOVA was performed (n=3, mean ± SD, * p < 0.05, ** p < 0.01). 
Adapted from [147]. 
 
 
  Results 
 
 
91 
 
 Antitumoral effects of EG5 siRNA transferred with GE11 polyplexes 3.4.3.4
 
EG5 (Eglin-5, also named Kinesin-5, KSP, or KIF11) is a key player in chromosome 
separation during mitosis and therefore an interesting target gene in cancer therapy. As 
displayed in Figure 47C, efficient EG5 gene silencing by GE11 polyplexes was 
demonstrated in Huh7 hepatocellular carcinoma cells at the mRNA level.  The biological 
antitumoral activity of EG5 siRNA was examined using Huh7/eGFPLuc cells (Figure 50). 
Only Mal-GE11 454 polyplexes of EG5 siRNA displayed high antitumoral activity (Figure 
50A) demonstrating significant ligand specificity again.  
 
 
Figure 50. Antitumoral effects of EG5 siRNA transfected with EGFR-targeted polyplexes. A) Metabolic 
activity of Huh7/eGFPLuc cells at 48 h after 4 h incubation with polyplexes. B) Cell cycle analysis of 
Huh7/eGFPLuc after 45 min treatment. Cells were analyzed after 48 h via flow cytometry. C) Fluorescence 
microscopy images of DAPI stained nuclei of Huh7/eGFPLuc cells at 48 h after 45 min polyplex treatment. Scale 
bars represent 20 µm. Cells were transfected with EG5 siRNA and ctrl siRNA using 454 polyplexes PEGylated 
with 0.8 eq Mal-GE11 or Mal-PEG. Core polyplexes were formed at N/P 10 with a RNA concentration of 25 
µg/mL, resulting in a final RNA concentration of 20 µg/mL after PEGylation. For statistical analysis a two-tailed t-
test (A) and 2-way ANOVA (B) (n=3, mean ± SD , *** p < 0.001, **** p < 0.0001) was performed. Adapted from 
[147]. 
 
G2/M arrest, another characteristic of EG5 gene blockade, was confirmed via flow 
cytometry (Figure 50B). An enhanced cell fraction in G2/M phase and a decreased 
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fraction of cells in G1 phase were observed only for cells treated with Mal-GE11 modified 
nanoparticles containing EG5 siRNA. Furthermore, the formation of mono-astral spindles 
typical for EG5 knockdown was shown for DAPI stained nuclei of cells (Figure 50C). 
Asters were predominantly found in cells treated with EG5 siRNA Mal-GE11 polyplexes, 
occasionally in EG5 siRNA Mal-PEG polyplex-treated cells, but never in control siRNA 
polyplex-treated cells. 
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3.5 Mesoporous silica nanoparticles for highly efficient siRNA 
delivery 
 
This chapter has been adapted from: 
Karin Möller, Katharina Müller, Hanna Engelke, Christoph Bräuchle, Ernst Wagner and 
Thomas Bein, “Highly efficient siRNA delivery from core–shell mesoporous silica 
nanoparticles with multifunctional polymer caps”, Nanoscale, 2016, 8, 4007-4019. 
 
 
A different approach for effective siRNA delivery is the use of mesoporous silica 
nanoparticles (MSNs). MSNs consist of solid inorganic materials with a stable matrix and 
a pore system (see chapter 1.5). MSNs are widely used for siRNA delivery, but as typical 
MSNs offer pore sizes of about 3 nm, siRNA is generally not loaded into the pores, but 
bound to the surface via PEI or other positively charged polymers [138, 193-195]. Very 
few studies are reported where MSNs were developed with larger pores for an internal 
loading of siRNA [141, 196, 197]. This approach is favorable, because siRNA is more 
protected from degradation and can be loaded in higher concentrations compared to only 
being attached to the surface. Accordingly, the development of silica nanoparticles with 
suitable pores for high siRNA loading and efficient delivery is presented in the following. 
 
3.5.1 Design of MSNs  
 
Large-pore mesoporous silica nanoparticles (LP-MSN) and medium-pore MSNs (MP-
MSN) with different chemical compositions and physical properties are shown in Table 3. 
MSNs were synthesized and characterized by Dr. Karin Möller (Department of 
Chemistry, LMU Munich) as described in [148]. LP-MSNs consisted of either pure silica 
(LP-1) or their internal particle surfaces were further modified with different mol% of 
amino and/or phenyl groups in order to electrostatically interact with siRNA (LP-2 – LP-
6). The small surface area of LP-2 to LP-4 (120-220 m
2
g
-1
) resulted from their large pore 
size and corresponding wall thickness. The pore size of LP-MSNs was around 10 nm. 
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Table 3. Sample composition and surface properties. Adapted from [148]. 
 
a
Determined from elemental analysis 
 
MP-MSNs were synthesized as core-shell particles equipped with a positively charged 
interior due to amino groups and a negatively charged outer shell coated with mercapto 
groups. The surface area decreased proportional to the increasing amount of internal 
amino groups and varied between 700 m
2
g
-1
 and 900 m
2
g
-1
. MP-MSNs displayed pore 
sizes between 4 nm and 5 nm.    
 
3.5.2 Biophysical characterization of MSNs 
 
The size of LP-MSNs and MP-MSNs was determined by transmission electron 
microscopy (TEM) (Figure 51 and Table 3). LP-MSNs were between 60 nm to 200 nm in 
size. The size distribution was heterogeneous as different diameters were found for one 
sample. The images indicate that LP-MSNs displayed a bottleneck-type pore morphology 
where large cavities are connected via smaller pore-openings. In contrast, evenly-sized 
MP-MSNs of 150 nm were found in all cases. The pore morphology revealed an ordered 
stellate arrangement with conically widening pores. 
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Figure 51. Transmission electron micrograph (TEM) images of A) LP-1, B) MP-1, C) MP-2 and D) MP-3. Scale 
bars represent 30 nm (A,D) and 40 nm (B,C). TEM was carried out by Steffen Schmidt (Department of Chemistry, 
LMU Munich). Adpated from [148]. 
 
The siRNA binding ability of LP-MSNs was determined in a gel shift assay (Figure 52). 
Increasing siRNA concentrations (2.5 µg, 6.6 µg or 12µg per mg MSN) were loaded into 
LP-2, 3 and 4. The gel electrophoresis showed very high siRNA binding for all samples, 
but also no siRNA release even after 1.5 h. 
 
 
Figure 52. Gel electrophoresis with samples LP-2, LP-3 and LP-4 loaded with either 2.5, 6.6, or 12 μg siRNA per 
mg MSN (increasing concentration from left to right). Gel electrophoresis was run at 120 V for 1.5 h. Adapted from 
[148]. 
 
Figure 53 shows the siRNA adsorption and release capability of MP-MSNs. Different 
siRNA concentration were offered (red line) to MP-MSNs and the uptake was measured 
after 15 min (orange dots) and 1 h (green dots). MP-1 with a pore size of 4.7 nm showed 
fast uptake of siRNA up to a concentration of 40 µg/mg MSN within 15 min and up to 78 
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µg/mg MSN after 1h in aqueous solution (Figure 53A). At pH 5 an even higher siRNA 
uptake of 150 µg/mg MSN after 15 min, of 275 µg/mg MSN after 1 h and of 386 µg/mg 
MSN after 1 d (blue dot) could be observed (Figure 53B). The elution of siRNA, which is 
important for further in vitro experiments, was measured in PBS buffer (pH 7.4) after 15 
min (light green stars) and 2 d (dark green stars). MP-1 released between 16 % and 40 
% of the adsorbed siRNA within 15 min and up to 55 % after 2 days. MP-2 with smaller 
pores of 3.9 nm eluted a higher siRNA amount of 66 % and 75 % after 2 d (Figure 53C). 
To enhance the siRNA release of MP-1 amino groups were coupled to the mercapto 
groups via disulfide bridges (MP-1-S-S). MP-1-S-S showed a significant slower 
absorption of siRNA than MP-1 (5 h instead of 1 h for a complete absorption) probably 
because of a pore size reduction due to the long linker (Figure 53D). Nevertheless, the 
elution of siRNA was markedly faster with 43-49 % after 15 min and 76 % and 81 % 
(depending on the loading) after 1 day. 
 
 
Figure 53. siRNA uptake and release with stellate MP-MSN. Aliquots of 100 μg of MSN were exposed to 100 μL 
of siRNA solutions with increasing concentrations. A) Uptake in MP-1 from water, and (B-D) uptake from MES 
buffer at pH = 5 into samples (B) MP-1, (C) MP-2, and (D) MP-1-S-S. Release experiments were performed in 
100 μL PBS buffer at pH = 7.4 in all samples. The red curve indicates the offered siRNA amount, and orange and 
green dots indicate the adsorbed siRNA after 15 minutes and 1 h, respectively. Light green and dark green stars 
are the cumulatively released amounts of RNA after 15 min and 2 days, respectively. Measurements were carried 
out by Dr. Karin Möller (Department of Chemistry, LMU Munich). Adapted from [148]. 
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In the following MSNs were combined with the sequence defined oligomer 454 (Figure 
54), because MSNs alone showed no gene silencing ability in initial experiments (see 
below). As MSNs are not equipped with any endosomal escape domain, the four Stps 
and two oleic acids of 454 should contribute to endosomal membrane disruption. The 
interaction between 454 and MSNs might either be formed by disulfide-bridges from 
MSN-mercapto groups and cysteine units in 454 or resulted from electrostatic 
interactions. 
 
Figure 54. Combination of multifunctional core–shell nanoparticles with 454. Medium-pore MSN particles MP-1 
are lined internally with amino groups and externally with mercapto groups. In sample MP-1-S-S all functional 
groups were transformed into disulfide-bridged amino groups. Particles are loaded with siRNA and capped with 
454 that covers the final particles with a positively charged layer (chemical moieties depicted in this scheme are 
abbreviated for clarity; C: cysteine, Y: tyrosine, K: lysine). Adapted from [148]. 
 
Successful siRNA retention of MP-1-S-S capped with 454 is shown in Figure 55. Loaded 
MSNs (5 wt% siRNA) were combined with different amounts of the oligomer. All samples 
retained high siRNA contents with some minor siRNA release that decreased with 
increasing oligomer amount. Importantly, the supernatants of the MES loading solution 
(MSN-SN) and the first PBS buffer wash solution (PBS-SN) contained only negligible 
amounts of siRNA showing that 454 did not form polyplexes with released siRNA from 
MSNs. 
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Figure 55. Gel electrophoresis of sample MP-1-S-S (5 wt% siRNA loading in the MSN) with an increasing amount 
of oligomer ranging from 1/100 up to 1.5/1 w/w polymer to particle. The first and the second supernatant solutions 
(SN) after sample preparation are included. Adapted from [148]. 
 
3.5.3 Gene silencing of MSNs 
 
For gene silencing experiments MSNs were loaded with eGFP siRNA or ctrl siRNA and 
transfected in KB/eGFPLuc cells. MP-1-S-S without 454 capping showed no gene 
silencing at all, when loaded with 5 wt% eGFP siRNA (Figure 56A, no oligomer). With 
increasing amounts of oligomer remarkably high transfection efficiency from 60 % up to 
90 % could be observed. The supernatants PBS SN and MES SN did not transfect 
showing that all three components (MSN, 454 and siRNA) are needed for a successful 
delivery system. For further experiments a w/w of 1/2 was chosen as higher oligomer 
concentrations did not display significant higher gene silencing. MP-MSNs are able to 
load high siRNA amounts (Figure 53). Therefore, MP-1 coated with 454 (w/w 1/2) and 
increasing siRNA cargos from 5 wt% up to 20 wt% were prepared (Figure 56B). Thus, 
particle concentration on cells could be reduced while the siRNA amount was kept at 0.5 
µg per well. The transfection efficiency was still high in all cases, therefore particle 
concentration and consequently the siRNA amount per well was further reduced (Figure 
56C) from 0.5 µg with the highest load sample (20 wt%) to 0.063 µg siRNA per well. As 
gene silencing efficiency decreased with decreasing siRNA amounts 0.5 µg siRNA per 
well turned out to be the optimal concentration for further experiments. 
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Figure 56. Gene silencing of MSNs. A) MP-1-S-S (5 wt% siRNA loading in the MSN) with an increasing amount 
of oligomer ranging from 1/100 up to 1.5/1 w/w 454 polymer to particle. The first and the second supernatant 
solutions (SN) after sample preparation are included. B) MP-1 coated with 454 (w/w 1/2) with increasing siRNA 
loadings of 5 wt%, 10 wt%, 13 wt% and 20 wt% siRNA, while keeping the total amount of siRNA at 0.5 μg per 
well. C) MP-1 coated with 454 (w/w 1/2) with decreasing siRNA concentrations/ well. MSNs were loaded with 
eGFP siRNA or ctrl siRNA and incubated on KB/eGFPLuc cells for 4h (A) or 45 min (B,C) (n=3, mean ± SD). 
Oligomer 356, applied with 200 ng of INF7 peptide-conjugated (eGFP or ctrl) siRNAs serves as positive control 
[57]. Adapted from [148]. 
 
The influence of different pores of MSN on transfection efficiency was examined in 
Figure 57. The medium-pore MSNs MP-1 with a pore size of 4.7 nm and MP-2 with a 
pore size of 3.9 nm were compared to the large-pore MSN LP-2 with pore sizes of 10 
nm. As seen before, MP-MSNs did not transfect without oligomer 454 (Figure 57A,B). 
MP-1 and MP-2 displayed the same high transfection efficiency with 454 (w/w 1/2) 
regardeless of the siRNA loading. Thus, the minimal pore size difference did not 
influence the transfection efficiency. On the other hand, knockdown efficiency of LP-2 
was only 60 % with 5 wt% siRNA decreasing with a higher siRNA load (8.8 wt%) (Figure 
57C).  This shows that not only pore size, but also particle morphology and charge 
density plays a role on transfection efficiency as LP-2 has a smaller surface area and 
thus high areal amino-group densities.  
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Figure 57. Gene silencing of MSNs. A) MP-1 coated with 454 (w/w 1/2) and B) MP-2 coated with 454 (w/w 1/2) 
with increasing siRNA loadings of 5 wt%, 10 wt% and 13 wt% and 20 wt% siRNA. C) LP-2 coated with 454 (w/w 
1/2) with 5 wt% and 8.8 wt% siRNA load. MSNs were loaded with eGFP siRNA or ctrl siRNA and incubated on 
KB/eGFPLuc cells for 45 min (n=3, mean ± SD). Oligomer 356, applied with 200 ng of INF7 peptide-conjugated 
(eGFP or ctrl) siRNA, serves as positive control [57]. Adapted from [148].  
 
MP-1-S-S and MP-1 were additionally capped with the standard cationic lipid DOTAP 
instead of 454 to examine the importance of the sequence-defined oligomer (Figure 58).  
 
Figure 58. Gene silencing of MSNs. MP-1-S-S and MP-1 capped with DOTAP with increasing siRNA loadings of 
5 wt%, 10 wt% and 20 wt% siRNA, while keeping the total amount of siRNA at 0.5 μg per well. MSNs were loaded 
with eGFP siRNA or ctrl siRNA and incubated on KB/eGFPLuc cells for 4 h (n=3, mean ± SD). Oligomer 356, 
applied with 200 ng of INF7 peptide-conjugated (eGFP or ctrl) siRNAs, serves as positive control [57]. Adapted 
from [148].  
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Figure 58 showes high gene silencing of these particles with different siRNA loadings, 
that was nevertheless not as high as with 454 (Figure 56A,B). The cell viability of MP-1 
was examined in Figure 59. MSN concentrations from 0.1 to 0.2 µg per mL for uncapped 
samples and from 0.025 to 0.2 mg per mL capped with 454 were incubated on 
KB/eGFPLuc cells for 45 min or 4 h. All samples did not influence the cell viability 
showing the excellent biocompatibility of MSNs. 
 
 
Figure 59. Cell viability of MP-1 with and without 454 (w/w 1/2) capping loaded with 5 wt% siRNA. KB/eGFPLuc 
cells were incubated with different MSN concentrations for 45 min or 4 h (n=3, mean ± SD). Adapted from [148]. 
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4 Discussion 
 
4.1 Integration of twin disulfides into sequence-defined oligomers 
for stabilization of siRNA polyplexes  
 
For efficient siRNA delivery in vivo several obstacles have to be overcome. One critical 
issue is the stability of polyplexes [146, 198, 199]. As siRNA consists of only 21 bp 
compared to other nucleic acids, for example pDNA with about 6000 bp, less 
interelectrolytic interactions with the positive backbone of oligomers take place during 
polyplex formation [72]. Therefore stability is more critical for siRNA polyplexes than for 
polyplexes formed with pDNA. Several stability domains like fatty acids and tyrosine 
trimers for hydrophobic interactions and terminal cysteine residues for disulfide bridge 
formation have been integrated into oligomers before [57, 73, 150]. A new motif, the 
CRC motif, was integrated into sequence defined oligomers by Philipp Klein (PhD 
student, Pharmaceutical Biotechnology, LMU Munich) and examined for its suitability in 
stabilizing siRNA polyplexes. In the current thesis, these CRC containing siRNA 
polyplexes were evaluated in uptake and gene silencing experiments. As CRC forms 
twin disulfides [151] and can be easily inserted into oligomers via SPS it offers good 
opportunities for an optimal stability motif. The replacement of terminal cysteines of a 3-
arm oligomer by one, two or three CRC motifs led to significant smaller particles. At the 
same time, the PDI decreased indicating a better compaction and homogenous particle 
formation of CRC-polyplexes. Additionally, the zeta potential increased with the insertion 
of CRC showing a higher positive surface charge of particles. These results 
demonstrated the positive effects of the CRC motif on particle formation. For PEGylated 
structures with and without FolA-ligand the size increased a little bit with the insertion of 
CRC, but more significant was the tendency towards big particles when FolA was 
present. Agglomeration effects of FolA due to its hydrophobicity have also been 
observed in other studies [146, 163]. Additionally, the zeta potential of PEGylated 
particles was examined. The surface charge of targeted oligomers is very important as 
unspecific interactions with cell membranes should be avoided [115]. PEGylated 
oligomers revealed a zeta potential of about 0 mV in all cases showing excellent 
shielding. Gel shift assays demonstrated that the insertion of CRC did not change the 
siRNA binding of 3-arm oligomers. In contrary, a better siRNA binding ability could be 
observed for PEGylated CRC-polyplexes compared to polyplexes formed with oligomers 
containing only one terminal cysteine. PEG is known to reduce the binding and 
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compaction ability of ethylenimine motifs in polyplexes [67, 86, 145]. Thus, the insertion 
of CRC seemed to improve the biophysical properties of PEGylated oligomers as better 
siRNA retention in gel shift assays indicated a higher stability of polyplexes. This higher 
stability could also be observed in the presence of serum and under reducing conditions 
for PEGylated CRC oligomers. The targeting effect of PEGylated polyplexes became 
obvious in fluorescence microscopy. Here, particles could only be found in FR 
overexpressing KB/eGFPLuc cells when they were equipped with FolA. This result could 
be confirmed in flow cytometry. Additionally, the influence of the CRC motif on size of 
non-PEGylated 3-arm oligomers could be verified in microscopy as big particles were 
found for 3-arm oligomers, whereas the insertion of three CRC motifs led to small and 
equal distributed particles. Unfortunately, the gene silencing ability of these 3-arm CRC 
oligomers was abolished. Here, the size reduction probably had a negative impact as 
larger particles are more efficient in cell culture transfections due to the promotion of 
endosomal escape [146, 200]. The lack of endosomal escape could also be observed for 
PEGylated oligomers as INF7 modified siRNA was needed for efficient gene silencing. 
Nevertheless, FolA-PEG containing particles with CRC motif showed high and receptor 
specific gene silencing with INF7 modified siRNA surpassing the transfection efficiency 
of oligomers with only one terminal cysteine. To sum it up, the insertion of twin disulfides 
improved the stability of polyplexes, but did not led to more efficient siRNA delivery in 
general. Non-PEGylated 3-arm oligomers displayed smaller and more defined particles, 
but lost transfection efficiency with the insertion of the CRC motif. On the other hand, 
PEGylated CRC-oligomers benefited from the CRC motif. They showed better siRNA 
binding ability and stability and led to efficient and ligand dependent gene silencing in 
comparison to PEGylated oligomers with only terminal cysteines. 
 
4.2 Folate-PEG-oligomer conjugates for targeted siRNA delivery 
 
Besides stability, another requirement for sufficient siRNA delivery is the direction of 
nanoparticles to their site of action without affecting non-target cells. Targeting ligands 
are widely used for this purpose. The folate receptor (FR) is a favourable tumor target 
receptor because of its overexpression in many tumor tissues [87, 88, 201]. Folic acid 
(FolA) has been proven to be a potent ligand for directing drugs to cancer cells [89, 94, 
202]. Not surprisingly, targeted siRNA formulations have already been reported by either 
direct conjugation of FolA with siRNA constructs [203-206] or incorporating FolA as 
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ligand into lipid [98, 207, 208] or polymer-based formulations [57, 103, 209, 210]. To meet 
the requirements of a successful targeted delivery system, a library of 42 multifunctional 
sequence-defined oligomers was created by Dr. Dongsheng He (PhD thesis 2016, LMU 
Munich) following a combinatorial strategy. To shield the positive charge of the 
polyplexes leading to unspecific interactions with negatively charged cell membranes 24 
PEG units were inserted. Cationic 2- or 4-arm oligomers with Stp or Sph for siRNA 
binding and endosomal buffering were examined based on the lead structure 356 [57]. 
Additionally, histidines for endosomal buffering, terminal cysteines for stabilization by 
disulfide crosslinking and tyrosine trimers for hydrophobic stabilization were integrated 
into oligomers in different combinations. The effect of these functional domains on siRNA 
binding and complexation was examined in gel shifts and ethidium bromide assays. As 
expected the larger cationic backbone of 4-arm oligomers led to a better siRNA 
compaction compared to 2-arm oligomers. Surprisingly, tyrosine trimers reduced siRNA 
binding and compaction which is contradictory to studies with non-PEGylated siRNA 
lipoplexes, in which the insertion of tyrosine trimers enhanced the stability of polyplexes 
[73]. A reason for this result could be the PEGylation of the targeted oligomers. PEG 
counteracts the hydrophobic interactions of tyrosines as it increases solubility. The best 
siRNA compaction could be achieved with 2-arm and 4-arm oligomers containing 
terminal cysteines but no further modification. This result indicated that the right charge 
density of the cationic backbone is an indispensible requirement. For gene silencing 
experiments in the current thesis, polyplexes were transfected on FR overexpressing 
KB/eGFPLuc cells with siRNA against eGFP with and without the endosomolytic INF7 
peptide conjugated to siRNA. In general, the use of INF7-siRNA led to better transfection 
efficiency due to the enhanced endosomal escape. Oligomers containing four arms or an 
enlarged number of cationic building blocks led to increased transfection efficiency 
because of their better siRNA binding and complexation. In contrary, the modification of 
oligomers with either tyrosine trimers or histidines reduced their gene silencing ability for 
both 2-arm and 4-arm oligomers. This can be explained with the low siRNA compaction 
of these oligomers. The integration of both tyrosine trimers and histidines into 2-arm 
oligomers, led to highly efficient gene silencing even without INF7 and at low N/P ratios, 
identifying this combination as the most effective. Four-arm oligomers with the same 
modification showed high knockdown as well, but additionally revealed toxic effects. 
Unfortunately, most oligomers did not transfect in a receptor-specific mode. Significant 
targeting effects could only be observed for #10, #12, #14 (2-arm-Y3) and #30 (4-arm-H), 
which could be partly verified in flow cytometry measurements. To provide a clearer 
overview, siRNA transfection properties of oligomers were summarized in Table 4. 
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Table 4. Summary of siRNA transfection properties
a
 
No. 
gene 
silencing 
INF7 
dependency 
receptor 
specificity 
toxicity 
356 ++ ++ ++ - 
#2 + ++ - - 
#4 ++ ++ - - 
#6 + ++ - - 
#8 + ++ - - 
#10 + - ++ + 
#12 + - ++ - 
#14 ++ ++ ++ - 
#16 + (20) + + (20) - 
#18 ++ - + - 
#20 ++ - + + 
#22 ++ ++ + - 
#24 ++ ++ + - 
#26 + ++ + - 
#28 ++ ++ - - 
#30 ++ ++ ++ - 
#32 + ++ - - 
#34 + ++ - - 
#36 - - - - 
#38 - - - - 
#40 ++ - + + 
#42 ++ + + + 
 
a
N/P ratio of 12 was used, unless defined differently (in brackets).  
Gene silencing (INF7-eGFP siRNA sequence specific reduction of marker gene expression):  
-, 0−20%; +, 20−60%; ++, 60−100%. 
Dependency on INF7: ++, transfection only with INF7 siRNA; +, more effective with INF7 siRNA; −, as effective 
with siRNA as with INF7 siRNA.  
Receptor specificity: −, no specificity; + moderate specificity (negative ligand control shows lower activity);  
++, specific (only FolA ligand shows transfection activity).  
Toxicity (metabolic cell activity): +, metabolic activity ≤80%; −, metabolic cell activity >80%. 
Adapted from [67].  
 
In contrary to the here presented siRNA polyplexes, experiments with pDNA polyplexes 
(performed by Dr. Petra Kos and Ana Krhac Levacic, Pharmaceutical Biotechnology, 
LMU Munich) revealed higher nucleic acid compaction and stability [67]. As mentioned 
before, an enhanced interaction of the negatively charged pDNA and the positively 
charged cationic backbone of oligomers takes place as pDNA is around 300 times larger  
than siRNA [72]. The pDNA transfection efficiency was enhanced with an increased 
number of oligomer arms and cationic building blocks comparable with siRNA 
transfections.  Furthermore, the insertion of tyrosine trimers and histidines into 2-arm 
oligomers turned out to be the best combination with the highest transfection efficiency 
consistent with siRNA transfections. These similarities were unexpected as pDNA and 
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siRNA carriers have to meet different prerequisites, such as nuclear versus cytosolic site 
of action. Thus, the common early steps including stability, endocytosis and endosomal 
release possibly contributed to the same preference of functional domains. Nevertheless, 
pDNA polyplexes displayed enhanced receptor specificity compared to siRNA polyplexes 
in general probably due to the higher stability. In conclusion, the screen of 42 FolA-PEG 
containing oligomers with different additional moieties offered valuable insights into 
structure-activity relations and revealed oligomers with suitable biophysical properties 
and high transfection efficiency.  
 
4.3 Native chemical ligation for the equipment of siRNA polyplexes 
with shielding and folic acid targeting 
 
Native chemical ligation (NCL) has been widely used for the synthesis of large peptides, 
and even total proteins [152-154]. With this method six sequence-defined oligomers from 
our library could be easily equipped with shielding domains and the targeting ligand FolA 
in order to examine structure-activity relationships and to find an optimal carrier without 
the need of a completely new synthesis. As mentioned before, shielding and targeting is 
important for sufficient in vivo delivery. Oligomers consisting of 2-arms with central or 
peripheral tyrosine trimers, 3-arms with or without tyrosine trimers and 4-arms with 
histidines were selected. The oligomers were modified via NCL by Dr. Can Yang Zhang 
(visiting PhD student at LMU Munich in 2013) with an alanine-PEG24 or FolA-PEG24 
reagent to determine the targeting effect. As seen before the siRNA binding ability was 
strongly improved with the number of cationic arms. PEGylated 2-arm oligomers showed 
almost no siRNA retention, whereas the siRNA binding increased with 3-arm and 4-arm 
oligomers. In contrary to chapter 3.2 the insertion of tyrosine trimers into 3-arm oligomers 
improved the siRNA retention and consequently polyplex stability. The shown benefit of 
tyrosine trimers is more consistent with previous studies [73]. Probably, the insertion of 
stability motifs into siRNA polyplexes might lead to different effects depending on the 
oligomer topology. In chapter 3.2, 2-arm and 4-arm oligomers did not profit from tyrosine 
trimers, whereas the here presented 3-arm oligomers and T-shaped oligomers in [73] 
revealed better biophysical properties. Additionally, PEGylated 3-arm oligomers with 
tyrosine trimers displayed the best particle sizes (<600 nm) whereas all other oligomers 
formed aggregates with siRNA. The zeta potential was significantly reduced after the 
NCL reaction showing the successful introduction of shielding reagents. For efficient 
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gene silencing INF7 modified siRNA had to be used to enhance the endosomal escape 
for PEGylated oligomers consistent with previous chapters. In case of 2-arm oligomers 
almost no gene silencing was observed, which can be explained with the insufficient 
siRNA binding. Interestingly, peripheral tyrosine trimers improved the transfection 
efficiency in comparison to central tyrosine trimers in 2-arm oligomers. The enhanced 
transfection efficiency of 3-arm oligomers especially with Sph compared to 2-arm 
oligomers can be explained with their improved siRNA binding and higher charge 
density. Surprisingly, 4-arm oligomers only showed moderate gene silencing. Receptor-
dependent transfection efficiency of FolA-PEG oligomers compared to their analogous 
without targeting ligands could be demonstrated with 3-arm/Stp (666), 3-arm/Y3 (668) 
and (very slightly) 4-arm/His (670). For all other topologies no targeting effect could be 
found. The transfection efficiency of alanine-PEG oligomers can be attributed to their 
large sizes, which led to unspecific cellular uptake and gene silencing. In flow cytometry 
experiments the enhanced uptake of FolA-targeted 666, 668 and 670 was confirmed. In 
this study, stability as a prerequisite for a successful siRNA delivery vehicle became 
obvious again as the insertion of tyrosine trimers and an increased number of positive 
charges led to more efficient siRNA binding and particle formation. Repeatedly, a higher 
stability and compaction could be observed with pDNA due to its larger size (experiments 
performed by Dr. Petra Kos, Pharmaceutical Biotechnology, LMU Munich). All NCL 
conjugates demonstrated efficient pDNA binding in agarose gel shifts and formed small 
particles of about 100 nm and 300 nm [145].  In in vitro experiments with pDNA, 
oligomers showed high transfection efficiency and receptor specificity. In contrary to 
siRNA transfections, the histidinylated 4-arm oligomer was the most effective one. To 
find out such structure-activity relationships, NCL as a tool to convert untargeted already 
existing oligomers from our library (>1000 oligomers) into FolA-targeted and PEGylated 
oligomers turned out to be an easy and effective method making the screen for an ideal 
in vivo delivery vehicle less cost- and time-consuming. 
 
4.4 Post-PEGylation of siRNA lipo-oligoamino amide polyplexes for 
receptor specific siRNA and miRNA delivery 
 
For tumor-targeted delivery of siRNA in vivo the size of nanoparticles plays an important 
role as well. Nanoparticles with a size below 5.5 nm are rapidly cleared by the urinary 
tract and eliminated from the body [211], whereas agglomerates block fine capillaries 
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[212]. In the current thesis, a post-PEGylation strategy was applied to provide well sized 
siRNA polyplexes with targeting ligands and PEG shielding. This method has been 
successfully used for pDNA/PEI polyplexes before [156-158]. Here, core nanoparticles 
were formed with siRNA or miRNA and sequence-defined cationic lipo-oligomers, which 
were further modified with PEG and targeting ligands. Two t-shaped lipo-oligomers, 454 
[73] and 595 [144], were chosen as they contain stabilizing tyrosine trimers and cysteine 
residues, formed siRNA polyplexes of 120 nm to 150 nm and have proven their gene 
silencing ability in previous studies. These core nanoparticles were surface shielded by 
reaction of cysteines not involved in disulfide cross-linkages with maleimido-PEG 
reagents, optionally containing the targeting ligands FolA, gE4-FolA or GE11. 
 
4.4.1 Post-PEGylation using tetra-glutamylated folic acid as ligand for 
receptor-targeted delivery 
 
This chapter has been adapted from: 
Katharina Müller, Eva Kessel, Philipp M. Klein, Miriam Höhn and Ernst Wagner “Post-
PEGylation of siRNA lipo-oligoamino amide polyplexes using tetra-glutamylated folic acid 
as ligand for receptor-targeted delivery”, Molecular Pharmaceutics, 2016, 13(7):2332-45. 
 
In the first post-PEGylation study, 454 and 595 polyplexes were modified with reagents 
consisting of maleimide, 28 PEG units and the targeting ligands FolA or tetra-γ-glutamyl 
folic acid (gE4-FolA) in increasing molar equivalents. The feasibility of the post-
PEGylation concept was shown by an Ellman’s assay monitoring the reaction of PEG-
maleimide with the cysteines of lipo-oligomers and by a decrease in zeta potential of 
polyplexes. Unexpectedly, FolA-PEG surface-modified polyplexes agglomerated, 
probably due to the hydrophobicity of folic acid [163], resulting in ligand-independent 
gene silencing. This problem was not observed in ligand-free PEGylation and was 
overcome by the use of gE4-FolA as targeting ligand. This modification can be 
considered as a biomimetic step, as polyglutamylation of folate by folyl-polyglutamate 
synthetase takes place in most organisms to increase its cellular retention and binding to 
DHFR enzyme [159, 213, 214]. Post-PEGylated gE4-FolA siRNA polyplexes displayed 
biophysical advantages, with sizes between 100 and 200 nm favourable for in vivo 
application, a receptor-specific uptake and effective gene silencing for a broad range of 
formulations. An additional advantage of the polyglutamylation might be the negative 
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surface charge of resulting particles (around −20 mV). The negative zeta potential 
prevents interactions with negatively charged serum proteins like albumin or negatively 
charged molecules such as HSPG on cell surfaces [215-217], and therefore might 
reduce adverse effects [218]. Receptor-mediated and effective gene silencing of gE4-
FolA PEGylated polyplexes was shown on human cervical carcinoma KB cells 
overexpressing the FR. A high knockdown efficiency could be obtained demonstrating 
the potency of the siRNA delivery system. Within an optimal degree of PEGylation, no 
reduced efficacy was found. Therefore, additional strategies, like the coupling of INF7 to 
siRNA, to enhance the endosomal escape, as observed for other related polyplex 
systems and in the chapters before, were not needed [57, 78, 219-221]. The FR 
specificity of transfections was proven via receptor blockade using folate saturated 
medium; 100−200 nm small siRNA particles containing the polyglutamylated FolA ligand 
lost their gene silencing ability upon FR blockade, whereas undefined agglomerates 
resulting from core polyplex modification with PEG-FolA still transfected KB cells in a 
receptor-independent manner. Flow cytometry measurements additionally proved the 
receptor specific uptake of siRNA polyplexes shielded with PEG-gE4-FolA. gE4-FolA 
PEGylated polyplexes were used to examine the biodistribution in mice after systemic 
circulation. These studies revealed destabilization of polyplexes by PEGylation as a 
critical factor limiting their in vivo application. A PEGylation of 3 mol eq led to immediate 
instability for 454 and 595 polyplexes in vivo, with most siRNA cleared via kidney and 
bladder already after 15 min. This problem was partially overcome by selecting the 595 
oligomer (containing two CRC stability motifs) [144] for polyplex core formation and an 
optimized lower degree of 1.5 eq of gE4-FolA PEGylation reagent. For this formulation 
persistence in mice up to 8 h as visualized by NIR fluorescence bioimaging could be 
seen, with a preferential accumulation in liver as typical for nanoparticles [222]. In 
previous in vivo biodistribution studies in mice, FR targeting 356 polyplexes circulated for 
only 15 min and were then cleared rapidly by the kidney due to their small size of only 
5.8 nm [57]. Here, 454 and 595 polyplexes with a size of about 200 nm were far less 
affected by renal clearance. In contrast to 356, a signal could be detected after 8 h in the 
liver and lung for 454, which was even higher for 595. Even PEGylated 454 polyplexes 
having a lower stability than 595 revealed persistence in mice after 8 h in lung, liver, and 
spleen. These results demonstrate the importance of sizes of nanoparticles for a 
successful in vivo biodistribution and arrival at their site of action. After 8 h mice were 
sacrificed to analyze the siRNA distribution of 595 formulations in organs. The lung 
accumulation noticed for the non-PEGylated particles was significantly reduced with 
PEGylation, especially for gE4-FolA polyplexes. Positively charged and lipid particles are 
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likely to be taken up by endothelial cells in the lung [223]. This might have been avoided 
with the negatively charged gE4-FolA particles. With the current formulations, only a 
moderate transient delivery into the tumor of mice was demonstrated. This is not 
surprising at all, when considering the low systemic polyplex stability. The destabilization 
of siRNA polyplexes by PEGylation is consistent with the findings using pre-PEGylated 
oligomers (chapter 3.2).  
 
4.4.2 Post-PEGylation using the peptide ligand GE11 for EGF receptor 
targeted siRNA and miRNA delivery 
 
This chapter has been adapted from: 
Katharina Müller, Philipp M. Klein, Philipp Heissig, Andreas Roidl and Ernst Wagner, 
“EGF receptor targeted lipo-oligocation polyplexes for antitumoral siRNA and miRNA 
delivery”, Nanotechnology, 2016, 27(46):464001. 
 
The post-PEGylation principle can be easily transferred to other ligands. The epidermal 
growth factor receptor (EGFR), a receptor tyrosine kinase, was chosen for the second 
study, as it is a favourable therapeutic target in cancer therapy [107]. EGFR is 
upregulated in several solid tumors which is correlated with poor cancer prognosis [108]. 
The peptidic ligand GE11 has proven acceptable binding ability to the EGFR, efficiency 
to deliver nanoparticles and, as compared with the natural ligand EGF, no mitotic activity 
[104, 113, 114, 224, 225]. Thus, GE11 was attached to 454 polyplexes with different 
molar ratios using the post-PEGylation principle. Resulting particles showed 
characteristics which would be favourable for in vivo application, such as polyplex sizes 
around 120 nm - 155 nm, a reduction in zeta potential from +40 mV without PEGylation, 
+15 mV with Mal-GE11, to +8 mV with Mal-PEG polyplexes, and a stable siRNA binding 
with Mal-GE11 particles even upon incubation in full (90%) fetal bovine serum for 24 h. 
Receptor-mediated enhanced uptake of GE11-PEGylated siRNA polyplexes could be 
demonstrated via flow cytometry in three different EGFR-positive cancer cell lines: T24 
bladder carcinoma, MDA-MB 231 breast cancer, and Huh7 liver cancer. This beneficial 
cellular uptake of siRNA translated into effective gene silencing by GE11-PEG modified 
nanoparticles, whereas non-PEGylated or PEGylated particles without targeting ligand 
had no sufficient gene silencing effect. Mal-GE11 454 polyplexes were not dependent on 
moieties enhancing the endosomal escape like INF7, which is often diminished for 
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PEGylated nanoparticles [57, 78, 221, 226]. In the next steps GE11-PEG 454 polyplexes 
were applied for antitumoral delivery of the tumor suppressive microRNA miR-200c or a 
therapeutic siRNA against EG5. miR-200c [165] is known to revert epithelial to 
mesenchymal transition by targeting ZEB1 [169] which also leads to less proliferative 
and migrating cells and to suppress chemoresistance towards doxorubicin by targeting 
TrkB and Bmi1 [170]. miRNA-200c additionally targets the proto-oncogene KRAS, which 
regulates cell differentiation, proliferation and survival [171]. Consistently, results with 
GE11 nanoparticles formulated with miR-200c mimics demonstrated downregulation of 
ZEB 1 via RT-qPCR, both in T24 and MDA-MB 231 cells, less proliferation, enhanced 
sensitivity of these cells against doxorubicin, and a change in cell cycle. In addition, 
inhibition of MDA-MB 231 tumor cell migration was observed for the EGFR-targeted miR-
200c mimic formulation but not the non-targeted formulation or the control RNA 
formulation.  Additionally, PEGylated formulations with EG5 siRNA were examined. EG5 
(Eglin-5, also known as Kinesin-5, KSP, or KIF11) belongs to the kinesin motor proteins; 
its main role is to separate anti-parallel microtubules from each other [227]. As 
malfunction in chromosome segregation is strongly related with the development of 
cancer, EG5 is a favorable gene to target for tumor therapy [228-230]. Efficient EG5 
knockdown by GE11-PEG 454 siRNA polyplexes could be verified by RT-qPCR. EG5 
knockdown resulted in cell cycle arrest in G2/M, also documented by the formation of 
mono-astral spindles, and tumor cell killing. Interestingly, several assays indicated that 
GE11 polyplexes may exert antiproliferative effects in an RNAi-independent manner. For 
example, a slightly decreased growth or migration of cells was observed after treatment 
with GE11 polyplexes containing ctrl RNA. It is known that GE11 polyplexes do not 
activate EGFR; in the contrary, natural EGFR signalling is inactivated through rapid 
endocytosis of polyplex–bound EGFR [104, 106, 107, 113], which may explain the 
additional antitumoral effects of the GE11 polyplexes. For these reasons, the GE11 
peptide ligand appears as very useful to target therapeutic RNAs to cancer cells. 
 
4.5 Mesoporous silica nanoparticles for highly efficient siRNA 
delivery 
 
Mesoporous silica nanoparticles (MSNs) have proven their efficiency as delivery systems 
for siRNA in many studies. However, siRNA was mainly attached on the outer surface of 
MSNs via PEI, which enhances its biodegradability and reduces the loading capacity 
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[138-140, 194, 196, 231, 232]. Constant development of MSN synthesis allows control 
and design of size (particles and pores), morphology, and pore structure [133]. Here, 
MSNs with different chemical compositions, inner and outer surfaces, pore sizes (large-
pore MSNs (LP-MSN) and medium-pore MSNs (MP-MSN)) and particle sizes were 
synthesized by Dr. Karin Möller (group of Prof. Thomas Bein, Department of Chemistry, 
LMU Munich) for efficient siRNA loading and delivery. MP-MSNs consisted of selectively 
modified inner and outer surfaces, which is important for siRNA loading. TEM images 
revealed particle sizes of 60 nm to 200 nm and different pore morphologies for LP-MSNs 
(bottleneck morphology) and MP-MSN (stellate morphology). For sufficient loading of 
negatively charged siRNA surfaces of MSNs were decorated with amino groups (>1 
mol%) that are positively charged at neutral pH. Gel electrophoresis showed high siRNA 
retention of LP-MSNs, but no siRNA release even after 1.5 h. Similar problems regarding 
nucleic acid release of LP-MSNs have been reported before [233-235]. Indeed, not only 
uptake, but also elution of siRNA in cellular environment is an important requirement for 
a delivery system. Efficient siRNA loading and release could be obtained with MP-MSNs. 
A minimum pore size of 5 nm had been supposed for efficient siRNA uptake in previous 
studies [233], but here, MP-2 MSNs with a pore size of only 3.9 nm were able to load 
very high siRNA amounts of at least 120 µg/mL. In general, the amount of siRNA 
uptaken into these MP-MSNs was the highest reported so far. Nevertheless, the siRNA 
uptake of MP-2 was slower compared to MP-1 probably due to a closer contact of siRNA 
with the pore surfaces because of the smaller pore size (3.9 nm vs. 4.7 nm), which 
reduces the progressive absorption. This observation is also confirmed when the velocity 
of siRNA loading of MP-1-S-S is compared to MP-1. Thus, not only pore size, but also 
pore morphology has to be considered regarding the siRNA release in particular. The 
bottleneck-like pores with smaller openings than pore diameters of LP-MSN prevented 
an efficient siRNA release. Additionally, a high concentration of protonated amino groups 
on the inner surface of MSNs facilitated the siRNA loading process. To sum it up, 
medium-pore sized MSN with stellate morphology and a high internal surface of amino 
groups turned out to be optimal for very high siRNA absorption up to 380 µg/mg and 
efficient siRNA desorption. For gene silencing experiments, MSNs were capped with the 
sequence-defined oligomer 454. 454 not only offers endosomal escape domains (Stp 
and oleic acid) that MSNs lack, but also free cysteines that can be used to couple 
functionalities such as targeting ligands for further experiments. Gel electrophoresis 
revealed sufficient siRNA retention of MP-1-S-S after coating with different amounts of 
454. Gene silencing better than 80 % could be shown with different siRNA and particle 
concentrations with MP-1, MP-2 and MP-1-S-S. It became very obvious, that sufficient 
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transfection efficiency could only be obtained when MP-MSNs were capped with 454. 
Efficient gene silencing could be shown with very low particle concentrations (2.5 µg 
MSN per 100 mL), which could not be achieved in other studies [197, 232]. Compared to 
MP-MSNs, LP-MSN did not show sufficient gene silencing probably due to the 
diminished siRNA release resulting from the bottleneck pore morphology. DOTAP 
capped MP-MSNs showed gene silencing as well. However, sequence-defined 
oligomers are preferable as capping system as DOTAP does not offer multifunctional 
domains, robustness and opportunities for future covalent modifications. In summary, 
MSNs together with sequence-defined oligomers are highly efficient and biocompatible 
siRNA delivery vehicles.   
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5 Summary 
 
The delivery of small nucleic acids triggering RNAi for cancer treatment is still a major 
challenge. Sequence-defined oligomers provide an excellent opportunity to meet all the 
demands an efficient and multifunctional siRNA or miRNA delivery system has to fulfil. 
The numerous requirements include stability in the blood stream, a suitable size to avoid 
rapid elimination or blockage of fine capillaries, shielding to prevent unspecific 
interactions with blood components or non-target cells and the equipment with receptor 
specific targeting ligands. After uptake into target cells, the delivery vehicles have to 
escape the endosome and subsequently release their cargo into the cytosol. Sequence-
defined oligomers can be synthesized easily and precise using solid phase-supported 
synthesis. With this method, building blocks for nucleic acid binding, shielding, targeting, 
stabilization, or endosomal escape can be stringed together in a precise manner 
following a modular design. Thus, in this thesis several formulations based on sequence-
defined oligomers for efficient and receptor specific siRNA and miRNA delivery have 
been developed and evaluated. 
In the first part, a new stability motif for sequence-defined oligomers was examined. The 
motif consisted of three amino acids, cysteine-arginine-cysteine (CRC), and has proven 
its suitability in the stabilization of peptide dimers by forming twin-disulfides in previous 
studies. In this thesis, siRNA polyplexes were evaluated containing oligomers with CRC 
integrated in ascending numbers into 3-arm non-targeted oligomers and into PEGylated 
folate receptor (FR)-targeted 2-arm oligomers. In both cases, the CRC motif had been 
integrated at the end of the arms instead of a single cysteine. A size reduction had been 
achieved in 3-arm oligomers with increasing numbers of CRC motifs, whereas it had not 
influenced the size of PEGylated oligomers. However, remarkably higher stability had 
been obtained with the insertion of the CRC motif in PEGylated polyplexes, also in the 
presence of serum and reducing agents. FolA dependent uptake and receptor specific 
gene silencing was demonstrated with PEGylated CRC-oligomers using endosomolytic 
peptide INF7 modified siRNA. In contrary, the insertion of the CRC motif abolished the 
transfection efficiency of non-PEGylated 3-arm oligomers completely.  
In the second part, a library of 42 oligomers with different topologies was evaluated in 
order to figure out structure-activity relationships and the optimal carrier for FR-targeted 
siRNA delivery. Starting from the lead structure 356, 2-arm and 4-arm oligomers had 
been modified with Stp or Sph for siRNA binding, tyrosine trimers and cysteines to 
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enhance stability and histidines to improve the endosomal escape. High siRNA binding 
and compaction had been achieved with 2-arm and 4-arm oligomers without further 
modification. In gene silencing experiments, oligomers with high charge density due to a 
large cationic backbone were advantageous. Nevertheless, the best candidates for 
efficient gene silencing turned out to be 2-arm oligomers with tyrosine trimers and 
histidine modification. Targeted delivery was obtained with 2-arm oligomers modified with 
tyrosine trimers and with 4-arm oligomers modified with histidines. 
The third part is based on native chemical ligation (NCL) as oligomer synthesis tool to 
facilitate the screening process for receptor-targeted siRNA delivery. Using NCL, non-
targeted 2-arm, 3-arm and 4-arm oligomers with different modifications from our existing 
library had been easily converted into FR-targeted and shielded oligomers without the 
need of a new synthesis. In this thesis, structure-activity relationships revealed enhanced 
siRNA binding with an increased number of cationic arms and a reduced particle size 
with the insertion of tyrosine trimers into 3-arm oligomers. Additionally, 3-arm oligomers 
with and without tyrosine trimer modification demonstrated efficient and receptor specific 
gene silencing. 
In the fourth part, the receptor specificity of siRNA and miRNA polyplexes was enhanced 
using a post-PEGylation strategy. Two t-shaped sequence-defined cationic lipo-
oligomers, 454 and 595, were used as core polyplexes and were further modified with 
maleimido-PEG reagents containing FolA or tetra-γ-glutamyl folic acid (gE4-FolA) 
ligands. Formulations with suitable sizes resulting in receptor specific uptake and high 
gene silencing without the addition of endosomolytic agents were only obtained with 
gE4-FolA. In vivo experiments revealed stability problems of the core polyplexes, which 
could be partly overcome by lowering the PEGylation degree and by using 595 
containing the CRC stability motif. Additionally, the post-PEGylation principle was 
transferred to the peptide ligand GE11 targeting the EGF receptor. Receptor specific 
uptake and gene silencing not only with eGFP siRNA functioning in a model system, but 
also with the therapeutic nucleic acids miR-200c and EG5 siRNA were achieved and 
several antitumoral effects were shown.  
In the fifth part, an alternative siRNA delivery system based on mesoporous silica 
nanoparticles (MSNs) has been evaluated. MSNs with medium-pore (MP) sizes 
favourable in siRNA absorption and desorption in combination with the t-shaped 
sequence-defined oligomer 454 achieved high gene silencing and excellent 
biocompatibility. 
  Appendix 
 
 
116 
 
6 Appendix 
 
6.1 Abbreviations 
 
AD-PEG adamantane conjugated to PEG  
Ago  argonaute protein 
apoB  apolipoprotein B  
bp  base pairs 
DGCR8 DiGeorge syndrome critical region gene 8 
DMEM Dulbecco`s modified Eagle`s medium 
DMSO dimethyl sulfoxide 
DOTAP 1,2-dioleoyl-3-trimethylammonium-propane (chloride salt) 
dsRNA double stranded RNA 
ECM  extracellular matrix 
EGF  epidermal growth factor 
EGFR  epidermal growth factor receptor 
EPR  enhanced permeability and retention  
EtBr  ethidium bromide 
2´F   2´-fluoro  
FBS  fetal bovine serum 
FolA  folic acid 
FR  folic acid receptor 
gE4-FolA tetra-γ-glutamyl folic acid 
GSH  glutathion 
Gtp  glutaroyl tetraethylene pentamine 
Gtt   glutaroyl triethylene tetramine 
2´-deoxy 2´H 
HBG  HEPES buffered glucose 
HEPES N-(2-hydroxyethyl)piperazine-N´-(2-ethanesulfonic acid)  
Hmgcr  3-hydroxy-3-methylglutaryl-CoA-reductase 
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INFα  interferon-α  
INF7 synthetic endosomolytic peptide derived from the influenza virus 
hemagglutinin HA2 N-terminus 
LNA  locked nucleic acid  
LPEI   linear polyethylenimine 
miRNA micro RNA 
mRNA  messenger RNA 
2´-MOE  2`-methoxyethyl 
MSN  mesoporous silica nanoparticles 
MTT  3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
Nbz  N-acyl-benzimidazolinone 
NCL  native chemical ligation 
NF-ĸB  nuclear factor ĸ-light-chain-enhancer of activated B cells 
2´OMe  2´-O-methyl  
PAA  poly(amino acid) 
PAMAM polyamidoamine 
PEG  polyethylene glycol 
Pol II  polymerase II 
Pre-miRNA miRNA precursor 
pri-miRNA primary miRNA 
PACT  protein activator of protein kinase PKR  
PAZ  PIWI-Argonaute-Zwille  
PEI  polyethylenimine 
PRR  pattern recognition receptor 
Ptp  phthaloyl tetraethylene pentamine 
RISC  RNA-induced silencing complex 
PKN3  protein kinase N3  
RNAi  RNA interference 
RRM2  M2 subunit of ribonucleotide reductase  
SD  standard deviation 
siRNA  small interfering RNA 
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Sph  succinoyl pentaethylene hexamine  
SPS  solid phase-supported synthesis 
Stp  succinoyl tetraethylene pentamine 
ssRNA single-stranded RNA 
SucA  Succinic acid 
TLR  toll-like receptors 
TEM  transmission electron microscopy  
TRBP  HIV-1 TAR RNA-binding protein  
3´UTR  3`untranslated region  
VEGF  vascular endothelial growth factor A  
 
6.2 Analytical Data 
 
Mass  spectra from compounds synthesized by Philipp Klein were generated by Sören 
Reinhard and Stephan Morys (PhD students, Pharmaceutical Biotechnology, LMU 
Munich). 
 
Mass spectrum of Mal-PEG-Folate (FolA): 
 
Mass calculated for C94H159N11O39 [M+H]+ 2067.08, mass found 2069.1 
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Mass spectrum of Mal-PEG-gE4-Folate (gE4-FolA): 
 
 
Mass calculated for C114H187N15O51 [M+H]+ 2582.25, mass found 2584.8. 
 
 
 
 
Mass spectrum of Mal-PEG: 
 
 
             Mass calculated for C69H130N2O33 [M+H]+ 1516.78, mass found 1512.53. 
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Mass spectrum of Mal-GE11: 
 
Mass calculated for C144H225N19O51: [M+H]
+
: 3036.6 Da. Masses found: 
[M+H]
+
: 3030.7 Da, [M+Na]
+
: 3053.5 Da, [M+K]
+
: 3070. 
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6.3 Publications 
 
6.3.1 Original articles 
 
EGF receptor targeted lipo-oligocation polyplexes for antitumoral siRNA and miRNA 
delivery; Müller K, Klein PM, Heissig P, Roidl A, Wagner E; Nanotechnology. 2016 Nov 
18; Epub 2016 Oct 13; 27(46):464001, doi: 10.1088/0957-4484/27/46/464001. 
Precise redox-sensitive cleavage sites for improved bioactivity of siRNA lipopolyplexes; 
Klein PM, Reinhard S, Lee DJ, Müller K, Ponader D, Hartmann L, Wagner E; 
Nanoscale. 2016 Oct 27; 8(42):18098-18104, doi: 10.1039/c6nr05767e. 
Post-PEGylation of siRNA lipo-oligoamino amide polyplexes using tetra-glutamylated 
folic acid as ligand for receptor-targeted delivery; Müller K, Kessel E, Klein P., Höhn M, 
Wagner E; Mol Pharm. 2016 Jul 5; 13(7):2332-45, doi: 10.1021/acs.molpharmaceut. 
6b00102. 
Targeted siRNA delivery using a lipo-oligoaminoamide nanocore with an influenza 
peptide and transferrin shell; Zhang W, Müller K, Kessel E, Reinhard S, He D, Klein PM, 
Höhn M, Rödl W, Kempter S, Wagner E; Adv Healthc Mater. 2016 Jun; 5(12):1493-504, 
doi: 10.1002/adhm.201600057.  
Combinatorial optimization of sequence-defined oligo(ethanamino)amides for folate 
receptor-targeted pDNA and siRNA delivery; He D, Müller K, Krhac Levacic A, Kos P, 
Lächelt U, Wagner E; Bioconjug Chem. 2016 Mar 16; 27(3):647-59, doi: 10.1021/acs. 
bioconjchem.5b00649. 
Multifunctional polymer-capped mesoporous silica nanoparticles for pH-responsive 
targeted drug delivery; Niedermayer S, Weiss V, Herrmann A, Schmidt A, Datz S, Müller 
K, Wagner E, Bein T, Bräuchle C; Nanoscale. 2015 May 7; 7(17):7953-64, doi: 
10.1039/c4nr07245f. 
Twin disulfides as oppurtunity for improving stability and transfection efficiency of 
oligoaminoethane polyplexes; Klein PM, Müller K, Gutmann C, Kos P, Krhac Levacic A, 
Edinger D, Höhn M, Leroux JC, Gauthier MA, Wagner E; J Control Release. 2015 May 
10; 205:109-19, doi: 10.1016/j.jconrel.2014.12.035.  
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Synthetic polyglutamylation of dual functional MTX ligands for enhanced combined 
cytotoxicity of poly(I:C) nanoplexes; Lächelt U, Wittmann V, Müller K, Edinger D, Kos P, 
Höhn M, Wagner E; Mol Pharm. 2014 Aug 4;11(8):2631-9, doi: 10.1021/mp500017u. 
Native chemical ligation for conversion of sequence-defined oligomers into targeted 
pDNA and siRNA carriers; Zhang CY, Kos P, Müller K, Schrimpf W, Troiber C, Lächelt 
U, Scholz C, Lamb DC, Wagner E; J Control Release. 2014 Apr 28;180:42-50, doi: 
10.1016/j.jconrel.2014.02.015.  
 
6.3.2 Review 
 
RNAi-based Nano-oncologicals: Delivery and clinical Applications; Müller K, Wagner E; 
In Nano-Oncologicals: New targeting and delivery approaches, Controlled release 
society and Springer; Part of the series Advances in Delivery Science and Technology. 
2014 Sep 06; 245-268. 
 
6.3.3 Meeting abstracts and poster presentations  
 
A new platform for siRNA delivery: core-shell mesoporous silica nanoparticles with 
multifunctional polymer caps, Möller
 
K, Müller
 
K, Engelke
 
H, Bräuchle
 
C, Wagner
 
E, Bein 
T; 14
th
 European Symposium on Controlled Drug Delivery, Egmond aan Zee, the 
Netherlands, April 2016 
miR-200c: function and delivery; Müller K, Klein PM, Kopp F, Roidl A, Wagner E; SFB 
1032 meeting, München, Germany , January 2016 
Conquer the barriers: optimization of sequence defined multifunctional nanocarriers for 
folate receptor targeted pDNA and siRNA delivery; He D, Müller K, Krhac Levacic A, 
Kos P, Lee DJ, Wagner E; 1st LMU-ChAN (China Academic Network) Scientific Forum, 
Munich, Germany, November 2015 
microRNA-200c and molecular nanoagents; Heissig P, Schrimpf W, Müller K, Lamb D, 
Wagner E, SFB 1032 meeting, Altötting, Germany, February 2015 
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Cargo-specific optimization of sequence defined non-viral nucleic acid carriers for folate 
receptor targeted pDNA or siRNA delivery; He D, Müller K, Kos P, Lee DJ, Lächelt U, 
Wagner E; XIX. Annual Meeting of German Society for Gene Therapy, Ulm, Germany, 
March 2014 
Native chemical ligation for conversion of sequence-defined oligomers of different 
topologies into targeted pDNA and siRNA carriers; Kos P, Müller K, Zhang CY, Troiber 
C, Lächelt U, Scholz C, Wagner E; Young Ideas in Nanoscience, NIM Workshop, 
Munich, Germany, November 2013 
Targeted sequence-defined oligomers of different topologies for pDNA and siRNA 
delivery synthesized via native chemical ligation; Kos P, Müller K, Zhang CY, Troiber C, 
Lächelt U, Scholz C, Wagner E; Nanosciences: Great Adventures on Small Scales, 
CeNS Workshop, Venice, Italy, September 2013 
Molecular nanoagents utilizing the intracellular microRNA machinery for switching 
functions in cells; Heissig P, Müller K, Wagner E; SFB 1032 retreat, February 2013 
 
6.3.4 Oral presentation 
 
Molecular nanoagents for anti-metastatic miR200c overexpression and detection, SFB 
1032 retreat, Frauenchiemsee, Germany, February 2014 
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6.4 Copyright 
 
Chapter 1.1, 1.2, 1.3, 1.4 (partly) and Figure 1, 2, 5: Reprinted/adapted from “Nano-
Oncologicals: New Targeting and Delivery Approaches, RNAi-based Nano-Oncologicals 
– Delivery and Clinical Applications, 2014, 245-268, Katharina Müller and Ernst Wagner, 
Editors: M.J. Alonso and M. Garcia-Fuentes, Controlled Release Society and Springer” 
with permission of Springer. 
Figure 6, 8, 9, 10 and 11: Reprinted/adapted from “Twin disulfides as opportunity for 
improving stability and transfection efficiency of oligoaminoethane polyplexes; Volume 
205; Philipp M. Klein, Katharina Müller, Christina Gutmann, Petra Kos, Ana Krhac 
Levacic, Daniel Edinger, Miriam Höhn, Jean-Christophe Leroux, Marc A. Gauthier, Ernst 
Wagner; 109-19; Copyright (2015); with permission from Elsevier. 
Figure 20 and 22: Reprinted from “Native chemical ligation for conversion of sequence-
defined oligomers into targeted pDNA and siRNA carriers; Volume 180; Can Yang 
Zhang, Petra Kos, Katharina Müller ,Waldemar Schrimpf, Christina Troiber, Ulrich 
Lächelt, Claudia Scholz , Don C. Lamb and Ernst Wagner; 42-50; Copyright (2014); with 
permission from Elsevier.  
Figure 23, chapter 3.4.2 (including figures) and chapter 4.4.1: Reprinted/adapted with 
permission from “Post-PEGylation of siRNA lipo-oligoamino amide polyplexes using 
tetra-glutamylated folic acid as ligand for receptor-targeted delivery; Katharina Müller, 
Eva Kessel, Philipp M. Klein, Miriam Höhn and Ernst Wagner; Molecular Pharmaceutics, 
2016, 13(7):2332-45. Copyright (2016) American Chemical Society. 
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